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Abstract 
The N M D A receptor is a heteromeric ligand-gated ion channel in the central nervous system 
(CNS). There are three families of N M D A receptor subunits with various combinations of 
NR1， NR2A-D and NR3A֊B subunits producing unique receptors with distinctive 
pharmacological and biochemical properties. Pharmacological and functional properties of 
the N M D A receptor are highly dependent on the composition of the receptor complex. The 
N M D A receptor is the focus of drug development for therapy and prevention of numerous 
neurological and psychiatric disorders. 
The focus of this thesis was to investigate N M D A receptor subtype selectivity of N M D A 
antagonists, in particular, RGH-896, a novel NR2B֊selective antagonist. The study has 
utilised radioligand binding competition binding assays with RGH-896 in native, recombinant 
and immunopurified N M D A receptor preparations. In addition, ligand autoradiography has 
been employed to quantify and delineate the regional distribution of [՝^H] RGH֊896 binding 
sites in rodent and human brain tissue. 
This study provides the first evidence that [^H] RGH-896 binds to a distinct binding site 
which displays a significantly lower affinity for spermidine compared to the [^H] Ro 25,6981 
binding site. In addition, the low sensitivity of [ 3 H] MK֊801 for unlabelled RGH-896 
compared to prototypical NR2B ligand ifenprodil is further evidence for the difference in 
binding sites. Novel immunopurification studies using [ 3 H] RGH-896, in contrast to [՝^H] CP 
101,606, binds to NR2B-containing receptors irrespective of N M D A receptor subunit 
combinations. Ligand autoradiography in human brain has shown a suφท่sing overall 
preservation of NR2B receptors in dementia with Lewy bodies (DLB) patients compared to 
age matched controls in the anterior cingulate cortex (ACC). However, this study has revealed 
the first evidence of an upregulation of NR2B receptors in ACC of DLB cases related to 
severity of auditory, but not visual hallucinations. 
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Chapter 1 
Introduct ion 
1.1 Neurological Disorders and Implications on Society 
Over the past decade, many research groups ( industr ia l and academic), have prov ided 
major advances in understanding the role o f neurological disorders that pose a threat 
to today 'ร society. As each laboratory has a part icular focus, in fo rmat ion can be 
gathered to prov ide society w i t h a v i ta l ind icat ion o f neurological disorders that are 
present in society and how to cope w i t h them. There are neurological disorders wh ich 
are c o m m o n in the general publ ic , where some symptoms are more dist inguishable 
than others. Neuro log ica l disorders can be d i f f i cu l t to diagnose as many symptoms 
can over lap. For example, a patient w i t h Parkinsons Disease w i l l show tremor at rest, 
muscle r ig id i t y hypokinesia and of ten dementia. First- l ine treatment w i t h L - D O P A 
w o u l d cont ro l the symptoms in the short te rm, but w o u l d cause drug- induced 
dyskinesias, in longer te rm treatment. I t is therefore cr i t ica l that more research is 
conducted to t ry and p inpoint a part icular defect for each disorder in order to treat 
each ind iv idua l w i t h appropriate medicat ion. Here is an overv iew o f how the central 
nervous system works and the impl icat ions when certain aspects o f the system fa i l , 
showing the problemat ic effects i t can have on society. Th is research reported here 
focuses on the glutamatergic system, i n part icular the N M D A receptor and its 
invo lvement in psychosis. 
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1.2 Central Nervous System 
The central nervous system (CNS) can be thought o f as an in fo rmat ion input, 
processing, storage, retr ieval , and output system. Internal s t imu l i f r o m the body and 
external s t imu l i f r o m the envi ronment prov ide in format ion sent v ia sensory nerves to 
the C N S , where i t is routed to appropriate bra in centres for processing into awareness 
o f sensations and perceptions, for storage in memory , and for the e l ic i ta t ion o f 
relevant motor responses. 
The brain is made up o f b i l l ions o f neurons wh ich are funct ional cel ls receiv ing 
in format ion f r o m other neuronal cells v ia dendrites and cel l bodies w h i c h conduct 
nerve impulses, or act ion potentials, no rma l l y in a d i rect ion away f r o m the ce l l body , 
where the nucleus o f the cel l is contained, to other neurons a long the axon (Figure 
l . l ) . The po in t where the axon terminal (presynapt ic) comes into contact w i t h other 
neurons or cells (postsynaptic) is cal led the synapse w i t h the space in between k n o w n 
as the synaptic c lef t . A t this po in t synaptic transmission can occur, by the release o f 
neurotransmitter f r o m the presynaptic terminal to in i t iate a response on the 
postsynaptic membrane. A s w e l l as neurons, there are g l ia l cel ls present in the brain 
wh i ch contr ibute to bra in func t ion by support ing neuronal funct ions. The most 
numerous g l ia in the bra in are astrocytes wh i ch support neurons and regulate the 
extracel lular ion ic and chemical env i ronment o f the bra in. 
The C N S comprises a long cy l indr ica l structure, the spinal cord and its anterior 
expansion, the brain. The brain is suspended in cerebrospinal fluid (CSF) wh i ch also 
f i l l s spaces cal led ventr icles inside the bra in. Th is dense fluid protects the brain and 
spinal cord f r o m shock and supplies neurons w i th in the brain w i t h respiratory gases 
and nutrients and removes waste matter. The human brain is the source o f the 
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conscious and cogni t ive m i n d . The m i n d comprises a set o f cogn i t i ve processes 
related to percept ion, interpretat ion, imaginat ion and memories, o f w h i c h a person 
may or may not be aware. Beyond cogni t ive funct ions, the brain regulates autonomic 
processes related to essential body funct ions such as respirat ion and heartbeat. 
ļ Dendritesy Neuntes 
ノ Axon 
F i g u r e 1.1: The basic parts o f a neuron (Bear et al., 1996). 
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1.3 Anatomy of the Brain 
There are three parts o f the brain that are common to al l mammats, the cerebrum, the 
cerebel lum and the brain stem (Figure 1.2). The cerebrum consists o f two cerebral 
hemispheres wh i ch are separated by a prominent central f issure and connected v ia the 
софиร ca l losum. The outer surface o f the cerebrum is the cerebral cortex. L y i n g 
behind the cerebrum is the cerebel lum, wh i ch is der ived f r o m the La t i n " l i t t le b ra in " . 
The bra in stem fo rms a stalk f r o m w h i c h the cerebral hemispheres and cerebe l lum 
sprout. The spinal cord is attached to the brain stem and is the ma jo r pathway o f 
in format ion f r o m the sk in , jo in ts and muscles o f the body to the brain and vice versa. 
T h a l a m u s a n d 
h y p o t h a l a m u s 
L i m b i c lobe 
Fronta l 
lobe 
C o r p u s 
ca l los i im 
O p t i c ch iasm 
Pa r ieta i lobe 
occ ip i t a l su lcus 
Occi^՝>ital 
lobe 
Pi լ น і ta ry g la n d / \ / \ 
M e d u l ๒ l\ 
S p i n a l co rd 
M i d b r a i n 
C e r e b e l l u m 
F i g u r e 1.2: A medial v iew o f human brain showing anatomical and structural 
organisat ion (Feldman et al" 1997). 
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1.4 Functions of the Brain 
Broadly speaking the brain has three regions, the forebrain, m idbra in and the 
h indbrain. The forebrain is the foundat ion o f perceptions, conscious awareness, 
cogni t ion and voluntary act ion. The cor t ica l neurons o f the cerebral cortex receive 
sensory in fo rmat ion f r o m perceptions o f the outside wo r l d , and command vo luntary 
movements. The thalamus forms an important relay centre, connect ing other regions 
o f the bra in , assisting in the integrat ion o f sensory in format ion . The thalamus conveys 
in fo rmat ion to appropriate areas o f the cerebrum. Pain and pleasure seem to be 
perceived by the thalamus. The hypothalamus role is in cont ro l l ing regions o f the 
autonomic nervous system, where it consists o f two centres, one for sympathetic 
nervous system, and the other for parasympathetic nervous system. Another role o f 
the hypothalamus is to moni tor the compos i t ion o f b lood , in part icular plasma solute 
concentrat ion, hence it is very r ich in supply o f b lood vessels. 
The midbra in acts as an important l i nk between the h indbrain and the forebrain. 
M idb ra in funct ions include rout ing, select ing, mapping and sort ing in fo rmat ion , 
inc lud ing in fo rmat ion perceived f r o m the env i ronment and in fo rmat ion that is 
remembered and processed throughout the cerebral cortex. 
The h indbra in dif ferent iates into the cerebel lum, pons and medul la where i t is an 
important pathway fo r the passage o f in fo rmat ion f r o m the forebrain to the spinal cord 
and vice versa. The cerebel lum is an important movement contro l centre where i t 
receives massive axonal inputs f r o m the spinal cord and the pons. The signals f r o m 
the pons relay in fo rmat ion f r o m the cerebral cor tex, speci fy ing the goals o f intended 
movements. The medul la contains important centres o f autonomic system. These 
centres cont ro l ref lex act ivi t ies, heart rate & b lood pressure. Other act ivi t ies 
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contro l led by the medul la include swa l low ing , cough ing , and the product ion o f sal iva. 
1.5 Neurotransmission 
In regular neurotransmission, an act ion potential f r o m one cel l can result in act ion 
potentials being produced in another ce l l , thus a l l ow ing communica t ion between 
them. Once molecules o f neurotransmitter are released f r o m a cel l as the result o f the 
f i r i ng o f an act ion potent ia l , they b ind to specif ic receptors on the surface o f the 
postsynaptic ce l l . In a l l cases in wh ich these receptors have been cloned and 
characterised in deta i l , i t has been shown that there are numerous subtypes o f receptor 
for any g iven neurotransmitter. As we l l as being present on the surfaces o f 
postsynaptic neurons, neurotransmitter receptors are found on presynaptic neurons. I n 
general, presynaptic neuron receptors act to inh ib i t fur ther release o f neurotransmitter. 
Neurotransmit ter receptors can be d iv ided into t w o types: G-prote in-coupled receptors 
(metabotropic) or l igand-gated ion channel receptors ( ionot rop ic) . 
The integral role o f neurotransmitters on the normal func t ion ing o f the brain makes i t 
clear to see h o w an imbalance in any one o f these chemicals could very possibly have 
serious c l i n i c ฝ impl icat ions fo r an ind iv idua l . B io log ica l dysfunct ion o f synaptic 
transmission o f various neurotransmitters of ten leads to such imbalances and is the 
ul t imate source o f condi t ions such as schizophrenia (glutamate) (Olney and Färber, 
1995), Parkinson's disease (dopamine) (Cotzias et al., 1969), and Alzheimer 's disease 
(acetylchol ine) ( D ' A m a t o et CiL, 1987; Selkoe, 1991). Henry Dale ( rev iewed in 
Tansey, 1991) classi f ied neurons into exclusive groups by neurotransmitter release 
(e.g. chol inerg ic , g lutaminergic, G A B A e r g i c ) . Several substances have been 
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ident i f ied as neurotransmitters. Acety lcho l ine can act as an exci tatory or an inh ib i to ry 
neurotransmitter. A l zhe imer ' ร disease is associated w i t h a decrease i n acety lchol ine-
secreting neurons ( D ' A m a t o et α/., 1987; Selkoe, 1991). Myasthen ia gravis, that is a 
weakness o f skeletal muscles, is a result o f a reduct ion i n acetylchol ine receptors 
(V incent et al., 2001). Serotonin (5—HT) is general ly an inh ib i to ry neurotransmitter 
w h i c h is invo lved w i t h mood , anxiety, and sleep induct ion . Levels o f serotonin are 
elevated in schizophrenia, hence the symptoms o f delusions, hal lucinat ions and 
w i thdrawa l (Tamminga, 1998b). Dopamine is general ly an exci tatory 
neurotransmitter o f the C N S . Parkinson's disease results f r o m the destruction o f 
dopamine-secret ing neurons (Cotzias et al" 1969), but drugs used to increase 
dopamine product ion can cause side effects as the therapeutic index is smal l . A m i n o 
acid neurotransmitters in the C N S , are glutamate and γ-aminobutyr ic acid ( G A B A ) . 
Glutamate is the main exci tatory transmitter whereas G A B A is the main inh ib i to ry 
transmitter in the C N S . G lyc ine is also an inh ib i to ry t ransmit ter ma in ly in the spinal 
cord . C l in i ca l l y , compounds targeted to the glutamate receptor may prevent 
neurological disorders where there is neural degenerat ion f r o m overexci tat ion, fo r 
example, in stroke (Szyd łowska et α/., 2007). O n the other hand, compounds targeting 
G A B A neurons by increasing G A B A func t ion can be used to treat epi lepsy 
(Benetel lo, 1995). Changes in glutamatergic t ransmission have also been invoked to 
exp la in pathologic mechanisms invo lved in stroke (Cho i and Rothman, 1990), 
epi lepsy (Slovi ter , 1991), Parkinson's disease (Tursk i et al, 1991), Hunt ing ton 'ร 
disease (Schwarcz et αΙ·, 1983) and A l zhe imer ' ร disease (Ulas et al., 1992). 
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1.6 L-Glutamate as a Neurotransmitter 
W h e n G A B A was recognised to show inh ib i to ry effects on neurons (Bazemore et al.、 
1956), w o r k by the Curt is et al., (1959) showed that glutamate produced a strong 
exci tatory effect. The f u l l acceptance o f the transmitter role o f L-glutamate was not 
achieved for a fur ther twenty years (Watk ins and Evans, 1981; Foster and Fagg, 1984; 
Watk ins , 1986). The major conclusions reached dur ing the 1980ร were that L-
glutamate was the predominant exci tatory neurotransmitter in the C N S ; i t mediates its 
actions v ia mul t ip le receptors and mal func t ion o f glutamate mediated receptors is 
l i ke ly to be invo lved in certain C N S disorders (Watk ins , 1988; Col l ingr idge and 
Watk ins , 1994). L-glutamate is the pr inc ipa l and ubiqui tous exci tatory transmitter in 
the CNS where its concentrations are higher than elsewhere in the body. Glutamate 
f r o m C N S neurons can originate f r o m either glucose, v ia the Krebs 's cycle, or 
g lu tamine, wh ich is synthesised f r o m gl ia l cells and taken up by neurons (Storm-
Math isen et al., 1986). Glutamate is stored in synaptic vesicles (Na i to and Ueda, 
!983) and upon depolarisat ion o f the nerve.terminal is released by calcium-dependent 
exocytosis. The action o f glutamate is terminated main ly by carrier mediated 
reuptake in to the nerve terminals and neighbor ing g l ia l cel ls. The glutamate taken up 
into g l ia l cells is converted by g lutamine synthetase into g lu tamine, wh i ch is then 
transported into ne ighbour ing nerve terminals, where it serves as a precursor for 
glutamate. L-glutamate acts through a variety o f ionotropic ( l igand-gated ion 
channels) and metabotropic (G-prote in coupled) receptors. There are four main 
subtypes o f glutamate receptors: i ) metabotropic receptors, і і ) a -amino-3-hydroxy-5-
methy l -4- isoxazole propionic acid ( A M P A ) , і і і ) kainate, and i v ) N-methyl-D-aspartate 
( N M D A ) . 
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1.7 Metabotropic Glutamate Receptors (mGluRs) 
The metabotropic glutamate receptors are d iamer ic G-protein coupled receptors 
(GPCRs) , l inked to intracel lular second messenger systems. These second messenger 
systems can ini t iate IP3 product ion and release intracel lular ca lc ium, or can inh ib i t 
adenyly l cyclase. They are located both pre- and postsynaptical ly, as w e l l as on non-
neuronal cel ls. Th is receptor f a m i l y provides a mechanism by wh i ch act ivat ion by 
glutamate can regulate a number o f important neuronal and g l ia l funct ions that are not 
typ ica l ly modulated by l igand gated ion channels (Conn, 2003). They are unusual in 
that they show no sequence homo logy w i t h other GPCRs, and in hav ing a large 
extracel lular N- termina l ta i l , w h i c h contains the glutamate b ind ing site, in contrast to 
most amine receptors, where the agonist b ind ing site is bur ied amongst the 
transmembrane domains. The mGluRs consist o f at least eight d i f ferent subtypes 
(mGluR i -mGluRg) , wh i ch have been classif ied into three groups based on sequence 
homology , pharmacological p ro f i le and coup l ing to intracel lular transduct ion 
pathways (Pin and Duvo is in , 1995; Conn and P in , 1997). Group I mGluRs consist o f 
m G l u i and mGlus ; Group п consist o f mGlu2 and mGlu3; and Group ш consist o f 
mGlu4, mGlUô, mGluy and mGlu8. 
1.8 a-amino֊3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
A M P A receptors, an ionotropic glutamate receptor f am i l y were c loned and expressed 
เท recombinant systems in the late 1980ร (Ho l lmann et al., 1989). The subunit 
constituents o f A M P A receptors are termed GluR | .7 wh i ch is based upon their 
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sequence homo logy . A M P A receptor subunits are approx imate ly 900 amino acids in 
length, and show around 65-75% sequence homo logy between subunits and appear to 
exist in a pentameric structure (see rev iew by Ho l lmann and Heinemann, 1994; 
Fer rer -Mont ie l and M o n t a i , 1996), al though further studies have suggested that they 
may exist w i t h a tetrameric structure (Mano and Teichberg, 1998; Rosemund et ai, 
1998). Each subunit o f the A M P A receptor consist o f three transmembrane domains 
( M l , M 3 and M 4 ) and one reentrant loop w i t h i n the membrane ( M 2 ) ( W o and 
Oswald , 1994; Bennett and Ding led ine, 1995). The M 2 reentrant loop is thought to 
f o r m the channel pore o f the receptor, determin ing the permeabi l i ty o f heteromeric 
receptors to Ca^՝^. A M P A receptors have t w o 150 amino acid sequences ( S I and S2) 
wh i ch are separated by the M 1 - M 3 membrane domains and appear to represent the 
agonist recogni t ion sites (see rev iew by Keinänen et al,、 1997). A M P A receptors 
were or ig ina l ly def ined using quisqualate as an agonist before A M P A was shown to 
be the preferred l igand (B leakman and Lodge, 1998). M a n y A M P A receptor agonists, 
inc lud ing A M P A , have been der ived f r o m classic structure act iv i ty studies using 
ibotenic ac id, quisqual ic acid and wal la rd i ine (Stensbol et ai, 2002). A M P A receptor 
agonists can vary considerably in the amount o f receptor desensit ization that they can 
induce. In i t ia l l y , A M P A compet i t ive antagonists inc luded 6֊cyano-7֊ 
ni t roquinoxal ine-2,3-d ione ( C N Q X ) and 6,7-d in i t ro-quinoxal ine-2,3-d ione ( D N Q X ) 
showed potent compet i t i ve antagonism o f quisqualate and kain i te induced [^H] 
G A B A release f r o m cul tured mouse cort ical neurons w i t h weaker effects on N M D A 
responses (Dre jer and Honore, 1988). However , later studies demonstrated that these 
compounds showed unsurmountable antagonism o f responses to N M D A in the baby 
rat (2-7 days o ld) hemisected spinal cord. Th is showed the effect was mediated v ia an 
act ion at the strychnine-insensit ive glycine receptor, thus lack ing select iv i ty (B i rch et 
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al., 1988). F rom these structures, other compet i t ive antagonists were developed wh ich 
included 2 ,3-d ihydroxy-6-n i t ro -7-su l famoy l -benzo(F)qu inoxa l ine ( N B Q X ) 
(Sheardown et al, 1990) and 1,4,7,8,9,10-hexahydro-9-methyl -6-n i t ropyr ido[3,4- / l -
quinoxal ine-2,3-dione ( P N Q X ) (Ohmor i et al., 1994). Sheardown et al (1990) 
demonstrated N B Q X to be neuroprotect ive in g lobal ischaemia in the gerbi l and 
subsequently in g lobal ischaemia in the rat (Buchan et al., 1991 ; Le Peil let et al., 
1992). A M P A receptor d is t r ibut ion in the C N S has been w ide ly studied using various 
techniques inc lud ing rad io l igand b ind ing o f f u ] A M P A (Monaghan et al., 1984), 
single ce l l R T - P C R (Bochet et al., 1994; Jonas et ai, 1994; Geiger et al., 1995), in 
situ hybr id isat ion histochemistry (Keinänen et al., 1990; V e r d o o m et al., 1991) and 
immunocytochemis t ry using A M P A receptor subunit antibodies (Petralla and 
Wentho ld , 1992). 
1.9 Kainate Receptors 
A n alternative ionotropic glutamate receptor f a m i l y is the kainate receptors that 
respond to both glutamate, wh i ch is their phys io log ica l l igand, or kainate wh ich is a 
drug f i rst isolated f r o m red alga Digenea simplex. Kainate receptor pharmacology and 
pathophysio logy are far less def ined than fo r A M P A receptors. The subunits 
compr is ing kainate receptors are termed G l u R 5 - G l u R 7 and K A 1 - K A 2 and were 
cloned showing h igh a f f in i t y b ind ing for [Зщ kainate (Werner et al., 1991; Herb et 
al., 1992; Kambo j et al., 1994). K A I and K A 2 share around 7 0 % sequence homology 
but less than 4 0 % homo logy w i t h the A M P A receptor subunits G l u R l - 4 . K A l and 
K A 2 subunits are w ide l y distr ibuted in the mammal ian C N S (Be t t๒r et ai, 1990; 
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Egebjerg et al., 1991 ; L o m e l i et al., 1992; Wisden and Seeburg, 1993) inc lud ing the 
cerebel lum, h ippocampus and the spinal cord. Kainate receptors have classical ly been 
impl icated in epileptogenesis where an intraperitoneal in ject ion o f kainate is used as a 
model for temporal lobe seizures. 
1.10 N-methyl-D-aspartate (NMDA) Receptor 
The N M D A receptor is a heteromeric l igand-gated ion channel in the C N S . N M D A 
receptors have a h igh density postsynaptical ly, a l though they are present 
presynaptical ly. Chemica l cross l ink ing studies and size exc lus ion chromatography 
have estimated a size o f native N M D A receptors to be ~730kDa (Brose et al., 1993) 
given the size o f N R l (~120kDa) and N R 2 (~160-180kDa) , results indicate a 
pentameric sto ichiometry, w i t h a subunit assembly that show d i f ferent phys io log ica l 
and pharmacological properties and are d i f ferent ia l ly d ist r ibuted throughout the CNS 
(Seeburg, 1993; Ho l lmann and Heinemann, 1994; M c B a i n and Mayer , 1994; Danysz 
et al., 1995). Debate is s t i l l ongo ing whether the receptors have a tetrameric or 
pentameric structure, as a number o f research groups, i nc lud ing Wen tho ld et al, 
1992; Sutc l i f fe et ai, 1996, Premkumar and Auerbach, 1997 & HawWn^ et al., 1999 
reported i t as a pentameric structure. M o r e recent ly, Laube et al., (1998) 
demonstrated that N M D A receptors show tetrameric assemblies. Each subunit 
consists o f a large extracel lu lar amino terminal doma in , three transmembrane 
hydrophobic regions, M l , M 3 & M4， wh i ch transverse the membrane, and an 
intracel lular carboxy termina l . The M 2 transmembrane domain forms a reentrant loop 
in the membrane, f o rm ing the channel pore (Figure 1.3). There are three fami l ies o f 
N M D A receptor subunits w i t h various combinat ions o f N R l , N R 2 A - D and N R 3 A - B 
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subunits producing unique receptors w i t h d is t inct ive pharmacologica l and 
b iochemical properties. The N R l subunit exists as eight dist inct isoforms wh ich arise 
v ia the insert ion or delet ion o f three short exon cassettes in the N- termina l (N1 ) and 
C-terminal ( С І , C2) domains o f the subunit protein (Ho l lmann et al., !993) . These 
are designated N R l - l a , N R l - l b to N R l - 4 a , and N R l - 4 b that are generated by 
di f ferent ia l messenger r ibonucleic acid ( m R N A ) . The N R 2 subunits are 40 -70% 
homologous to one another, but are on ly 18% homologous to N R l . The N R 3 A - B 
subunit f am i l y was described by Das et al., 1998 and Chatterton et al., 2002. NR3 
subunits do not appear to f o r m funct ional N M D A receptors when expressed together 
w i t h either N R l or N R 2 subunits alone (i.e. N R 1 / N R 3 or N R 2 / N R 3 contain ing 
receptors), wh i le it has been reported that N R 3 subunits expressed i n Xenopuร oocytes 
along w i t h N R l f o r m exci tatory g lyc ine receptors that are unaffected by glutamate or 
N M D A (Chatterton et ai, 2002) , al though controversial as other laboratories have 
been unable to reproduce these f ind ings. When expressed in combinat ion w i t h both 
N R l and N R 2 subunits, NR3 subunits suppress N M D A channel un i tary conductance 
and Ca 2 + permeabi l i ty relat ive to N R 1 / N R 2 conta in ing receptors (Ciabarra et al., 
1995; N ish i et al., 2 0 0 1 ; Matsuda et ai, 2002; Sasaki et ai, 2002) . The N M D A 
receptor subunits focused on in this thesis are N R 1 / N R 2 B and N R 1 / N R 2 A / N R 2 B 
combinat ions. Therapeut ic signif icance o f non-selective antagonists and blockers o f 
the N M D A receptor has been l im i ted by the extensive side effects, inc luding 
psychotomimet ic symptoms and effects on learning and memory . Specif ic 
antagonists o f the N R 2 B subunit may have the ab i l i t y to show better potent ial as 
therapeutic reagents due to their h igh a f f in i t y and improved select ivi ty. 
Consequent ly, i t should be possible to develop drags that are selective or specif ic to 
part icular combinat ions o f subunits. 
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F i g u r e 1.3: ( А ) The N M D A receptor showing the large extracel lu lar amino domain , 
three transmembrane domains ( M l , M 3 & M 4 ) and the reentrant loop ( M 2 ) and the 
intracel lu lar carboxy domain . (B) The structures o f the channel pore where the 
reentrant loop ( M 2 ) forms the opening o f the N M D A receptor (W i l l i ams , 1997). 
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1 Л 0 Л N M D A F u n c t i o n a l P r o p e r t i e s 
Funct ional N M D A receptor complexes are fo rmed w i t h an obl igatory N R l subunit 
w i t h at least one N R 2 subunit, wh ich can be a combinat ion o f N R l , N R 2 A - D and/or 
N R 3 A - B subunits. Pharmacological and funct ional properties o f the N M D A receptor 
are h igh ly dependent on the compos i t ion o f the receptor complex due to the 
d is t r ibut ion o f the various N M D A receptor populat ions in the C N S . For example, 
N R 1 / N R 2 C compounds w o u l d p r imar i l y target the cerebel lum (Wenze l et al., 1997), 
whereas N R 1 / N R 2 B antagonists w o u l d predominant ly target the hippocampus, 
cerebral cortex, str iatum and the o l factory bulbs (Luo et α/., 1997; Charton et al,, 
1999). 
N M D A receptors are act ivated by glutamate and co-agonist g lyc ine, where the 
b ind ing site f o r g lyc ine is located on the N R l subunit (Kurya toV et ai, 1994; W a f f o r d 
et al., 1995; H i ra i et al., 1996; K e w et al, 2000) and the b ind ing site for glutamate is 
located on the N R 2 subunit (Laube et al., ! 997 ; Anson et αι., 1998). The glutamate 
b ind ing site is understood to act l ike a venus f l y trap (Madden, 2002) where regions 
S I and S2 changes conformat ion f o l l o w i n g act ivat ion (Figure 1.4). A t resting 
membrane potent ia l , the N M D A receptor is b locked in a voltage-dependent manner 
by Mg2+， meaning act ivat ion occurs f o l l o w i n g depolarisat ion o f the postsynaptic 
membrane. The most f requent ly used agonist at the glutamate recogni t ion site o f 
N M D A receptor is N M D A i tsel f w h i c h is a synthetic analogue o f L-glutamate 
(Watk ins , 1962), where i t shows sl ight select iv i ty between receptor subtypes. Other 
selective agonists include aspartate, quinol inate and homocysteate. Co-agonist fo r the 
g lyc ine b ind ing domain is p r imar i l y g lyc ine, but other co-agonists include D-serine 
and D-cycloserine. 
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F i g u r e 1.4: Co- local isat ion o f residues in f luenc ing proton sensi t iv i ty o f N M D A 
receptor ( L o w et al., 2003). 
1.10.2 N M D A M o d u l a t o r y B i n d i n g S i tes 
There are numerous sites on the N M D A receptor that can act to inh ib i t , activate or 
enhance the func t ion o f the receptor inc lud ing the po lyamine site, z inc b ind ing 
domain , as w e l l as reduct io๙oxidat ion and p H sensor sites (Kemp and McKeraan , 
2002). N M D A receptors are coupled to h igh conductance cat ionic channels 
permeable to K+， Na+ and Ca^^ ( M c B a i n and Mayer , 1994) (Figure 1.5). The property 
o f h igh Ca^^ permeabi l i ty render N M D A receptors suitable fo r their ro le in mediat ing 
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synaptic plast ic i ty, wh i ch underl ie learning processes and development (CoUingr idge 
and Singer, 1990; Danysz et al, 1995). The zinc modulatory site on the extracel lu lar 
surface o f the receptor inhib i ts N M D A receptor funct ion in a voltage-dependent 
manner. Endogenous po lyamineร, spermidine and spermine, appear to modulate 
N M D A receptor funct ion by various mechanisms. Sacaan and Johnson (1989) 
postulated that polyamineร enhanced the b ind ing o f g lyc ine to N M D A receptors in 
sub-saturating concentrat ions showing glycine-dependent s t imulat ion. In saturating 
concentrations ( < 2 0 0 n M ) o f g lyc ine, po lyamineร st imulate receptor opening, showing 
glycine- independent s t imulat ion (W i l l i ams et al., 1990; Lynch et al, 1995), whereas, 
in higher concentrations ( > 2 0 0 n M ) o f g lyc ine, polyamineร b lock N M D A receptors in 
a voltage-dependent manner (Rock and MacDona ld , 1992a&b) and hence decrease 
the a f f in i ty o f the receptor fo r glutamate (W i l l i ams et al.y 1995). 
1.10.3 S y n a p t i c P l a s t i c i t y 
Synaptic plast ic i ty is the ab i l i ty o f the connect ion, or synapse, between two neurons to 
change in strength. There are several under ly ing mechanisms that co-operate to 
achieve synaptic plast ic i ty, inc lud ing changes in the amount o f neurotransmitter 
released into a synapse and changes in how ef fect ive ly cells respond to those 
neurotransmitters (Gaiarsa et al., 2002). Since memories are postulated to be 
represented by vast ly interconnected networks o f synapses in the bra in , synaptic 
plast ic i ty is one o f the important neurochemical foundat ions o f learning and memory . 
N M D A receptors appear to p lay a p ivo ta l ro le in long term depression ( L T D ) , long 
term potent iat ion ( L T P ) and developmental plast ic i ty. L T P is a long- last ing 
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enhancement o f the effectiveness o f synaptic t ransmission that is induced by brief, 
h igh-f requency afferent s t imulat ion. Prolonged low- f requency st imulat ion can 
produce a related phenomenon termed L T D , w h i c h involves a reduct ion in synaptic 
ef f icacy. L T P has been found in various brain areas (see Tsumoto , 1992) but was f i rst 
demonstrated by Bl iss and Lømo (1973) in the h ippocampus. The N M D A receptor 
has been accepted as a cr i t ica l step in the in i t ia t ion o f L T P f o l l o w i n g Ca2+ entry in to 
the postsynaptic ce l l , where the receptor must be i n the appropriate state fo r L T P to be 
induced. D is rup t ion o f the N M D A receptor, i n part icular the N R l subunit led to early 
postnatal death o f transgenic mice (Forrest et CiL, 1994). Moreover , mice that 
overexpress N R 2 B subuni t exhib i t enhanced h ippocampal L T P , pro longed N M D A 
receptor currents and improved memory (Tang et al" 1999). L T P , L T D and spatial 
learning are important mechanisms o f synaptic p last ic i ty as these require the 
act ivat ion o f N M D A receptors in the hippocampus. 
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F i g u r e 1.5: The N M D A receptor showing the b ind ing o f both glutamate and g lyc ine 
together w i th modulatory sites inc lud ing Mg^^^ site, po lyamine site, redox reagent site, 
H+ sites & the PCP b ind ing site (Feldman and Quenzer, 1984). 
38 
1.10.4 N M D A R e c e p t o r D i s t r i b u t i o n i n t h e C N S 
1 Л 0 . 4 Л Exp ress ion o f N M D A Recepto rs 
The expression o f N M D A receptors in the developing and adul t brain, has been 
ident i f ied using in situ hybr id isat ion. Messenger r ibonucleic ac id ( m R N A ) encoding 
the N R l subunit is d istr ibuted throughout pre- and postnatal development (Watanabe 
et al., 1993; Taka i et ai, 2003). In developing rats, N R l m R N A levels in the cortex 
and hippocampus increase nearly three f o l d f r o m postnatal day 3 to day 15 and 
approx imate ly doubled f r o m day 15 to day 67 (Frank l in et α/., 1993; R iva et al., 1994; 
N o w i c k a and Kaczmarek, 1996). In contrast, cerebel lum and bra in stem showed no 
change in N R l m R N A levels between postnatal days 3 and 15 but levels also doubled 
f r o m day 15 to day 67 (Frank l in et ai, 1993). S imi lar f ind ings were also found by a 
d i f ferent group, a l though they found that expression levels in the h ippocampus peaked 
at postnatal day 10 and decl ined f r o m then on (Puj ic et fl/., 1993). The highest levels 
o f m R N A encoding N R l in the adult rodent brain are found in the o l factory bu lb , and 
the lowest levels are seen in the spinal cord. Intermediate levels are found in the 
f rontal cortex, h ippocampus and cerebel lum (Frank l in et al., 1993; Akazawa et al" 
1994). S imi la r f ind ings o f the expression levels have also been reported when using 
antibodies to N R l subunits (Petral la et al" 1994; Benke et й/.， 1995; Thompson et ai, 
2000, 2002). 
The modulatory subunits, N R 2 A - D , are d i f ferent ia l ly expressed (Watanabe et ai, 
1993; Taka i et ai, 2003) in the C N S . F r o m in situ hybr id isat ion analyses (Monyer et 
α/., 1992; Watanabe et al,、 1994; Wenze l et al" 1997; Ra f i k i et ai, 1998; Goebel and 
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Poosch, 1999), the d is t r ibut ion o f the m R N A levels o f the N R 2 A - D show specif ic 
developmental regulat ion throughout the bra in. The N R 2 A subuni t is expressed 
postnatal ly in the brain. N R 2 B subunits are w ide ly expressed throughout the entire 
embryonic brain and f r o m the early stage o f development, but expression is restricted 
to the forebrain postnatal ly ( M o r i and M ish ina , 1995; Wenze l et al., 1997). The 
N R 2 C subunit appears postnatal ly and is prominent in the cerebel lum. The N R 2 D 
subunit is ma in ly present in the diencephalon and the brainstem at embryonic and 
neonatal stages (Watanabe et al., 1993; Takai et al., 2003). The N R 3 subunit is 
abundant w i t h i n the late prenatal and early postnatal brain development (รนท et al., 
1998). Highest levels o f N R 3 A are expressed in the neocortex, thalamus, amygdala 
and sub icu lum (Ciabarra et al., 1995; Sucher et al., 1995; W o n g et al., 2002). NR3 
subunits show restricted spat io-temporal d istr ibut ions w i t h N R 3 A being 
predominant ly expressed dur ing development, a l though expression in certain neuronal 
populat ions persists in adults, and N R 3 B restricted to somatic motoneurones o f the 
brainstem and spinal cord (N ish i et al., 2 0 0 1 ; Chaf fey and Chazot, unpubl ished). 
In situ hybr id isat ion does not clearly define expression o f the resultant protein 
subunits in the C N S . Immunocy tochemica l local isat ion studies have shown N R l 
protein levels to be prominent in al l bra in areas, wh ich is consistent w i th m R N A 
expression (Brose et al., 1993). N R 2 A protein is found throughout the brain but 
highest levels are detected in the hippocampus, cerebral cor tex, thalamus, cerebel lum 
and str iatum (Wenzel et al., 1995; L u o et al., 1997; Thompson et al., 2000). The 
N R 2 B subunit is predominant ly found i n the h ippocampus, cerebral cortex, str iatum 
and the o l factory bulbs (Luo et al., 1997; Charton et al., 1999). In accordance w i t h 
m R N A levels, N R 2 C protein is almost exclusively expressed in the cerebel lum 
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(Wenzel et al., 1997). N R 2 D subunits are restricted to the spinal co rd , brainstem 
regions, s t r ia tum, thalamic regions and the o l factory bulbs (Dunah et ๗., 1998). 
1.10.4.2 B i o c h e m i c a l Ev i dence f o r N M D A Recep to r Sub types 
Funct ional N M D A receptor complexes require an obl igatory N R l subuni t w i t h at 
least one N R 2 subunit ; a combinat ion o f N R l , N R 2 A - D and/or N R 3 A - B subunits 
(Figure 1.5). The f i rs t group to demonstrate that N R l and N R 2 subunits do coexist in 
adult and develop ing bra in , by immunoprec ip i ta t ion using N M D A receptor subunit-
specif ic antibodies was Sheng et al (1994) . Th is study invest igated the actual 
compos i t ion o f the N M D A receptors in the rat neocortex where the subunits are 
present as heteromeric complexes o f considerable heterogeneity. These studies 
imp l ied , but d id not demonstrate that N R l , N R 2 A and N R 2 B subunits coexisted 
w i t h i n a receptor complex. Further studies using a combinat ion o f immunoa f f i n i t y 
chromatography and immunoprec ip i ta t ion , have shown direct ly the co-associat ion o f 
N R l , N R 2 A and N R 2 B subunits i n an N M D A receptor subpopulat ion o f adult 
mammal ian brain (Chazot and Stephenson, 1997b). Pharmacological and funct ional 
properties o f the N M D A receptor are h igh ly dependent on the compos i t ion o f the 
receptor complex. 
1.10.5 D r u g T a r g e t s o f t h e N M D A R e c e p t o r 
The N M D A receptor is the focus o f drug development for therapy and prevent ion o f 
numerous neurological and psychiatr ic disorders. Excessive act ivat ion o f N M D A 
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receptors produces an increase o f glutamate causing exc i to tox ic i ty o f the C N S wh i ch 
is impl icated in various neurological condi t ions inc lud ing ischemic neuronal cel l 
death and epi lepsy (Cho i and Rothman, 1990; D ing led ine et al., 1990). Abno rma l 
expression, funct ion or regulat ion o f N M D A receptors may be invo lved in psychoses 
and some neurodegenerative disorders (Cho i , 1988; Carlsson and Carlsson, 1990). 
Pathological ly , glutamate acting as an exc i to tox in can be invo lved in extending the 
damage o f an acute cerebral i n ju ry such as stroke or in i t ia t ing neurodegeneration in 
chronic i l lness such as epi lepsy or Hunt ing ton 'ร chorea (Whetsel l and Shapira, 1993). 
Agents that b lock the N M D A receptor, fo r example, ketamine, have been shown to 
al leviate pain in human c l in ica l tr ials. However , the smal l therapeutic w i n d o w relat ive 
to side effects, such as, hal lucinat ions, dysphor ia, and loss o f co-ord inat ion, make 
these compounds unattract ive for chronic pain therapy (Hock ing and Cousins, 2003). 
Therefore, benef ic ia l treatments o f such cases need to target the N M D A receptor to 
b lock or reduce N M D A receptor act iv i ty , or potentiate the act iv i ty o f the receptor. 
1.10.5.1 Non-select ive N M D A An tagon i s t s 
Therapeutic s igni f icance o f nonselective antagonists and blockers o f the N M D A 
receptor has been l im i t ed by the extensive side effects, inc lud ing psychotomimet ic 
symptoms and effects on learning and memory . For example, N M D A receptor 
antagonists that funct iona l ly inh ib i t N M D A receptors can w o r k in three ways. F i rs t ly 
v ia the phencycl id ine (PCP) site o f the receptor situated in the channel pore. 
A l ternat ive ly , by compet i t ive antagonism b ind ing to the pr imary transmitter site, or 
by b ind ing to the strychnine-insensit ive g lyc ine site (G lyc ine в site). [ 3 H ] M K - 8 0 1 
binds to the activated state o f the N M D A receptor comp lex ; i t has been used as a 
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funct ional assay in vitro to investigate modula t ion by ion channel blockers ( W o n g et 
al. y 1988), glutamate and g lyc ine recogni t ion site l igands (Foster and W o n g , 1987; 
Foster et al.， 1992) and polyamineร (W i l l i ams et al, 1989). These non-selective 
N M D A receptor antagonists al l show inadequate select iv i ty and therefore cause many 
unwanted side effects. Consequently, due to the d ivers i ty o f the N M D A receptor 
subtypes, there is encouragement to develop more selective compounds to a part icular 
receptor subtype wh i ch lack the side effects o f the nonselective antagonists. 
1.10.5.2 Select ive N M D A An tagon is t s 
Researchers are st i l l developing new l igands that b lock or reduce the act iv i ty o f 
N M D A receptors for therapeutic benefi t as neuroprotect ive agents, anticonvulsants 
and analgesics. It is thought that inappropriate act ivat ion o f N M D A receptors are 
invo lved w i t h a number o f neurodegenerative and psychiatr ic disorders (see Section 
1.10.6). Non-compet i t i ve antagonists, i fenprod i l and haloper ido l are subtype 
selective N M D A receptor antagonists specif ic to the NR2B-con ta in ing receptor 
(W i l l i ams , ! 993 ; W i l l i a m s et al., 1994; Lynch et ๘.， 1995; I l y i n et al., 1996; L y n c h 
and Gal lagher, 1996; Coughenour and Cordon, 1997). I fenprod i l was or ig ina l ly 
k n o w n as a ai-adrengeric antagonist, but its N M D A act iv i ty was discovered in the late 
1980ร showing that i fenprod i l was an N M D A antagonist w i t h a novel 
pharmacological p ro f i le (Carter et al.， 1988; Reynolds and M i l l e r , 1989). I fenprod i l 
b locks severฝ other types o f receptors and channels inc lud ing voltage dependent Ca^"^ 
channels (Adeagbo, 1984; B i t on et ai, 1995) and σ-sites (Contreras et ai, 1990), 
showing it is not ideal due to its lack o f overal l receptor select iv i ty. Ha loper ido l is a 
dopaminergic antagonist wh ich has an 8-10- fo ld higher a f f i n i t y for N M D A receptors 
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contain ing the N R 2 B subunit compared to other N M D A receptors thus showing the 
same subunit speci f ic i ty as i fenprod i l ( I l y i n et al., 1996; L y n c h and Gallagher, 1996). 
T w o compounds wh ich are structural ly s imi lar to i fenprod i l and haloper idol are CP 
101,606 [{R *, R * ) -4 -hydroxy- (4 -hydroxypheny l ) -ß-methy l -4 -pheny l -1 -piper i d ine-
ethanol] and Ro 25,6981 [(R:(*),S(* ; )֊a-(4-hydroxyphenyl)-ß-methyl-4-
(pheny lmethy l ) -1 -p iper id inepropanol [ (+ / - ) -Ro 25-6981] ] (Figure 1.6), have been 
developed as h igh a f f in i ty N R 2 B subunit specif ic antagonists (Chenard et al, 1995; 
Br imecombe et al., 1998; Mu te i et al., 1998; Tamiz et al., 1998). These al l b ind to a 
s imi lar recogni t ion site, termed the i fenprod i l site (Figure 1.7) and are selective for 
the N R 2 B subuni t -containing receptors. CP 101,606 and Ro 25,6981 are 
phenylethanolamines and act by an interact ion w i t h one o f the po lyamine recogni t ion 
sites o f the receptor complex by increasing the sensi t iv i ty o f the receptor to negative 
modulat ion by protons ( K e w and Kemp , 1998; M o t t et al., 1998). Ro 25,6981 shows 
no a f f in i ty for the non-compet i t ive b ind ing sites o f phencyc l id ine (PCP) and (+) -5-
methyl -10,11 -d ihydro-5^-d ibenzo[a , í í |cyc lohepten-5 ,10- imine ( M K - 8 0 1 ) (Fischer et 
al., 1997; Mu te i et al.' 1998; L y n c h et al., 2001). Ro 25,6981 binds N R 1 / N R 2 B and 
N R 1 / N R 2 A / N R 2 B subtype receptors w i t h s imi lar h igh af f in i t ies , indicat ing Ro 
25,6981 to be selective for al l NR2B-con ta in ing subtype receptors (Hawk ins et al., 
1999). CP 101,606 shows further select iv i ty as it can dist inguish between 
N R 1 / N R 2 A , N R 1 / N R 2 B and N R 1 / N R 2 A / N R 2 B subtype receptors showing h igh 
select iv i ty for N R 1 / N R 2 B as has been shown in single channel record ing (Br imcombe 
et al., 1997) and in cy to tox ic i ty studies (Boeckmann and A i zenman , 1996). 
Ro 25,6981 and CP 101,606 are rout inely used as reference compounds in research o f 
NR2B-se lect ive N M D A receptor antagonists. There are many new NR2B-se lect ive 
N M D A receptor antagonists in development f r o m major pharmaceut ical companies 
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based on the funct ional groups required for b ind ing in the structure o f i fenprod i l , fo r 
example, the compound investigated in this thesis, RGH-896 (Figure 1.8). Throughout 
this thesis, one o f the testing hypothesis is that RGH-896 w i l l resemble Ro 25,6981 
closer than CP 101,606 fo r its N M D A subtype select iv i ty. 
45 
H a l o p e r i d o l 
OH R o 25,6981 
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R G H - 8 9 6 
F i g u r e 1.6: Chemica l Structure o f N M D A Antagonists 
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NT 
Glutamate 
F i g u r e 1.7: The i fenprod i l b i nd ing doma in showing a hydrophob ic ring for the phenyl 
r i ng , an electrostatic pocket fo r the central basic n i t rogen, a hydrophob ic and H-bond 
acceptor pocket for the phenol group (Chazot, 2004) 
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F i g u r e 1.8: Chemica l structure o f NR2B-select ive N M D A antagonists in 
development f r o m major pharmaceut ical companies (McCau ley , 2005). 
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1.10.6 T h e r a p e u t i c T a r g e t s f o r N R 2 B s u b u n i t - s e l e c t i v e N M D A A n t a g o n i s t s 
N R 2 B subunit-selective N M D A antagonism may have therapeutic appl icat ions for 
many C N S disorders. These antagonists show better potent ial as therapeutic reagents 
due to their h igh a f f in i t y and improved select ivi ty. The N R 2 B selective compound 
i fenprod i l has shown to have neuroprotect ive effects in an imal models o f stroke 
w i thout the unwanted side effects associated w i t h non-selective N M D A antagonists 
(Got t i et al, 1988). Th is study showed that i fenprod i l was able to reduce in farct ion 
vo lume in a dose-dependent manner, when administered after m idd le cerebral artery 
occlusion in the cat (Got t i et al, 1988). M o r e recently, CP 101,606 and Ro 25,6981 
have shown neuroprotect ive effects in animal models, producing m i n i m a l side effects 
at max ima l l y neuroprotect ive doses (Kemp et al, 1999). Consequent ly, there are 
potent ial therapeutic targets for N R 2 B subunit-selective antagonists wh ich are 
discussed in detai l be low. 
1.10.6.1 Pa in 
Pain is a disabl ing accompaniment o f many medical condi t ions; consequently pain 
contro l is o f great importance. N M D A receptors have been reported to have an 
invo lvement w i t h the induct ion and maintenance o f central sensit isation dur ing pain 
states. N M D A receptors are important in the plast ic i ty o f the synaptic processes o f the 
nervous system, such as sensit isation o f the nocicept ive pathways (Sandkuhler, 2000). 
In the !980ร, two groups recognised that N M D A antagonists inh ib i ted the 
hyperexc i tab i l i ty o f spinal cord nocicept ive neurons induced by C- f ibre s t imulat ion 
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(Davies and Lodge, 1987; D ickenson and Su l l i van , 1987). In animal studies, N R 2 B -
selective antagonists are ant inocicept ive at doses be low those that impa i r motor 
coord inat ion and show st imulant act iv i ty (Boyce et αΐ.' 1999; Ch izh et al, 2001). A 
study by W e i et al (2001) ut i l ised mice overexpressing N R 2 B receptors in the 
forebrain and demonstrated enhanced pain behaviour compared w i t h cont ro l animals, 
suggesting a potent ial cort ical site o f act ion o f N R 2 B receptor antagonists. The 
N R 2 B subuni t -containing receptors are thought to p lay an important role in pain 
states; hence NR2B-select ive antagonists target ing the dorsal horn o f the spinal cord 
(Boyce et al., 1999) or the anterior c ingulate cortex ( W e i et al., 2001) may be useful 
f o r the treatment o f chronic pain. The restr icted d is t r ibut ion o f the N R 2 B receptors 
makes them promis ing candidates as targets o f side effect free analgesic drugs 
(Gurw i t z and We izman , 2002). 
1.10.6.2 H u n t i n g t o n ' s Disease 
Hunt ing ton 's Disease ( H D ) is an autosomal dominant ly inheri ted neurodegenerative 
disorder characterised by progressive brain deter iorat ion, wh ich commences in 
adul thood w i th progressive degeneration and death. I t is characterised by 
ext rapyramidal movement disorder, cogn i t ive func t ion and behavioural changes 
(Kremer et al., 1992). N M D A receptor-mediated exc i to tox ic i ty has been suggested to 
be invo lved in the pathogenesis o f H D . H D results f r o m the expansion o f 
po lyg lu tamine repeat in the protein designated huntingtin (hit), in the N-terminus o f 
the receptor. H D is main ly affected by the neurodegeneration o f striatal medium-s ized 
spiny project ion neurons, where expression o f the N R 2 B subuni t -contain ing receptor 
is increased relat ive to other N R 2 conta in ing subunits ( L i et al., 2003). Fur thermore, 
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the earliest changes associated w i t h neuronal expression o f mutant hit are increased 
N M D A receptor-mediated current, disrupted ca lc ium homeostasis and enhanced 
vu lnerab i l i ty to N M D A - m e d i a t e d exc i to tox ic i ty ( L i et al., 2004). Th is creates the 
prospect that a selective interact ion o f mutant htt w i t h N R l /NR2B-sub type N M D A 
receptor may expla in the selective suscept ibi l i ty o f medium-s ized spiny project ion 
neurons in H D . Therefore, an interact ion between htt and NR2B-con ta in ing N M D A 
receptors in the early neurodegeneration o f H D , support the use o f NR2B-se lec t ive 
antagonists in the presymptomat ic or early stages o f the disease. 
1.10.6.3 s t r o k e 
A n ischemic stroke occurs when a b lood c lot b locks a b lood vessel or artery, or when 
a b lood vessel breaks, interrupt ing b lood flow to an area o f the brain causing a chain 
reaction cal led the " ischemic cascade". The only current ly approved stroke therapy, 
tissue plasminogen activator, is a th romboly t ic that targets the thrombus w i t h i n the 
b lood vessel. In the ischemic bra in there is an excessive amount o f glutamate in the 
extracel lular space (Szatkowski and A t t w e l l , 1994; Rossi et ai, 2000) wh i ch is 
thought to induce hyperact ivat ion o f N M D A receptors causing an i n f l ux o f Ca^"^ in to 
neurons and u l t imate ly leading to cel l death (Rothman and Olney, 1986; Cho i and 
Rothman, 1990). N M D A receptor antagonists, in part icular, g lyc ine-b ind ing site 
antagonists are been tested in animal models o f stroke to inh ib i t hyperact ivat ion o f 
N M D A receptors. B y targeting the g lyc ine site on the N M D A receptor, the r isk o f 
unwanted adverse effects seen w i t h non-selective N M D A receptor antagonists and 
channel blockers are reduced. Med ia l cerebral artery occlusions ( M C A O ร ) are a 
pathological ha l lmark o f stroke patients. A recent study using electrocoagulat ion o f a 
uni lateral m idd le cerebral artery distal to the o l factory tract using spontaneously 
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hypertensive rats, demonstrated a g lyc ine-b ind ing site antagonist SM-31900 showed 
signi f icant neuroprotect ive effects even when administered one hour f o l l o w i n g 
M C A O (Ohtani et al., 2002, 2003) . Other investigators target ing the g lyc ine b ind ing 
site have reported a reduct ion in infarct vo lume when treatment is in i t iated 10 minutes 
(Takaoka et ai, 1997), зо minutes (Takáno et al., 1997), one hour (Tanaka et al., 
1995) or six hours (Bord i et al., 1997; Reggiani et al., 2001) after M C A O . The use o f 
g lyc ine-b ind ing site antagonists may prove benef ic ia l i n the treatment o f stroke in the 
future. 
1.10.6.4 P a r k i n s o n ' s Disease 
In Parkinson's disease (PD) , degeneration o f the dopaminergic nigrostr iatal pathway 
leads to enhanced transmission at N M D A receptors conta in ing N R 2 B subunits. 
Accord ing ly , pharmacological dopamine replacement w i t h chronic 1-3,4-
d ihydroxyphenyla lan ine ( L - D O P A ) treatment represents the most ef fect ive 
therapeutic opt ion (Lang and Lozano, 1998). However , al though L - D O P A is ef fect ive 
therapeutical ly, i t also possesses a narrow therapeutic index, d isabl ing adverse 
compl icat ions can occur inc lud ing motor fluctuations and dyskinesias (Obeso et al., 
2000). N M D A receptor antagonists have been shown to potentiate the actions o f L-
D O P A in rats, and the l ow a f f in i t y N M D A antagonist amantadine has been shown to 
improve L -DOPA- induced dyskinesias in humans (De l Dot to et al., 2 0 0 1 ; Mar ino et 
al., 2003). N M D A receptor antagonists have also been shown to potentiate the actions 
o f dopamine receptor agonists in animal models o f PD suggesting these compounds 
may be benef ic ia l fo r the treatment o f P D (K lockgether and Tu rsk i , 1990). I fenprod i l 
showed ef f icacy in ге5Єфіпе-ІгеаІесі rat mode l o f PD , as w e l l as in l -methy l -4 -
phenyl-1,2,3,6- tetrahydropyr id ine (MPTP)- t reated marmosets (Nash et al., 1999; 
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Nash et al., 2000) ; however , a smal l c l in ica l t r ia l in wh ich i fenprod i l was used as an 
add-on therapy w i t h L - D O P A in PD pateients fa i led to demonstrate s igni f icant 
therapeutic benef i t (Montastruc et al, 1992). Ro 25,6981 and CP 101,606 have been 
characterised in vivo where Ro 25,6981 has potentiated the act ion o f dopamine 
receptor agonists in lesioned rats (Löschmann et ed., 2004). Steece-CoUier (2000) 
studied the ant iparkinsonian effects o f CP 101,606 in rodents and non-human 
primates. In rats, CP 101,606 decreased haloper idol catalepsy, whereas in M P T P -
treated monkeys, the selective antagonist reduced parkinsonian motor symptoms by 
- 2 0 % . Another study using MPTP- les ioned parkinsonian monkeys treated w i t h 
levadopa were g iven an N M D A antagonist L Y 2 3 5 9 5 9 and this s ign i f icant ly 
attenuated dyskinesias (Papa and Chase, 1996). More recently, intracerebral 
pharmacological studies in a rat model o f P D suggests an overact iv i ty o f N R 2 B -
contain ing N M D A receptors w i th in the st r ia tum is responsible for mediat ing 
park insonism (Nash and Brotch ie, 2002). As a result, these precl in ical data, taken 
together w i t h results f r o m c l in ica l studies o f N M D A receptor antagonists, suggest that 
NR2B-se lect ive antagonists ho ld therapeutic u t i l i t y as ant iparkinsonian agents. 
1.10.6.5 A l z h e i m e r ' s Disease 
Alzhe imer ' ร disease ( A D ) is a progressive neurodegenerative disease characterised by 
mental deter iorat ion w i t h d i f fuse neuronal loss. A m y l o i d - ß peptide is elevated in the 
brains o f patients w i t h A D and is bel ieved to be causative in the disease process. 
Recent f ind ings have demonstrated that non- tox ic amounts o f secreted amylo id-ß 
peptide reduce synaptic plast ic i ty and glutamatergic transmission (Kamenetz et al., 
2003). N M D A receptors play a p ivota l role in the synaptic mechanisms o f learning 
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and memory (Bl iss and Co l l ingr idge, 1993). M e m o r y is one o f the earliest cogni t ive 
funct ions to be affected dur ing the normal aging process (A lber t and Funkenstein, 
1992). There are declines in expression o f N M D A receptors w i t h increasing age in 
humans (Piggott et al., 1992), monkeys (Wenk et ai, 1991), dogs (Magnusson et al., 
2000), rats (Tamaru et al., 1991) and mice (Magnusson, 2001) . Changes in both 
N M D A receptor b ind ing and m R N A expression o f the ε2 ( N R 2 B ) subunit in the 
prefrontal cort ical regions in mice have been shown to be related to wo rk ing memory 
def ic i ts (Ba i et al., 2002). A further study by Ba i et al (2004) in macaque monkeys 
revealed a s igni f icant decrease in m R N A expression o f N R 2 B subunit in the 
prefrontal cortex and the caudate nucleus. Studies have reported that glutamate 
induced-exc i to tox ic i ty interferes w i t h normal neurotransmission and glutamate 
receptor act ivat ion in disorders inc lud ing A l zhe imer ' ร disease ( A D ) (Cho i , 1988). 
Furthermore, K o h et ai, 1990 and Mat tson et al., 1999, have described how glutamate 
receptors can interact w i t h amy lo id precursor protein or ß-amylo id , wh ich can lead to 
benef ic ia l or damaging effects on neurons. In a transgenic animal model , 
overexpression o f the N R 2 B subunit in the forebrain had proved to enhance act ivat ion 
o f N M D A receptors and therefore an enhancement i n learning and memory (Tang et 
al., 1999) in various behavioural tasks. These observations suggest the N M D A 
receptor cou ld play a s igni f icant role in the neurob io logy o f A D . 
1.10.6.6 Demen t i a w i t h L e w y Bodies 
Dement ia w i t h L e w y Bodies ( D L B ) is the second most frequent neurodegenerative 
dement ing disorders after A lzhe imer ' ร disease (Byrne et ai, 1989; M c K e i t h et al., 
լ996) . D L B is c l in ica l l y characterised by progressive dementia, wh ich is f requent ly 
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accompanied by park insonism and psychiatr ic symptoms (Lu is et ai, 1999). D L B is 
pathologica l ly characterised by the presence o f cytoplasmic inclusions o f a-synucle in, 
a cytoplasmic prote in associated w i t h synaptic vesicles, in the cerebral cortex and in 
the nuclei o f the bra in stem. L e w y bodies ( L B ) occur as th in f i laments in the f o r m o f 
eosinophi l ic inclusions, seen most ly in the cerebral cortex, part icular ly in the c ingular 
gyrus, in parahippocampal gyrus, in temporal neocortex, in amygdala and also in the 
nucle i o f the brain stem, ma in ly in the substantia nigra and in locus coeruleus 
( M c K e i t h et al., 1995). I t is bel ieved that patients w i t h L B in the brain stem are 
connected w i t h movement disorders, in the l imb ic system w i t h psychosis and in the 
cortex w i t h depression. Psychosis can be the most d is turb ing feature o f D L B , where 
patients w i t h D L B of ten have complex hal lucinat ions ( M c K e i t h et αΙ.， 1996) and 
depressive symptoms (Hard ing et al, 2002). A c l in ica l study has been conducted to 
compare neurotransmitter amino acid levels in the cerebrospinal fluid and the 
cerebrospinal/plasma ratios using an ion-exchange chromatographic method. It was 
found that there were no alterations in concentrations o f glutamate, aspartate and 
G A B A in the cerebrospinal fluid o f D L B patients compared to a contro l group 
( M o l i n a et al, 2005). 
1 Л 0 . 6 Л Psychosis 
The w o r d psychosis was f i rst used by Ernst von Feuchtersieben in 1845 as an 
alternative to insanity and mania. Psychosis is a cond i t ion in wh i ch a person is not in 
contact w i t h real i ty un l ike most normal people. A l t hough the general term is 
psychosis, this cond i t ion can take many fo rms, d i f f e r i ng i n symptoms and diagnosis. 
These psychotic condi t ions are associated w i t h abnormal i t ies in the central nervous 
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system (CNS) . The most common psychotic disorders o f the CNS include 
schizophrenia and b ipolar af fect ive disorder. Others include mania, delusional 
(paranoid) disorders and psychot ic depression. Occasional ly , it can be d i f f i cu l t to 
diagnosis psychotic condi t ions, as most patients have a mix tu re o f symptoms. 
Psychosis is characterised by delusions, hal lucinat ions, incoherent communica t ion , 
i l log ica l th ink ing and disorganised behaviour. 
1.10.6.7.1 Sch i zoph ren ia 
I n 1908, Eugen Bleuler in t roduced the term 'sch izophrenia ' , de f in ing the expression 
as 'when someone cannot tel l the di f ference between what is real and what is 
imag inary ' . The c l in ica l features o f the heterogeneous disorder schizophrenia usually 
appear in late adolescence or ear ly adul thood, where Kreapel in (1919) found that 
3.5% o f cases o f dementia praecox began before the age o f 10, w i t h a further 2 .7% 
arising between the ages o f 10 and 15. B leu ler (1911) suggested that about 5% o f 
cases o f schizophrenia had their onset pr io r to the age o f 15. Schizophrenic 
symptoms can be d iv ided into posi t ive, negative and cogni t ive symptoms. Delusions 
(paranoia, false bel iefs), hal lucinat ions (visual and audi tory) , and thought disturbances 
are classif ied as posit ive symptoms where these are addi t ional to normal l i fe 
experience, whereas negative features wh i ch lack normal experience include 
depression, w i thdrawal f r o m social contacts, incapabi l i ty to feel pleasure (anhedonia) 
and flattening o f emot ional responses. Cogni t ive defects invo lve def ic i ts in attention 
and memory . Schizophrenia is thought to be a neurodevelopmental disorder rather 
than a neurodegenerative disorder, as Harr ison (1997) reported that schizophrenia 
affects the cerebral cortex in the f irst few months o f prenatal development. Post 
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mortern analysis o f schizophrenic brains show evidence o f misplaced cor t ica l neurons 
w i t h abnormal тофһо1оду， suggestive o f defect ive cel l migra t ion dur ing early 
development. 
1 Л 0 . 6 . 7 Л Л A r e a o f the B r a i n A f f e c t e d by Sch i zoph ren ia 
There are many sections o f the brain that can be affected in schizophrenia, for 
example, abnormal funct ion in the basal gangl ia is thought to contr ibute to paranoia 
and hal lucinat ions (Heckerร et al., 1991). A schizophrenic hav ing d i f f i cu l t y in 
p lanning and organisat ion w i l l have defects in the f rontal lobe o f the bra in wh ich is 
cr i t ica l to p rob lem so lv ing and higher level reasoning (Fuster, 1999). Ag i ta t ion is 
brought about by the l imb ic system o f the bra in wh ich controls emot ion (Stevens, 
1973; Ch iodo and Bunney, !983 ) . Impa i red h ippocampal fo rmat ion mediates 
learning and memory d i f f i cu l t ies . V isua l disturbances are caused by damage to the 
occip i ta l lobe whereas the audi tory system is responsible for audi tory hal lucinat ions. 
As ment ioned there are many affected bra in regions that are associated w i t h the 
pathophysio logy o f schizophrenia, al l l inked by either exci tatory, inh ib i to ry or 
dopaminergic connections (Figure 1.9). Exc i ta tory cort ical efferent pathways project 
to subcort ical regions in the bra in conta in ing dopamine cel l bodies or te rmina l , wh i le 
dopaminergic pathways modulate cor t ica l exci tatory neurons, hence, N M D A 
blockade produces dopaminergic hyperact iv i ty (Lewis and L iebermann, 2000). The 
anterior c ingulate cortex ( A C C ) is impl ica ted to play a key role in the pathogenesis o f 
schizophrenia. Schizophrenia usual ly involves abnormal i t ies in brain funct ions related 
to A C C inc lud ing emot ion , affect (Hempel et al., 2003) and cogn i t ion (Carter et ai, 
2 0 0 1 ; Salgado-Pineda etai, 2003) (Figure 1.9). 
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F i g u r e 1.9: A f fec ted bra in regions i n schizophrenia showing the var ious connect ing 
pathways i nvo l ved between bra in areas (Lew is and L iebermann, 2000) 
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.1.10.6.7.1.2 D o p a m i n e Hypo thes is o f Sch i zoph ren ia 
The dopamine hypothesis o f schizophrenia was proposed by Carlsson and L indqv is t 
(1963) where i t was stated the over act iv i ty o f dopamine i n the mesencephalic 
project ions to the l imb ic str iatum was invo lved . Schizophrenic symptoms can be 
prompted by the administrat ion o f amphetamine (Angr is t et al, 1974) w h i c h releases 
dopamine in the bra in , produc ing p r imar i l y posi t ive symptoms o f schizophrenia. D rug 
therapy act ing on dopamine type Օշ– receptors is benef ic ia l for cont ro l l ing the 
posi t ive symptoms o f the disease, but not the negative or cogni t ive defects. Dopamine 
treatment o f schizophrenia can either b lock postsynaptic dopamine receptors or inh ib i t 
the release o f dopamine f r o m the presynaptic c lef t . The dopamine theory is st i l l 
unable to expla in the mul t ip le characteristics o f schizophrenia. 
1.10.6.7.1.3 G l u t a m a t e Hypo thes is o f Sch i zoph ren ia 
Glutamate is the pr inc ipal exci tatory neurotransmitter in the bra in. Glutamate 
hypofunc t ion in the CNS cou ld be due to inadequate glutamate release, over act iv i ty 
o f glutamate transporters remov ing glutamate f r o m the synaptic c lef t or defective 
receptors. The in i t ia l report o f the glutamate hypothesis o f schizophrenia was the 
observation o f l ow levels o f glutamate in cerebrospinฝ fluid samples f r o m 
schizophrenic patients ( K i m et al, 1980). Further evidence that glutamate dysfunct ion 
is invo lved in the pathogenesis o f schizophrenia involves phencycl id ine (PCP) and its 
congener ketamine (Javitt and Z u k i n , 1991; Krys ta l et αί.， 1994). They have been 
shown to induce psychosis in humans that closely resembles schizophrenia, and are 
representative o f not only the posi t ive symptoms and cogni t ive defects o f the disease, 
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but also the negative symptoms (Ad le r et al., 1999). PCP was or ig ina l ly int roduced 
into science as a surgical anaesthetic, but was soon w i thd rawn due to patients 
report ing psychot ic events inc lud ing hal lucinat ions, disoriented speech and behaviour. 
Fo l l ow ing the w i thd rawa l o f PCP, ketamine was introduced as a dissociat ive 
anaesthetic but the ext rapyramidal side effects were suppressed w i t h the 
administrat ion o f benzodiazepines or prevented w i t h barbiturates. PCP is a non­
compet i t ive N-methyl-D-aspartate ( N M D A ) receptor antagonist, as are ketamine and 
M K - 8 0 1 (d izoc i lp ine) . These b ind w i t h i n the channel pore o f the receptor in its 
activated state and b lock the transmission o f glutamate, hence causing hypofunc t ion 
o f glutamate act iv i ty . F o l l o w i n g g row ing evidence o f the psychotomimet ic effects 
produced by this class o f N M D A receptor antagonists, PCP-induced psychosis is 
w ide ly been used as an in vivo exper imental model o f schizopføenia (Jarvit t and 
Z u k i n , 1991). 
I t is hypothesised that schizophrenia affects many brain regions in early development 
inc lud ing the m idbra in , nucleus accumbenร, thalamus, temporo- l imbic and prefrontal 
cortices (Selemon and Goldman-Rak ic , 1999). Connect ing tracts, inc lud ing 
cort icostr iatal , thalamocort ical and cor t icocort ica l association f ibre al l ut i l ise 
glutamate as a neurotransmitter (Hunt ley et al., 1994). Defects in glutamate 
transmission in these connect ing tracts produced some c l in ica l f ind ings o f 
schizophrenia (Weinberger, 1993). Recent ly, abnormali t ies in glutamatergic 
transmission have been reported in the anterior c ingulate cortex (Brodmann 'ร area 24) 
wh ich is local ised w i t h i n a gyrus on the media l surface o f each hemisphere, border ing 
on the corpus ca l losum (Zavitsanou et ai, 2002) 
60 
Since glutamatergic and dopaminergic systems are closely related i n the forebrain 
(Kotter, 1994), i t is unclear whether glutamate hypofunc t ion is the pr imary defect in 
schizophrenia or a secondary change due to excessive act ivat ion o f dopamine 
receptors. Increased dopaminger ic act iv i ty can inh ib i t glutamatergic func t ion and can 
result in a hypoglutamatergic state in schizophrenia (Kot ter , 1994). 
1.11 Aims of the Study 
The focus o f this study is to characterise a novel putat ive N R 2 B subtype selective 
compound R G H - 8 9 6 , current ly in Phase I I c l in ica l tr ials. A series o f radio l igand 
b ind ing experiments w i l l be performed in rodent adult forebrain and N R 1 / N R 2 B 
transfected H E K 293 cel ls, to determine the a f f i n i t y o f RGH֊896 for the N R 2 B 
subtype N M D A receptor complex in compar ison to other established prototyp ica l 
NR2B-select ive antagonists. In order to d i rect ly measure the a f f in i t y o f RGH-896 fo r 
N R 1 / N R 2 A / N R 2 B subtype, an immunopur i f i ca t ion strategy was employed. T o 
conduct this assay, a speci f ic anti-peptide ant ibody against the N M D A N R 2 A subunit 
w i l l be developed in order to produce an an t i -NR2A ant ibody co lumn . Th is co lumn 
w i l l be ut i l ised to immunopu r i f y i ng N R 1 / N R 2 A / N R 2 B receptors expressed in H E K 
293 cells in order to determine the a f f in i ty o f RGH-896 fo r this subtype. B y 
conduct ing these studies, the testing hypothesis w i l l establish the subtype select iv i ty 
o f RGH-896 in compar ison to Ro 25,6981 (binds to al l N R 2 B conta in ing receptor 
subtypes) or CP 101,606 (binds to on ly N R 2 B conta in ing receptor subtypes), to 
determine i f R G H - 8 9 6 displays a pharmacological p ro f i le closer to Ro 25,6981 than 
CP 101,606. 
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Rodent and human autoradiography studies w i l l be used to determine anatomical 
d is t r ibut ion o f N R 2 B subtype using the pharmaco log icฝ def ined radio l igand ["^H] 
RGH֊896. The invo lvement o f N R 2 B subtype in human D L B w i l l be probed 
focusing on the anterior c ingulate cortex ( A C C ) and a range o f psychot ic symptoms. 
Here the hypothesis to test is the levels o f anterior c ingulate cortex N R 2 B receptors 
correlates w i t h the psychot ic symptoms displayed by D L B suffers. 
62 
Chapter 2 
Pharmacological Characterisation of NMDA NR2B-Selective 
Antagonists 
2.1 Introduction 
The N M D A receptor is the focus o f drug development for therapy and prevent ion o f 
numerous neurological and psychiatr ic disorders. Benef ic ia l treatments o f such cases 
can target the N M D A receptor to b lock or reduce N M D A receptor act iv i ty , or 
potentiate the act iv i ty o f the receptor. The therapeutic usefulness o f non-selective 
N M D A antagonists and N M D A channel blockers is l im i ted due to extensive adverse 
effects, inc lud ing psychotomimet ic symptoms (Krys ta l , 1994) and effects on learning 
and memory (Malhotra er al., 1996) . Due to the d ivers i ty o f the N M D A receptor, 
there is encouragement to develop selective compounds wh ich lack the side effects o f 
the non-selective antagonists, where researchers are developing new ligands that 
b lock or reduce the act iv i ty o f N M D A receptors. The N R 2 B subunit is a va l id target 
for treatment o f many CNS pathologies (Chazot, 2004) , and thus is the focus o f 
N M D A receptor antagonism using novel NR2B-se lec t ive compounds. The structures 
o f many nove l antagonists are based upon the basic structure o f i fenprod i l , a non­
selective N M D A receptor antagonist (Carter et al., 1988; Reynolds and M i l l e r , 1989). 
T w o compounds wh ich are structural ly s imi lar to i fenprod i l are CP 101,606 and Ro 
25,6981 w h i c h have been developed as h igh a f f in i t y N R 2 B subuni t specif ic 
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antagonists (Chenard et al,, 1995; Br imecombe et al, 1998; Mu te l et al., 1998; Tamiz 
et αΙ.， 1998). CP 101,606 and Ro 25,6981 b ind to a s imi lar recogni t ion site, termed 
the i fenprodi l site and are selective for the N R 2 B subuni t -containing receptors. Us ing 
radiol igand b ind ing techniques, Ro 25,6981 binds N R 1 / N R 2 B and N R 1 / N R 2 B / N R 2 A 
subtype receptors w i t h s imi lar h igh af f in i t ies, ind icat ing Ro 25,6981 to be selective 
for al l NR2B-con ta in ing subtype receptors (Hawk ins et ai, 1999). CP 101,606 shows 
further select iv i ty as it can dist inguish between N R 1 / N R 2 A , N R 1 / N R 2 B and 
N R 1 / N R 2 A / N R 2 B subtype receptors showing h igh select iv i ty for N R 1 / N R 2 B as has 
been shown in single channel record ing (B r imcombe et ai, 1997) and in cy to tox ic i ty 
studies (Boeckman and A izenman , 1996). Ro 25,6981 and CP 101,606 are rout ine ly 
used as reference compounds in research o f NR2B-select ive N M D A receptor 
antagonists. There are many novel NR2B-se lec t ive N M D A receptor antagonists being 
developed for their potent ial as therapeutic reagents as a result o f their h igh a f f in i t y 
and improved select iv i ty. 
Radio l igand b ind ing studies help to determine whether a drug w i l l produce 
therapeutic effects or adverse effects at the various receptor subtypes in the brain. 
Th is type o f study is one method o f mapping the d is t r ibut ion o f a part icular receptor 
in d i f ferent areas in the C N S . The basis o f radio l igand b ind ing studies is to show 
b ind ing o f the radio l igand (L ) to the receptor complex (R) to f o r m a radio l igand-
receptor complex ( R L ) . The radiol igand-receptor complex is more common ly 
described as the ' bound ' l igand, whereas the unbound radio l igand is referred to the 
' f ree ' rad io l igand. T o per fo rm radio l igand b ind ing , the reaction must reach steady-
state equ i l i b r i um based on the law o f mass act ion, where: -
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^^^^ρίον (R) + Radio l igand (L ) Radiol igand-Receptor Comp lex (RL ) 
W h e n per fo rming radio l igand b ind ing , i t is necessary to account for non-specif ic 
b ind ing , where the radiol igand binds to receptors other than the one o f interest. 
Consequent ly, it is essential to measure both total and non-specif ic b ind ing , in order 
to determine specif ic b ind ing to the receptor o f interest. Non-speci f ic b ind ing is 
assessed using the presence o f a h igh concentrat ion o f an unlabel led compound that 
binds essential ly to al l receptors o f interest. 
RGH-896 is a h igh ly selective compound for the N R 2 B subunit developed by Gedeon 
Richter, Hungary. W h e n compar ing RGH-896 w i t h С І -1041 (a selective N R 2 B 
antagonist) and M K - 8 0 1 (a non-selective antagonist) fo r funct iona l a f f in i t y , both 
R G H - 8 9 6 and С І -1041 inh ib i ted N M D A - e v o k e d [Ca"'^]i-elevation in a concentrat ion 
dependent manner in cel ls expressing the subunit combinat ion h N R l / h N R 2 B where 
max ima l inh ib i t ion achieved for RGH-896 and С І -1041 was 83 .6% and 85 .4% 
respectively, and M K - 8 0 1 showed f u l l i nh ib i t ion (personal communica t ion w i t h 
Gedeon Riether) . 
The a im o f this chapter is to characterise the pharmacological p ro f i le o f a prototyp ica l 
NR2B-se lec t ive antagonist i fenprodi l and a novel NR2B-se lec t ive compound, R G H -
896 using a series o f radio l igand b ind ing assays w i t h native and recombinant N M D A 
receptors. 
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2.2 M e t h o d s 
2 .2 .1 M e m b r a n e P r e p a r a t i o n 
Fo l l ow ing concussion and decapitat ion, adult male Sprague-Dawley rat brain (250-
300g) was removed f r o m the sku l l . Forebrain tissue was dissected f r o m the who le 
brain by removal o f the cerebel lum, medul la and spinal cord. Us ing co ld 
homogenisat ion buf fe r ( 5 0 m M Tris֊HCl, p H 7.4, conta in ing 5 m M E D T A , 5 m M 
E G T A , 3 2 0 m M sucrose), forebrain tissue was homogenised in a Dounce glass/glass 
homogeniser. Homogenised forebrain tissue was equal ly placed into JA20 tubes pr ior 
to centr i fugat ion at 2 , 2 0 0 ф т , 4°c for 10 minutes. The supernatant was carefu l ly 
removed and retained on ice. The remain ing pellet was resuspended in co ld 
homogenisat ion buf fer and the later two steps were repeated. The supernatants were 
pooled together and centr i fuged at 1 5 , 0 0 0 ф т , 4°c for 30 minutes. Th is supernatant 
was discarded and the resuspended pellet was gent ly homogenised to a smooth 
mix ture w i t h addi t ional homogenisat ion buf fe r required for the assay. The forebrain 
preparation was al iquoted into 1ml fract ions and f rozen at ֊20°c. The protein 
concentrat ion o f the forebrain membrane preparat ion was determined by a L o w r y 
assay ( L o w r y et al, 1951). 
2.2.2 L o w r y A s s a y 
Protein concentrat ion o f the forebrain membrane preparat ion was determined using 
the method o f L o w r y ēt ăl (1951). A series o f standards were set-up (three repeats for 
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each concentrat ion) using a standard prote in, bov ine serum a lbumin ( B S A ) , at a range 
o f concentrat ions f r o m 0 - 1 0 0 μ g / m L f r o m a stock o f 1 m g / m L . In paral le l , a series o f 
various concentrations o f protein to be assayed, in this case, forebrain membrane 
preparations were set-up (three repeats for each concentrat ion). Reagent A ( 2 % (พ / v ) 
sod ium carbonate, O . I M sod ium hydrox ide, 0 .5% (พ /v ) laury l sulfate (SDS)) , reagent 
В ( 2 % (พ / v ) sod ium potassium tartrate) and reagent с ( 1 % ( พ / v ) copper sulphate) 
were assembled in the ratio o f 100:1:1 respectively to f o r m reagent D. 0 .5mL o f 
reagent D was added to each tube and vortexed before incubat ing at r o o m temperature 
for 10 minutes. A n addi t ion o f 50μL o f Fo l i n solut ion (Fo l in & Ciocalteu'ร phenol 
reagent: water (1:1)) was added and vortexed pr ior to incubat ion at r oom temperature 
for 30 minutes. T o stop the react ion, 0 .5mL o f water was added to each tube and 
m ixed we l l . The absorbance o f each tube was determined where the opt ical density 
(O.D. ) at λ = 750nM， using a spectrophotometer, in a I m L plastic cuvette. Each 
concentrat ion analysed produced an average f r o m three tubes. F r o m a standard curve, 
o f absorbance against concentrat ion, the protein concentrat ion o f the samples assayed 
in μ g / m L can be est imated. 
2.23 R a d i o l i g a n d B i n d i n g 
W e l l washed adult male rat Sprague-Dawley forebrain membranes (100μ§ protein) 
(section 2.2.1) or transfected Н Е К 293 cel l homogenates (100μ§ prote in) were 
incubated (three repeats for each concentrat ion), w i t h rad io l igand, assay buf fer 
( 2 5 m M sod ium phosphate buf fer , p H 7.4), and compound of interest in a total vo lume 
o f 200μL, fo r 2 hours at room temperature. Non-speci f ic act iv i ty was def ined in each 
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assay. The assay was terminated and bound radio l igand was col lected by rapid 
filtration through Whatman GF /B f i l ters, pre-soaked in l O m M sodium phosphate 
buf fer , p H 7.4. The filters were washed (3 X 3 m L ) using ice-cold lO raM sodium 
phosphate buf fer , p H 7.4, using a Brandei cel l harvester. Fi l ters were transferred into 
sc int i l la t ion vials w i t h Ecoscint A l i qu id sc int i l la t ion cockta i l fluid ( I m L ) and 
incubated overnight at r oom temperature. Bound radioact iv i ty was quant i f ied using 
Packard Tr i -Carb 1600TR scint i l la t ion spectrophotometer w i t h a count ing t ime of 3 
minutes per v ia l . The data was analysed using GraphPad Pr ism version 4.0. 
2.2.3.1 [^H] R G H - 8 9 6 S a t u r a t i o n B i n d i n g Assay 
For [^H] R G H - 8 9 6 saturation exper iments, w e l l washed forebrain membranes 
(1 m g / m L ) (section 2.2.1) (ЮОцЬ) were incubated in 2 5 m M sod ium phosphate buf fer 
p H 7.4, in the presence o f a range o f concentrat ions o f [^H] R G H - 8 9 6 ( 0 . 5 - 8 0 n M , 
20μL) to a f ina l vo lume o f 2 0 0 μ L . A l l concentrat ion points inc luded three repeats for 
each concentrat ion were incubated fo r 2 hours at r oom temperature. Non-speci f ic 
b ind ing was def ined using Ro 25,6981 (10"^M). The assay was terminated by rapid 
f i l t ra t ion (section 2.2.3). 
2.2.3.2 [ 3 H ] R o 25,6981 C o m p e t i t i o n B i n d i n g Assay 
[ 3 H ] Ro 25,6981 compet i t ion b ind ing assays were per formed w i t h i fenprod i l ( l O ^ M ― 
10 3 M ) using both forebrain and N R 1 / N R 2 B or N R 1 / N R 2 A / N R 2 B transfected H E K 
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293 cel l homogenates, de f in ing non-speci f ic b ind ing w i t h i fenprod i l ( lO ^^M) or R G H -
896(10 -^M) . 
[^H] Ro 25,6981 and [^H] M K - 8 0 1 compet i t ion b ind ing assay ( in the presence o f 
Ι Ο μ Μ glutamate) were per formed to further characterise the pharmacologica l prof i le 
o f unlabel led RGH-896 . Non-speci f ic b ind ing o f [^H] Ro 25,6981 was def ined using 
RGH-896 ( l O ' ^ M ) , whereas non-specif ic b ind ing o f [^H] M K - 8 0 1 was def ined using 
ketamine ( ІО ^'М). The protocol was carr ied out as described in section 2.2.3. 
2.2.3.3 [ 3 H ] R G H - 8 9 6 C o m p e t i t i o n B i n d i n g Assay 
[ 3 H ] RGH-896 compet i t ion b ind ing assays were per formed w i t h Ro 25,6981 ( 1 0 ՜ ' ' M 
- 10"''M) and spermidine (10"^M ― 10"^M) de f in ing non-specif ic b ind ing w i t h Ro 
25,6981 ( lO ' ^M) as described in section 2.2.3. 
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2.2.4 A n a l y s i s o f R a d i o l i g a n d B i n d i n g A s s a y D a t a 
2 .2 .4 .1 Ana lys i s f o r C o m p e t i t i o n B i n d i n g Studies 
Results f r o m the compet i t ion studies were analysed by non-l inear least square 
regression using GraphPad Pr ism version 4.0 for either a one-site and a two-si te 
b ind ing model . The compet i t ion results were analysed by a s igmoidal dose response 
curve w i t h a variable slope. To analyse one-site or two-si te b ind ing , the F-test was 
used to assess whether the one-site or the two-si te compet i t ion mode l best f i t the data, 
where p<0.05 was signi f icant . The IC50 values for compet i t ion curves f i t ted to a one-
site compet i t ion mode l were calculated f r o m the f o l l o w i n g equat ion, where:-
A + {B֊A) 
メ 1 + 10* ' ՜ ' °^ '^ ՝ "^ 
A and В = the m i n i m u m and m a x i m u m percentage specif ic b ind ing respectively 
Y = specif ic b ind ing at a f i xed concentrat ion o f d isplac ing drug 
X = logio concentrat ion o f the displacer 
IC50 = concentrat ion o f the displacer wh ich inhib i ts 5 0 % o f the specif ic b ind ing o f the 
radio l igand. 
The IC50 values fo r compet i t ion curves f i t ted to a two-s i te compet i t ion model were 
calculated f r o m , 
A+{B֊A) 
Y 
F raet ioni 
+ 
ғraet ioni 
1 + 10 ( .v- log/C,„2) 
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Where; A , B， X and Y are as above, (1) and (2) = the h igh and low a f f in i t y sites for the 
one-site and two-si te b ind ing models, the apparent inh ib i t ion constants (K i ) were 
calculated using the Cheng and Prusof f equat ion (Cheng and Prusoff , 1973), 
^ ^ ^ ^ " լ 、、 
1 + 
Kd 
Where: -
ICso = concentrat ion o f rad io l igand g iv ing 5 0 % o f the specif ic b ind ing 
[ L ] = [^H] concentrat ion 
K D = dissociat ion constant f r o m saturation b ind ing o f the radio l igand in forebrain 
membranes. 
2.2.4.2 Da ta Ana lys i s f o r S a t u r a t i o n B i n d i n g Studies 
Results f r om saturation studies were analysed by non- l inear least square regression 
using GraphPad Pr ism version 4.0. The saturation data were analysed by either the 
one-site or two-si te b ind ing hyperbola. The F-test was used to assess whether the one-
site or the two-si te model f i t the data best where p<0.05 was signi f icant. 
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The K D values for saturation curves f i t ted to a one-site hyperbola were calculated f r om 
the f o l l o w i n g equat ion, 
K D + X 
Where:-
Y = specif ic bound [^H] R G H - 8 9 6 
X = concentrat ion o f [ 3 H ] R G H - 8 9 6 
В max = m a x i m u m number o f b ind ing sites 
Saturation data was f i t to the l ine by l inear regression using GraphPad Pr ism fo r the 
Rosenthal t ransformations, 
F (x ) = ax + b 
Where : -
F (x ) = specif ic bound [^H] RGH-896 / [ ^H ] RGH-896 free 
А = 5Іоре֊(1/Ко) 
X = specif ic bound [ 3 H ] RGH-896 
b = X-ax is intercept (Bmax/Ko) . 
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2.3 Results 
In order to min imise the adverse effects o f N M D A receptor antagonists, i t is necessary 
for compounds in development to be subtype selective antagonists specif ic to the 
NR2B-con ta in ing receptor. Here, we pharmacologica l ly characterise a novel putat ive 
NR2B-se lec t ive antagonist, R G H - 8 9 6 . Compet i t ion b ind ing studies determine the 
inh ib i t i on constant (K i ) o f unlabel led compounds for receptors o f interest. B y 
measuring the K i o f various compounds, i t is possible to def ine the pharmacology and 
subtype-select iv i ty o f a range o f unlabel led compounds. 
2 .3 .1 [ 3 H ] R G H - 8 9 6 C o m p e t i t i o n B i n d i n g t o F o r e b r a i n M e m b r a n e s 
Previous studies have ut i l ised spermidine to def ine specif ic b ind ing to N R 2 B -
conta in ing receptors (Hawk ins et al, 1999; Chazot et al, 2002) in l igand 
autoradiography studies (see also Chapter 3). The effect o f spermidine on [^H] Ro 
25,6981 and [^H] RGH-896 b ind ing to adult rat forebrain was invest igated, def in ing 
non-specif ic b ind ing using Ro 25,6981 ( lO ' ^M) . Results are shown in Figure 2 .1 . 
Ana lys is o f these data using a one site compet i t ion mode l , shows spermidine 
displayed an apparent pICjo o f 2.16 ± 0.9 for [ 3 H ] RGH-896 b ind ing (K i value o f 
5 . 3 4 m M ) , and an apparent pICiio o f 3.13 ± 0.1 for [ 3 H ] Ro 25,6981 b ind ing (K i value 
o f 3 8 2 μ Μ ) . 
W e l l washed forebrain homogenates were used and assayed in compet i t ion studies 
using Ro 25,6981 (10 " "м ― ւօ՜՚^ ւվ) b ind ing , de f in ing non-speci f ic value o f [ 3 H ] 
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R G H - 8 9 6 w i t h Ro 25,6981 (ւօ՜-՛՛м). Results are shown in Figure 2.2. These data 
were best-f i t to a one-site compet i t ion model produc ing a p ICjo o f 7.8 土 0.2 (K i value 
o f 11.7nM) 
2.3.2 [ 3 H ] R G H - 8 9 6 S a t u r a t i o n B i n d i n g t o F o r e b r a i n M e m b r a n e s 
Saturation b ind ing studies were per formed to determine the equ i l i b r i um dissociat ion 
constant ( K D ) and the m a x i m u m number o f b ind ing sites (Bmax) o f [ ՝ ^ H ] RGH֊896 in 
we l l washed forebrain membranes. Saturat ion b ind ing studies used [ Ή ] RGH-896 
( 0 . 5 n M - 8 0 n M ) , and def ined non-specif ic b ind ing w i t h Ro 25,6981 ( lO ' ^M) . Results 
shown in Figure 2.3 were best f i t ted to a one-site b ind ing hyperbola w i t h the 
corresponding Rosenthal t ransformat ion. Analys is o f the saturation data using non­
linear least square regression showed that [ ՝ H ] RGH-896 bound w i t h a K D o f 6.5 ± 4.6 
n M , and a Bmax o f 738.1 土 45.2 fmo les /mg o f protein ( two repeats o f the same 
forebrain preparat ion). In compar ison [ "Ή] M K - 8 0 1 , wh ich w i l l b ind to al l N M D A 
receptors, displays a Bmax o f 1.8 pmo leร /mg protein (Chazot et al., 1 9 9 3 ) . Thus, 
i l lustrat ing RGH-896 is selective for a subpopulat ion o f N M D A complexes, that is 
those conta in ing N R 2 B subunit (41%) . whereas M K - 8 0 1 w i l l b ind to al l major 
N M D A receptors (Chazot and Stephenson, 1997b). 
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2.3.3 [ З н ] R o 2 5 , 6 9 8 1 C o m p e t i t i o n B i n d i n g t o F o r e b r a i n M e m b r a n e s 
In paral le l , wel l -washed forebrain membranes and N R 1 / N R 2 B transfected Н Е К 293 
cel l homogenates were assayed in compet i t ion studies using i fenprod i l (10 ― 10՜ 
-^M), de f in ing non-speci f ic b ind ing o f [ 3 H ] Ro 25,6981 w i t h i fenprod i l (10"^M). 
Results are shown in Figure 2.4. Compet i t ion data were analysed using a s igmoidal 
model w i t h a var iable slope, where the F-test determines whether the one-site or the 
two-s i te compet i t ion best f i t the data. These data were best-f i t to a two-si te 
compet i t ion mode l , compr is ing h igh- and l ow-a f f i n i t y b ind ing sites in the rat io 88 : เ 2 
(high:low %, SD = 7 ) , which yielded a plCjositel of 7.14 土 0.1 and pIC5osite2 of 3.89 
土 1.2 fo r forebrain membranes (K i for the h igh a f f i n i t y site 1 o f 3 7 n M ) . Ana lys is o f 
N R 1 / N R 2 B expressed in Н Е К 293 cel l homogenates were best-f i t to a two-si te 
compet i t ion model (Пн = -0.65 ± 0 . 1 ) ， c o m p r i s ๒ h igh- and l ow-a f f i n i t y b ind ing sites 
in the ratio 86:14 (h igh: low %， SD = 5 ) , wh i ch displayed a pICsositel o f 6.88 土 0.1 
and pICiiosite2 o f 4.44 土 0.9 (K i for the h igh a f f in i t y site o f 6 6 n M ) . 
Compet i t ion b ind ing studies were carr ied out in rat forebrain membranes using 
i fenprod i l (10"^M - ΙΟ -'Ίνΐ), de f in ing non-speci f ic b ind ing o f [՝^H] Ro 25, 6981 w i th 
R G H - 8 9 6 (10"^M) and [^H] M K - 8 0 1 w i t h ketamine (10"^M), respectively. Us ing [^H] 
Ro 25 ,6981 , these data were best-f i t to a two-s i te compet i t ion mode l , conta in ing h igh-
and l ow-a f f i n i t y b ind ing sites in the rat io 41:59 (h igh : low %, S D = 29)， wh i ch yielded 
a pICgositel o f 6.45 土 0.7 and pICsosite 2 o f 5.05 ± 0.4 (K i value for h igh a f f i n i t y site 
o f 180nM) . Us ing [ 3 H ] M K - 8 0 1 , data were best-f i t to a two-si te compet i t ion model 
(Пн = -0.36 ± 0 . 1 ) , conta in ing h i g h - and l ow-a f f i n i t y b i n d i n g sites in the rat io 25:75 
(h igh : low %， S D = Π ) , wh ich displayed a pICsositel o f 6.93 土 0.2 and pIC5osite2 o f 
4.3 土 0. լ ( K i value fo r h igh a f f in i ty site o f 150 n M ) (Figure 2.5). 
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In the next series o f exper iments, compet i t ion curves were generated for unlabel led 
RGH-896 b ind ing using adult rat forebrain membranes and N R 1 / N R 2 B transfected 
Н Е К 293 cel l homogenates, def in ing non-speci f ic o f [ 3 H ] Ro 25,6981 w i th R G H - 8 9 6 
(10"^M) and [ 3 H ] M K - 8 0 1 w i t h ketamine (10 ՝^M), respectively. In adult rat forebrain 
membranes, using [Зн] Ro 25 ,6981 , data were best-f i t to a two-si te compet i t ion model 
(Пн = -0.91 ± 0.2), conta in ing h i g h - and l ow-a f f i n i t y b ind ing sites in the ratio 86:14 
(h igh: low %, SD = 4)， wh i ch y ie lded a pICsositel o f 7.82 土 0.1 and pIC5osite2 o f 5.45 
± 0.6 (K i for the h igh a f f in i ty site o f 7 .8nM) . In contrast, R G H 896 el ic i ted m in ima l 
displacement o f [^H] M K - 8 0 1 (p lCio < 5.0) (Figure 2.6). 
In N R 1 / N R 2 B transfected cel l homogenates, using [ 3 H ] Ro 25 ,6981 , the data were 
best-f i t to a two-si te compet i t ion model (Пн = -0.56 土 0.3), compr is ing h igh- and l ow-
a f f in i t y b ind ing sites in the ratio 13:87 (h igh : low %, SD = 5)， wh ich y ie lded a 
pICsositel o f 7.74 土 1.5 and pICsosi tel o f 5.79 土 0.3 (K i value fo r high a f f in i t y site o f 
9 .5nM) . In contrast, R G H 896 el ic i ted m in ima l displacement o f [ 3 H ] M K - 8 0 1 (pICso 
< 5.0) (Figure 2.7). 
2.3 .4 [ 3 H ] R o 2 5 , 6 9 8 1 C o m p e t i t i o n B i n d i n g t o C o m p a r e N R 1 / N R 2 B - a n d 
N R 1 / N R 2 A / N R 2 B - s u b t y p e R e c e p t o r s 
Compet i t ion b ind ing curves were generated using unlabel led R G H - 8 9 6 and either 
N R 1 / N R 2 B or N R 1 / N R 2 A / N R 2 B co-transfected subunit combinat ions in Н Е К 293 
cel ls, de f in ing non-specif ic o f [^H] Ro 25,6981 w i t h RGH-896 ( lO-^M) . 
The compet i t ion curves for unlabel led R G H - 8 9 6 b inding using N R 1 / N R 2 B 
transfected Н Е К 293 cel l homogenates were best-f i t to a two-si te compet i t ion model 
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(Пн = -0.83 土 0.3)， compr is ing h igh- and l ow-a f f i n i t y b ind ing sites in the rat io 18:82 
(high:low %, SD = 19), which yielded a pICsositel of 7.56 土 1.3 and pIC5osite2 of 
5.70 土 0.3 р (K i value for the h igh a f f in i t y site o f 13.9nM). Data for unlabel led R G H -
896 b ind ing using N R 1 / N R 2 A / N R 2 B transfected Н Е К 293 cel l homogenates 
produced compet i t ion curves wh ich were best-f i t to a two-si te compet i t ion model 
( П н = -0.52 ± 0.2)， compr is ing h igh- and l ow-a f f i n i t y b ind ing sites in the rat io 46:54 
(h igh: Iow ฯ。、 SD = 20) , wh ich y ie lded a pICsositel o f 7.67 土 0.6 and pIC5osite2 o f 
5.74 ± 0.6 (K i value fo r the h igh a f f in i t y site o f 11 · I n M ) (Figure 2.8). 
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F i g u r e 2.1 ะ The ef fect o f spermidine on [^H] Ro 25, 6981 and [ 3 H ] RGH-896 b ind ing 
to adult rat forebrain membranes was invest igated, de f in ing non specif ic b ind ing 
using Ro 25, 6981 ( l O ' ^ M ) . Results shown are mean 土 s ta^^ deviat ion fo r fou r 
repeats o f the same forebrain preparation. 
78 
125 
с 100 
Log [Ro 25,6981] (M) 
-5 -4 
F i g u r e 2.2: W e l l washed adult rat forebrain membranes were used and assayed in 
compet i t ion b ind ing studies using Ro 25,6981 (10 " м - 10"^М), def in ing non-specif ic 
b ind ing w i t h Ro 25,6981 (Ю'^ 'М) . These data were best-f i t to a one-site compet i t ion 
model w i t h an overal l pICso o f 7.8 土 0.2 ( K i = 11.7 п М ) . Results shown are mean 士 
standard deviat ion for two repeats o f the same forebrain preparat ion. 
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F i g u r e 2.3: W e l l washed forebrain membranes were used and assayed in saturation 
b ind ing studies preformed using ["^H] RGH֊896 (0 .5nM-80nM) , de f in ing non-specif ic 
b ind ing w i t h Ro 25， 6981 (lO'^^M). Representative results shown are best-f i t to a one-
site b ind ing hyperbola. Analys is o f the saturation b ind ing data using non-l inear least 
square regression and hyperbola f i t showed that [՝^H] R G H - 8 9 6 bound w i th a K D o f 
6.5 土 4 . 6 n M and a в max is 738.1 ± 45.2 fmo les /mg o f protein. 
A : Saturat ion b ind ing curve o f [^H] RGH-896 b ind ing , de f in ing non-speci f ic b ind ing 
w i t h Ro 25,6981 (10"^M) 
B: Rosenthal t ransformat ion o f the saturation data 
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F i g u r e 2.4: Pharmacological compar ison o f adult rat forebrain membranes and 
N R 1 / N R 2 B transfected Н Е К 293 cel l homogenates using paral lel i fenprod i l 
compet i t ion b ind ing studies, de f in ing non-specif ic b ind ing w i t h Ro 25,6981 (10"^M). 
Results shown are mean 土 s ta^^ deviat ion for 2-5 repeats o f the same forebrain 
preparat ion. 
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F i g u r e 2.5: W e l l washed adult rat forebrain membranes were used and assayed in 
compet i t ion b ind ing studies using i fenprod i l ( IO՜^M - ΙΟ 'Ίνΐ), def in ing non-specif ic 
b ind ing o f [ 3 H ] Ro 25, 6981 w i t h R G H - 8 9 6 ( l O -'^M), and [ 3 H ] M K - 8 0 1 w i th ketamine 
( I O ^ 'M), respectively. Results shown are mean ± standard deviat ion fo r f i ve repeats o f 
the same forebrain preparat ion. 
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F i g u ř e 2.6: W e l l washed adult rat forebrain membranes were assayed in compet i t ion 
b ind ing studies using RGH-896 (10" ' °M - Ш 5 М ) ， de f in ing non-speci f ic o f [ 3 H ] Ro 
25, 6981 w i t h R G H - 8 9 6 (IQ-'^M), and o f [^H] M K - 8 0 1 w i t h ketamine (ւօ՜-՛՛м), 
respectively. Results shown are mean 士 standard deviat ion for three repeats o f the 
same forebrain preparat ion. 
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F i g u r e 2.7: Compet i t ion curve for RGH-896 b ind ing using N R 1 / N R 2 B transfected 
Н Е К 293 cel l homogenates, def in ing non-specif ic b ind ing o f [Ή] Ro 25,6981 w i t h 
RGH-896 ( lO ' ^M) , and fu] M K - 8 0 1 w i th ketamine (іо-^'м), respectively. Results 
shown are mean 土 s ta^^ deviat ion for four repeats o f the same forebrain 
preparation. 
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F i g u r e 2.8: Compet i t ion curve for RGH-896 b ind ing using N R 1 / N R 2 B or 
N R 1 / N R 2 A / N R 2 B co-transfected Н Е К 293 cel l homogenates, de f in ing non-specif ic 
b ind ing o f [^H] Ro 25,6981 w i t h RGH-896 (10"^M). 
N R 1 / N R 2 B : Results shown are mean ± sta^^ deviat ion for four repeats o f the 
same forebrain preparat ion. Mean K i value for h igh a f f in i t y site is 13.9nM 
N R 1 / N R 2 A / N R 2 B ： Results shown are mean 土 s ta^^ deviat ion for four repeats o f 
the same forebrain preparat ion. Mean K i value for h igh a f f in i t y site is 1 l . l n M . 
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3.4 Discussion 
I fenprod i l was or ig ina l ly k n o w n as a α 1 .adrenergic antagonist, but its N M D A receptor 
act iv i ty was discovered in the late 1980ร showing that i fenprod i l was a non­
compet i t ive N M D A antagonist w i t h a novel pharmacological p ro f i le (Carter et αΙ·， 
1988; Reynolds and M i l l e r , 1989). I fenprod i l displays an approximately 400- fo ld 
higher funct ional a f f in i ty for N R 1 / N R 2 B than N R 1 / N R 2 A conta in ing receptors 
measured in the f rog ooctye system (W i l l i ams , 1993) and in transfected Н Е К 293 
cells (Gal lagher et α/·， 1996). Ear ly development o f h igh a f f i n i t y N R 2 B subunit 
specif ic antagonists produced the phenylethanolamines wh i ch inc luded Ro 25， 6981 
and CP 101,606 wh ich are structural ly s imi lar to i fenprod i l (Chenard et al" 1995; 
Br imecombe et al.， 1998; M u t e i et al" 1998; Tamiz et al., 1998) (see Chapter 1). A 
number o f h igh a f f in i ty i fenprod i l congeners have been developed as potential 
subtype selective antagonists ( rev iewed in McCau ley , 2005). 
These NR2B-subtype selective groups o f antagonists have potential as 
neuroprotectants (D i et al.， 1997; K e m p et al., 1999; G i l l et al., 2002) , anticonvulsants 
(Barton and Wh i te , 2004; Bar ton et al.， 2004)， analgesics (Boyce et al.， 1999; Chizh 
et al., 2001) , antipsychotics ( G r i m w o o d et al., 1999) and in the treatment o f many 
CNS disorders, as they can select ively target subpopulat ions o f N M D A receptors that 
are invo lved in specif ic phys io logica l funct ions or specif ic pathologies. Exc i to tox ic i ty 
can result f r o m sustained or excessive act ivat ion o f N M D A receptors or f r o m normal 
act ivat ion o f receptors in defected neurons (Waxman and L y n c h , 2005). Several 
phenylethanolamines, l ike i fenprod i l , are neuroprotect ive in vitro and in vivo models 
o f a var iety o f neurological disorders and many lack the side effects associated w i th 
non-subunit-select ive N M D A antagonists (Kew and K e m p , 1998). N M D A receptor 
antagonists have been shown to be ef fect ive in d i f ferent models o f in vitro and in vivo 
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exper imental brain in jury . CP 101,606 potent ly inh ib i ted glutamate-mediated tox ic i ty 
in hippocanไpal neurons w i th 100-fold less ef fect on cultured cerebellar cells (Menn i t i 
et αι., 1997). In vivo, CP 101,606 has been shown to b lock 5 0 % o f in i t ia l pressure rise 
(4֊fold above basal) and total ly b lock the second-phase pressure increase in a rat 
model o f intracranial pressure f o l l o w i n g head trauma (Gray, 2000). 
A n i m a l studies have indicated an important physio logical role for N M D A receptors in 
both the induct ion and maintenance o f neuropathic pain states (Parsons, 2001). in vivo 
studies have indicated NR2B"Selective antagonists are antinociceptive properties at 
doses below those that impa i r motor coord inat ion and el ic i t s t imulant act iv i ty (Boyce 
et ai, l 9 9 9 ; C h i z h et α/., 2001) . 
A n addit ional therapeutic area that may benefi t f r o m the properties o f N R 2 B selective 
antagonists is neurodegenerative diseases, for example, Parkinson'ร disease (PD) . 
Intracerebral pharmacological studies in rat models o f P D suggest that overact iv i ty o f 
NR2B-con ta in ing N M D A receptors w i th in the str iatum is responsible for mediat ing 
parkinsonism (Nash and Brotch ie , 2002). Hence by select ively target ing the N R 2 B 
N M D A receptors w i t h i n the st r ia tum, N R 2 B antagonists cou ld exh ib i t ant i ­
parkinsonian act iv i ty , wh i le being absent o f the side effects observed w i t h non­
selective N M D A antagonists. 
There are numerous N R 2 B selective antagonists tested pre-c l in ica l ly and in c l in ica l 
tr ial that b lock or reduce the act iv i ty o f N M D A receptors to have therapeutic benefi t 
fo r the patient. 
Herein, this chapter focuses on the pharmacological properties o f a novel N R 2 B 
selective l igand R G H - 8 9 6 , wh ich current ly represents the most advanced drug 
candidate in this class, using a series o f radio l igand b ind ing assays. 
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A series o f in i t ia l experiments were per formed to val idate the assay system to be 
adopted. Non-spec i f ic b ind ing is determined by measuring radio l igand b ind ing in the 
presence o f a concentrat ion o f unlabel led compound that binds essential ly al l the 
receptors. Previous studies have ut i l ised spermidine to def ine non-specif ic b ind ing o f 
N R 2 B receptors (Hawk ins et al, 1999; Chazot et al, 2002) part icu lar ly in l igand 
autoradiography experiments (See also Chapter 3 and 4) . A series o f radio l igand 
b ind ing results using unlabel led spermidine (10՜^-10՜^ M ) showed that spermidine 
displays a s ign i f icant ly lower (42- fo ld) a f f in i t y for the [ 3 H ] R G H - 8 9 6 b ind ing site 
compared to the ["Ή] Ro 25,6981 b ind ing site ind icat ing spermidine is over lapping 
the Ro 25,6981 b ind ing site more than the R G H - 8 9 6 b ind ing site. Th is is 5ифгІ8Іп§ as 
spermidine has been rout inely used to def ine non-specif ic b ind ing w i t h Ro 
25,6981 and [^H] CP-101,606 (Hawk ins , 1999; Chazot et al., 2002; Sheahan and 
Chazot, unpubl ished). Interest ingly, this novel f i nd ing indicates [^H] R G H - 8 9 6 and 
[•^H] Ro 25,6981 are b ind ing to dist inct, but over lapping sites. 
Subsequent to this in i t ia l f i nd ing , Ro 25,6981 (10"' 'M) was selected to def ine non­
specif ic b ind ing. Th is was based on two cr i ter ia: Ro 25,6981 displaced [^H] RGH-896 
w i t h a K j in close agreement w i t h previous studies (Mu te l et al, 1998; H a w k i n s et al, 
1999; Chazot et al., 2002; Sheahan and Chazot, unpubl ished), and the K D value for 
[ З н ] RGH-896 ( K D = 6 .5пМ) in adult rat forebrain membranes using Ro 25,6981 (10՜ 
•"'M) to def ine non-specif ic b ind ing , was in close agreement w i t h previous unpubl ished 
Gedeon Richter precl in ica l studies (personal communica t ion) . 
The prototypical compound, i fenprodi l was investigated using a series o f compet i t ion 
b ind ing exper iments. The i fenprodi l compet i t ion curves (Figures 2.4 and 2.5), were 
best-f i t to a two site curve using both [ 3 H ] Ro 25,6981 and [ 3 H ] M K - 8 0 1 in both 
nat ive and recombinant N R 1 / N R 2 B receptor preparations. I fenprod i l shows a s imi lar 
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a f f i n i t y b ind ing fo r NR1 /NR2B-sub type subunit (66nM) and forebrain membranes 
( 3 7 n M ) when using [^H] Ro 25 ,6981 . Th is biphasic phenomenon in forebrain shows 
that i fenprodi l can d iscr iminate at least two subpopulat ions o f N M D A receptors that 
are d i f ferent ia l ly expressed dur ing development (W i l l i ams , 1993). The biphasic 
observat ion has also been demonstrated in h ippocampal neurons (Legendre and 
Westbrook, 1991). I fenprod i l displays a h igh a f f in i ty fo r N R 1 / N R 2 B subtype 
receptors expressed in Н Е К 293 cel l homogenates, whereas receptors conta in ing 
N R 1 / N R 2 A , N R 1 / N R 2 C and N R 1 / N R 2 D subunits are al l re lat ive ly insensit ive to 
i fenprod i l b ind ing (Priestley et al., 1995; W i l l i ams , 1995; G r i m w o o d et CiL, 1996; 
Varney et CiL, 1996; Avenet et al., 1997; Hess et ai, 1998). I fenprod i l has been 
shown to interact w i t h several other types o f receptors and channels inc lud ing voltage 
dependent Ca^* channels (Adeagbo, 1984; B i ton et al., 1995) and σ-sites (Contreras et 
ai, 1990), par t ia l ly exp la in ing the l ow-a f f i n i t y b ind ing site in both native and Н Е К 
293 cel ls, consequently showing that i fenprodi l is not ideal due to its lack o f 
select iv i ty in both forebrain membranes and Н Е К 293 cel l homogenates. Th is low 
a f f i n i t y site has been detected in Н Е К 293 cells using other N R 2 B l igands, and 
appears not to be due to σ-sites (Chaf fey & Chazot, unpubl ished observations). 
Researchers have developed novel NR2B-sub type selective antagonists based upon 
the structure o f i fenprodi l but w i thout the a f f in i ty for many o f these other sites 
(McCau ley , 2005). 
T o broaden our knowledge o f the properties o f R G H - 8 9 6 , compet i t ion studies were 
designed to look at [ 3 H ] M K - 8 0 1 b ind ing and [ 3 H ] Ro 25,6981 b ind ing in both rat 
forebrain membranes and N R 1 / N R 2 B transfected Н Е К 293 cel l homogenates, 
s imultaneously. Us ing rat forebrain membranes, [^H] Ro 25,6981 is h igh ly sensitive 
to R G H - 8 9 6 , whereas [ 3 H ] M K - 8 0 1 is insensit ive to RGH-896 . In compar ison, 
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compet i t ion b ind ing studies showed comparable displacement by i fenprod i l o f [^H] 
M K - 8 0 1 and [ 3 H ] Ro 25,6981 b ind ing (Figure 2.5). Displacement curves in both 
cases were best f i t to a two site compet i t ion model , d isplay ing a h igh and low a f f in i ty 
b ind ing sites w i th s imi lar respective af f in i t ies. The contrast ing allosteric coup l ing to 
the M K - 8 0 1 b ind ing site displayed by i fenprodi l and R G H - 8 9 6 indicate further 
evidence for a fundamental d i f ference in the b ind ing sites o f the NR2B֊selective 
l igand fami ly . Future experiments are required to assess allosteric sensit iv i ty o f R G H -
896 using shorter sub-equi l ib r ium b ind ing t imepoints. Further novel N R 2 B l igands 
show s imi lar effects to RGH-896 (Chaf fey & Chazot, unpubl ished), indicat ing a 
c o m m o n property for some members o f this class o f l igand. 
F o l l o w i n g on f r o m studies in rat forebra in, R G H - 8 9 6 was tested in recombinant 
homogenates using N R I / N R 2 B and N R 1 / N R 2 A / N R 2 B transfected Н Е К 293 cel ls. 
A l l data for compet i t ion studies using unlabel led R G H - 8 9 6 were best-f i t to a two-si te 
compet i t ion model compr is ing o f a h i gh - and a l ow-a f f i n i t y b ind ing site. The h igh-
a f f in i ty site is presumably b ind ing N R 1 /NR2B-con ta in ing receptors (pICsosite 1 = 
7.56), whereas the low a f f in i t y site (pIC5osite2 = 5.70) is l i ke ly to be b ind ing non-
N R 1 /NR2B-con ta in ing receptors, as discussed previously. This was con f i rmed using 
untransfected Н Е К 293 cel l homogenates (not shown) . These data together suggest 
R G H - 8 9 6 ( lO ' ^M) is the appropriate concentrat ion to def ine specif ic b ind ing in future 
experiments. Compet i t ion studies displayed an apparent very s imi lar h igh a f f in i ty o f 
R G H - 8 9 6 for N R 1 / N R 2 B receptors (pICso = 7.56) and N R 1 / N R 2 A / N R 2 B receptors 
(pICso = 7.67) in transfected Н Е К 293 cel l homogenates. These data suggest that 
R G H - 8 9 6 displays l i t t le select iv i ty fo r N R 1 / N R 2 A / N R 2 B receptors in comparison to 
N R 1 / N R 2 B receptors. It should be noted that when expressing mul t ip le subunits in 
Н Е К 293 cells that a complex mix tu re o f receptor combinat ions are produced. In 
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order to d i r e c t l y measure the a f f in i ty o f R G H - 8 9 6 for N R 1 / N R 2 A / N R 2 B subtype, an 
immunopur i f i ca t ion strategy was employed, wh i ch is described in Chapter 3. 
In conclus ion, the novel f ind ings in this chapter indicates [՝Ή] R G H - 8 9 6 and [^H] Ro 
25,6981 are b ind ing to dist inct, but over lapping sites due to [^H] R G H - 8 9 6 been 
insensit ive to spermidine. The contrast ing al losteric coup l ing to the M K - 8 0 1 b ind ing 
site displayed by i fenprod i l and RGH-896 indicate further evidence fo r a fundamental 
d i f ference in the b ind ing sites o f the NR2B-se lec t ive l igand fam i l y . RGH֊896 is 
s imi lar to Ro 25 ,6981 , as these data suggest that RGH-896 displays l i t t le select iv i ty 
for N R 1 / N R 2 A / N R 2 B receptors in compar ison to N R 1 / N R 2 B receptors. 
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Chapter З 
Immunopurification and Pharmacological Characterisation of 
Recombinant NR1/NR2A & N R 1 / N R 2 疆 Subtypes 
Expressed in НЕК 293 Cells 
3 .1 Introduction 
Ant ibodies are used rout inely in research to probe for specif ic interactions o f proteins 
due to their unique structure. They consist o f t w o ident ical domains to f o rm the arms 
o f the 'Y ' -ร t ruc tu re , where the third domain fo rms the base o f the Ύ ' - s t r u c t u r e . The 
two domains that carry the antigen b ind ing sites are known as Fab fragments, and the 
protein domain that is invo lved in immune regulat ion is termed the Fc fragment. The 
two heavy-chain polypept ides ๒ the 'Y ' -s t ruc tu re are identical and are approx imate ly 
55kDa. The two l ight-chain polypeptides are also identical but are around 25kDa in 
size. One l ight chain associates w i th the amino- termina l region o f one heavy chain to 
f o r m an antigen b ind ing domain . The carboxy- termina l region o f the two heavy chains 
f o l d together to f o r m the Fc domain . The four polypept ide chains are held together by 
d isul f ide and noncovalent bonds (Figure 3.1). 
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F i g u r e 3 . 1 : An t i body b ind ing domains 
93 
Due to their unique structure, antibodies are very useful as selective tools to study the 
structure and funct ion o f b io log ica l macromolecules as they recognise a specif ic 
antigen unique to its target. B y using immunoprec ip i ta t ion or immunopur i f i ca t ion 
strategies, the subunit composi t ion o f native receptors can be delineated and quant i f ied 
(e.g. Chazot and Stephenson, 1997b). 
In situ hybr id isat ion studies have shown N M D A receptor subunit m R N A s have 
dist inct d is t r ibut ion patterns in adult brain as we l l as dur ing development (Watanabe 
et al., 1993). Receptor autoradiography studies ident i f ied four pharmacologica l ly 
d ist inct ive native N M D A receptor subtypes where the anatomical d is t r ibut ion 
matched the d is t r ibut ion o f m R N A encoding NR2A֊NR2D (Bul le r et al., 1994). The 
heterogeneity o f the N M D A receptor was f i rs t suggested by in situ hybr id isat ion 
wh ich showed m R N A expression o f N M D A receptors where the N R l subunit is 
expressed throughout the bra in, whereas N R 2 subunits are co-local ised in various 
brain regions (Wenzel et ai, 1995). Colocal isat ion o f receptors is not def in i t i ve proof 
that two subunits actual ly coexist w i th in the same receptor molecule. Sheng et al 
( 1994) were the f i rst group to use an immunoprec ip ia t ion technique, to demonstrate 
using N M D A receptor subunit-specif ic ant ibodies, that N R l and N R 2 subunits do 
coexist i n deve lop ing and adult brains, a l though this study d id not show the exact 
composi t ion o f the complexes. M a n y studies imp l ied the co-existence o f N R 2 A and 
N R 2 B together w i t h N R l , but i t was s t i l l not proved unt i l Chazot and Stephenson 
(1997b) displayed direct co-association o f N R l , N R 2 A and N R 2 B subunits in an 
N M D A receptor subpopulat ion o f adult mammal ian brain using a double 
immunopur i f i ca t ion / immunoprec ip i ta t ion strategy. 
Further characterisation o f the receptor co-existence has looked at studies i nvo l v ing 
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pharmacological and phys io log ica l properties o f recombinant N M D A receptors using 
radiol igand b ind ing techniques and single channel recordings. In 1993, C i k et al, 
described the op t ima l condi t ions for expression in mammal ian Н Е К 293 cells o f 
N M D A receptor subtypes, in part icular, N R l and N R 2 A . These opt imal condi t ions 
looked at a t ime course for transfection and the ratio o f c D N A required to achieve 
max ima l transfection levels. Co-transfect ion o f mammal ian cells w i th p C I S N R 1, 
N R 2 A and N R 2 B c D N A produces a heterogeneous m i x o f N R 1 / N R 2 A , N R 1 / N R 2 B 
and N R 1 /NR2A/NR2B subtype receptors (Br imecombe et al., 1997) wh ich are 
d i f f i cu l t to study ind iv idua l l y . 
M a n y funct ional studies have looked at the select iv i ty o f various NR2B-sub type 
selective N M D A antagonists versus simple d imer ic N M D A receptor subtypes 
expressed in cel l l ines. A study by Hawk ins et al (1999) showed [^H] Ro 25,6981 
binds to both N R 1 / N R 2 B and N R 1 / N R 2 A / N R 2 B subtype receptors w i t h s imi lar h igh 
af f in i t ies ( K D = 10.5 土 1.7nM and 10.9 土 1 ·2ηΜ respect ively) , suggesting Ro 25,6981 
binds to a l l N M D A receptors conta in ing the N R 2 B subunit. A later study by Chazot 
et al (2002) suggested that [^H] CP-101,606 binds only to N R 1 / N R 2 B subtype 
receptors, but not to N R 1 / N R 2 A or N R 1 / N R 2 A / N R 2 B subtype receptors. Th is 
indicates that CP 101,606 is affected by the presence o f other NR2- type subunits 
w i t h i n the complex. 
Th is chapter describes the development and characterisation o f a panel o f a n t i - N R 2 A 
specif ic antibodies w h i c h w i l l be ut i l ised to produce an an t i -NR2A immunoa f f i n i t y 
co lumn, essentially as described by Chazot et al (2002) . The immunoa f f i n i t y co lumn 
w i l l be val idated through solubi l isat ion and immunopur i f i ca t ion o f N R 1 / N R 2 A 
receptors expressed in Н Е К 293 cells. In order to investigate the select iv i ty o f the 
novel NR2B-se lec t ive antagonist RGH-896 described in Chapter 2, us ing a 
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recombinant approach, p C I S N R 1, N R 2 A and N R 2 B c D N A subunits w i l l be expressed 
in H E K 293 cells. T o isolate the N R 1 / N R 2 A / N R 2 B f r o m N R 1 / N R 2 B receptors 
f o l l o w i n g t r ip le subunit- t ransfect ion, we w i l l ut i l ise an immunopur i f i ca t ion strategy 
w i t h a novel an t i -NR2A (1381-1394) immunoa f f i n i t y co lumn. A n t i - N R 2 A ( 1 3 8 1 -
1394) correlates to the amino acid sequence, i.e. the peptide f r om wh ich the ant ibody 
is der ived. The ant ibody w i l l then b ind to this region o f the receptor subunit . T o 
establish the pharmacological properties o f this novel compound R G H - 8 9 6 , isolated 
N R 1 / N R 2 A / N R 2 B w i l l be analysed using a radio l igand b ind ing technique to 
determine direct ly the a f f in i t y o f RGH-896 for this N M D A t r imer ic subtype. 
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3.2 Methods 
3.2.1 P roduc t i on of a n t i - N M D A R 2 A A n t i b o d y 
3.2.1.1 Peptide Conjugation by means of the Glutaraldehyde Method 
This method was adopted to cross-link the anti-NR2A peptide, 
KRCPSDPYKHSLPSQ (corresponds to amino acids 1381-1394), to the carrier 
protein by a reaction with the N-terminus of the peptide using thyroglobulin as a 
carrier protein previously described by Chazot and Stephenson (1997a). Equal 
amounts (4mg) of thyroglobulin and peptide were dissolved in 2mL 0.1 M sodium 
hydrogen carbonate buffer, containing freshly thawed 0.05% (v/v) gluteraldehyde. 
The peptide-carrier protein complex was incubated at room temperature in a glass test 
tube for 16 hours with vigorous shaking. The addition of 200fiL լ M glycine ethyl 
ester, pH 8.0 terminated the reaction and was left to stand at room temperature for 30 
minutes. The peptide-carrier protein conjugate was separated from the uncoupled 
peptide by dialysis against phosphate buffered saline (PBS) ( lOmM sodium hydrogen 
phosphate, l .VmM potassium hydrogen phosphate, 137mM sodium chloride, 107mM 
potassium chloride, pH 7.4) for 4 hours at 4°c with hourly 500mL buffer changes. 
The dialysed peptide-protein conjugate was diluted with PBS to a final concentration 
of 1 mg/mL and stored in ւՕՕրԼ aliquots at -20°c until use. 
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3.2.1.2 Inoculat ion Procedure 
A vial (ЮОцЬ) of freshly thawed conjugated peptide-protein carrier was added to 
200pL of sterile PBS and emulsified with an equal volume (300pL) of Freunds 
complete, using a wide bore needle and syringe. The preparation was injected 
intramuscularly into both hind legs of a female New Zealand White rabbit. Initial 
immunisation was performed with Freunds complete, whereas, subsequent 
immunisations, at 1 month intervals, were performed with Freunds incomplete. The 
rabbit was bled from the marginal ear vein 7-10 days fol lowing booster injections, 
where 10-15mL blood was collected. Blood was allowed to stand at room 
temperature for 2 hours and clot contraction was allowed to occur for 16 hours at 4°c. 
The cellular material was removed by centrifugation at 12,000 X g for 10 minutes at 
4°c. The remaining serum was stored at -20°c in I m L aliquots. 
3.2.1.3 Production of a Peptide A f f in i t y Column 
The production of a peptide affinity column is used to imitate the coupling of the 
peptide to the carrier protein. When using a peptide-carrier protein conjugate to raise 
an antibody, high non-specific binding can cause a problem. It is therefore essential to 
carry out affinity purification of the anti-peptide antibodies from the resultant 
antiserum to remove the anti-carrier protein antibodies. 
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3.2.1.3.1 Coupling of Peptides to Sepharose Beads via Primary Amine Groups 
0.35g of activated CH-sepharose was allowed to swell in lOOmL water for 15 minutes 
at room temperature. The swollen sepharose was then placed on a sintered glass filter 
and washed with I m M HCl (lOOmL) at 4°c. The sepharose was equilibrated with 
0.1 M sodium hydrogen carbonate pH 8.0, containing 0.3M sodium chloride (25mL), 
and transferred to a capped tube in I m L equilibration buffer. ImL of 5mg/mL peptide 
dissolved in equilibration buffer was added to the sepharose and incubated for 1 hour 
at room temperature with gentle mixing. The reaction was terminated by placing the 
sepharose on a sintered glass filter and washing with equilibration buffer (25mL). The 
sepharose was returned to a capped tube and all remaining active groups were blocked 
by incubation with O.IM Tris-HCl pH 8.0, containing 0.5M sodium chloride (3mL) for 
1 hour at room temperature with gentle mixing. The sepharose was washed 4 times 
each and alternately with O.IM acetic acid, pH 4.0， containing 0.5M sodium chloride, 
and O.IM Tris-HCl pH 8.0, containing 0.5M sodium chloride. The sepharose was then 
poured into a 25mL column, washed with PBS (20mL) and stored in PBS containing 
0.02% (พ/v) NaN3, at 4°c until use. 
3.2.1.4 Peptide A f f in i t y Ant ibody Puri f icat ion 
The peptide column was washed with lOOmL Tris Buffered Saline (TBS) (50mM 
Tris, 0.9% (พ/v) sodium chloride, pH 7.4). Seram (3-4mL) was added to the column 
and was gently shaken at room temperature for 2 hours. The unbound serum was 
collected and frozen at -20°c for further analysis. The column was washed under 
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gravity with 50mL TBS. The bound fractions were eluted with 50mM glycine (pH 
2.3) and quenched with 2M Tris to neutralise the elutant. The absorbance of the 
collected fractions were measured at O.D. λ = 280nm using a spectrophotometer. The 
peak fractions were pooled together before dialysis using TBS over night at 4°c. The 
collected dialysate was measured at O.D. λ ะะ 280nm. The concentration of the 
antibody in mg/ml was calculated using the Beer Lambert Law, 
С = A 
where, 
с = concentration of antibody 
A = absorbance of the antibody at λ = 280nm 
Є = molar extinction coefficient 
L = 1cm path length 
The column was regenerated with 50mL TBS and stored in TBS supplemented with 
0.02% (พ/v) NaN3 at 4°c until further use. 
3.2.2 Screening of the an t i -NMDA Antibodies using SDS-PAGE Electrophoresis 
and Immunoblot t ing 
The technique of immunoblotting was described by Chazot & Stephenson (1997b). 
100 
3.2.2.1 Preparat ion of the Gel 
The resolving acrylamide gel (7.5%) was prepared by mixing 3mL running gel buffer 
(1.5M Tris, 8mM EDTA, pH 8.8 containing 0.4% (w/v) SDS), 3mL 30% 
acrylamide/Bis-acrylamide solution, 6 mL dHsO, 6μ ᄂ Ν,Ν,Ν',Ν'-
Tetramethylethylenediamine (TEMED) & 60ļ iL 10% (พ/ν) ammonium persulphate 
(APS). The Polyacrylamide solution was immediately poured into a Hoefer^M Dual 
Gel Caster using 10 X 10 cm plates with 1mm spacers. Approximately ЮОцЬ of 
saturated butanol was added to smooth the top of the gel. Gels were covered with 
parafilm and were allowed to polymerise for 1-2 hours. Gels were stored into tissue 
paper soaked with electrode buffer pH 8.8 (50mM Tris, 384mM glycine, 1.8mM 
EDTA, pH 8.8 containing 0 . 1 % (w/v) SDS,) at 4°c， until use. 
3.2.2.2 Chloroform/methanol Preparation of Gel Samples for SDS-PAGE 
A given amount of protein sample (100μ§) was prepared and made up to a volume of 
I00μL in an Oppendorf. To this, 4 volumes of methanol were added before vortexing 
and pulsing up to 13,000 rpm at 4°c. Chloroform (1 volume) was added, vortexed 
and pulsed to 13,000 rpm at 4°c. Distil led water (3 volumes) was added, vortexed 
and centrifuged for 1 minute at 13,000 фгп at 4°c. The samples were carefully 
placed on ice and the top layer was removed making sure not to disturb the 
intermediate phase of the sample. To this, 1 volume of methanol was added, vortexed 
and centrifuged for 4 minutes at 13,000 ф т at 4°c. The supemanent was removed 
and the remaining pellet was left to dry for 30 minutes. The dried protein samples 
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were prepared for SDS-PAGE by resuspending the protein pellet in 5pL sample 
buffer (30mM sodium hydrogen phosphate, 30% (v/v) glycerol, 0.05% (v/v) 
bromophenol blue, pH 7.0 containing 7.5% (พ/v) S D S ) , 8ĮXL dH20 and 2μՆ(W0mM) 
DTT, giving a final volume of 15μL. The samples were boiled at 95°c for 5 minutes, 
before pulsing at 6,000 rpm and vortexing to ensure the samples are evenly mixed. 
The samples were now ready for analysis by SDS-PAGE. 
3.2.2.3 SDS-PAGE 
The set gel was clamped into a HoeferTM Mighty Small I I vertical slab SE260 unit. 
The stacking gel was prepared by mixing 2.3mL Ճ11շ0, 0.65mL 30% acrylamide/Bis-
acrylamide solution, I m L stacking gel buffer (0.5M Tris, 8mM EDTA, pH 6.8 
containing 0 .4% (w/v) SDS, ) , 5[xL T E M E D & 8 0 I Í L A P S . The Polyacrylamide 
solution was immediately poured onto the set gel and 10-well comb was inserted into 
the stacking gel. Once the stacking gel was polymerised, the comb was removed and 
the wells were washed with water. Electrode buffer was poured into the wells and in 
the base of the unit. Protein samples (15μL) and pre-stained standards (protein 
molecular weight range 200-6.5 kDa, Sigma) were loaded into the wells using a 
Hamilton syringe. Electrophoresis was carried out at a starting current for 30 minutes 
of 10mA, increasing to 15mA, until the dye-front reached the bottom of the gel. 
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3.2.2.4 Immunobtot t ìng 
Following SDS-PAGE, the proteins from the gel were transferred onto nitrocellulose 
membrane in a transfer cassette. The cassette was set up on the white side with 
sponge, 2 pieces of blotting paper, nitrocellulose membrane, gel, and 2 pieces of 
blotting paper and sponge, which had all been pre-soaked in transfer buffer (25mM 
Tris, 192mM glycine, 20% (v/v) methanol) and all bubbles had been removed by 
rolling each layer with a test tube. The sandwiched cassette was placed into a 
Hoefer™ TE series Transphor transfer tank fi l led with transfer buffer to transfer the 
proteins to the nitrocellulose membrane at a voltage of 50V for 2.5 hours at room 
temperature. 
Following the transference of proteins, the nitrocellulose membrane was incubated in 
lOmL blocking buffer (5% (พ/v) dried milk, 0.2% (v/v) т ween 20， in TBS 
supplemented with 50μL 2M sodium hydroxide per 50ml buffer) for 1 hour at room 
temperature with gentle shaking. The appropriate affinity-purified primary antibodies 
were diluted in incubation buffer (2.5% (พ/v) dried milk in TBS) to specific 
concentrations (0.5-2 μ g/mL) and incubated overnight at 4°c with gentle shaking. 
Following incubation, the nitrocellulose was washed 4 X lOmL wash buffer (2.5% 
(พ/v) dried milk, 0.2% (v/v) Tween 20 in TBS) every 10 minutes with gentle shaking 
at room temperature. The nitrocellulose membrane was incubated with horseradish 
peroxidase (HRP) labelled secondary antibody (dependent upon the species the 
primary antibody was raised in) at a dilution of 1:2000 in lOmL incubation buffer at 
room temperature for 1 hour with gentle shaking. The unbound secondary antibody 
was removed by a series of 4 X lOmL wash buffer every 10 minutes at room 
temperature with gentle shaking. After washes, the nitrocellulose membrane was 
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rinsed with TBS to remove any excess wash buffer. Immunoreactive bands on the 
nitrocellulose membrane were developed in a developing solution (68mM p-coumaric 
acid (lOOfxL), 1.25mM luminol ( lOmL), 30% hydrogen peroxide (6μL)) for 1 minute 
at room temperature. The drained immunoblot was wrapped in cling f i lm and taped 
into a developing cassette. Exposure times (1-5 minutes) to Hyperf i lm™ differed 
depending upon the intensity required. The f i lm was developed in Kodak Polymax 
RT developer and replenisher and fixed in Kodak Polymax RT fixer and replenisher 
at room temperature. 
Following peptide affinity purification of anti-NRl (17-35 Cys) (A), anti-NR2A 
(1381-1394) (B) and anti-NR2B (40-60) (c), the specificity and optimum 
concentration (0.5-1ц§/тЬ) of these antibodies were determined (Figure 3.2) prior to 
use in immunopurification studies later in this chapter. The lower mołecular weight 
species are likely to be proteolytic fragments. 
ᄃ=> 
В 
I— 175kDa 
- l l5kDa 
55kDa 
l75kDa 
l l5kDa 
55kDa 
С 
175kDa 
115kDa 
― 55kDa 
Figure 3.2ะ Peptide affinity purification of anti-NRl (17-35 Cys) (A), anti-NR2A 
(1381-1394) (B) and anti֊NR2B (40-60) (c). 
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3.2.3 c D N A P repa ra t i on o f Mouse p C I S N R l , p C I S N I ^ A a n d p C I S N R 2 B 
3.2.3.1 Transformat ion of Competent E-coli Cells 
This method of transformation was performed essentially by Dagert and Ehrlich 
(1979). A frozen aliquot (ЮОцЬ) of HB 101 competent cells from -80°c stocks were 
thawed on ice for 5 minutes. The stock cDNA ( Ipg /pL) was diluted with sterile 
water to a final concentration of 20ng/ļxL. The HB 101 competent cells (lOOfxL) were 
gently mixed with plasmid D N A (10μL) and were incubated on ice for 30 minutes. 
The cell mixture was given a heat shock by placing in a 42°c water bath for 1 minute 
and returning on ice for a further 2 minutes. To the mixture, 9(ЮμL Luria Bertani 
(LB) Broth media containing ampicill in (50ņg/mL), was added to the transformed 
cells and was incubated on an orbital shaker at 250 X g for 1 hour at 37°c. The cell 
suspension was plated onto culture plates (47g LB Broth containing ampicillin 
(50μg/mL) and 1.5% (w/v) solid agar) and was incubated at 37°c for 18-20 hours in 
an inverted position. 
3.2.3.2 Ampl i f ícat ion and Puri f icat ion of Plasmid D N A 
3.2.3.2.1 Preparation of Small Scale Culture of Plasmid D N A 
LB Broth ( 1 OmL) containing ampicill in Լ50μg/mĽ) was added to a sterile 50mL 
centrifuge tube. One colony from the culture plate was isolated using a sterile loop 
and added to the LB Broth. This small culture was incubated for 18-20 hours in an 
orbital shaker at 250 X g at 37°c. 
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3.2.3.2.2 Glycerol Stocks of Transformed Competent E-coli Cells 
LB Broth (500I_IL) containing 50% (v/v) sterile glycerol and ampicill in (50ц§/тЬ) 
was added to ЗООцЬ of the small overnight culture. This cell culture mixture was 
immediately aliquoted to a cryogenic vial and stored at ֊80°c until further use. 
3.2.3.2.3 Preparation of Large Scale Culture of Plasmid DNA 
LB Broth (500mL) containing ampicil l in (50μg/mL) was inoculated with 3mL of 
small overnight culture in a sterile 500mL flask. This large scale culture was 
incubated for 18-20 hours in an orbital shaker at 250 X g at 3 7 で 
3.2.3.3 Harvesting the Large Scale Cul ture and Pur i fy ing the Plasmid D N A using 
QIAGENTM Plasmid Max i K i t 
The large overnight culture was transferred into two ice-cold centrifuge tubes and 
centrifuged at 6,500 X g for 10 minutes at 4°c. The supernanent was discarded and 
the pellet was resuspended into ice-cold PI buffer ( lOmL). The bacteria containing 
plasmid was lysed by the addition of P2 buffer ( lOmL) with gentle inversion and was 
incubated at room temperature for 5 minutes. The mixture was neutralised with ice-
cold P3 buffer ( 1 OmL) by gentle inversion and was incubated on ice for 20 minutes. 
The mixture was centrifuged at 14,000 X g for 30 minutes at 4°c. The clear lysate 
was removed and placed in a fresh tube. A QIAGEN^M 500 tip was equilibrated with 
QBT buffer ( lOmL) and the lysate was gently poured into the column and allowed to 
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pass through under gravity. The column was washed twice with QC buffer (2 X 
3mL), followed by the addition of QF buffer (15mL) to elute the plasmid DNA. Ice-
cold isopropanol (0.7 Vol) (10.5mL) was added to the eluted DNA, before 
centrifugation at 14,000 X g for 30 minutes at 4°c. The remaining pellet was washed 
with ice-cold ethanol ( ImL ) and left to air dry for 30 minutes. The purified DNA was 
dissolved in TE buffer (500цЬ) ( lOmM Tris, I m M EDTA, pH 8.0) and stored at 4°c 
until the purity and the yield of DNA was determined. 
3.2.3.4 Quanti f ícat ion and Determination of the Pur i ty of DNA Yield 
The purity and concentration of the plasmid D N A was determined by measuring the 
optical density (O.D.) at λ=260ηηι and λ=280ηπι (Sambrook et al., 1989) against TE 
Buffer. The ratio of the O.D. at λ=260ηΓη and x=280nm should be within the range of 
1.8-2.0. The plasmid DNA concentration at λ=260ηιη where the O.D.= l , corresponds 
to approximately 50μg/mL for double stranded DNA (dsDNA). The plasmid DNA 
was diluted in TE buffer to a final concentration of 1ц§/тЬ and was aliquoted into 
100μL fractions and stored at -20°c until use. 
3.2.4 P r e p a r a t i o n o f D M E M / F 1 2 M e d i u m + L - G l u t a m i n e 
Al l procedures were performed using sterile conditions. Dulbecco's Modif ied Eagle 
Medium/F12 (DMEM/F12) 1:1 mix, containing HEPEร (15mM) and L-glutamine was 
supplemented with 10 % (v/v) heat inactivated fetal calf serum (FCS), 40mL of 7.5 % 
(พ/v) NaHCOa and penicillin (5001 บ /mL) I streptomycin (500 μ g/mL) solution (20 
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mL). The pH of the final volume of the medium was adjusted to pH 7.6 using NaOH 
( lOM). The medium was filter-sterilised using a 0.2μηη Nalgene filter unit and stored 
at 4°c until use. 
3.2.5 Subcuttur ing of Н Е К 293 Cells 
Н Е К 293 cells were grown in 250mL Greiner culture flasks at 37°c in 5% ՇՕշ in 
DMEM/F12 medium containing L-glutamine in a Shell Lab CO2 incubator. The cells 
were subcultured weekly by the removal of the old medium and a wash with pre-
warmed sterile phosphate buffered saline (PBS) ( lOmL). Following 1 minute 
incubation in trypsin-EDTA (2mL) at 37°c, DMEM/F12 medium containing L-
glutamine ( lOmL) was added to the cells. The cells were then separated by gentle 
pipetting. Finally, the cell suspension (2mL) was added to a fresh flask containing 
lOmL of DMEM/F12 medium containing L-glutamine, which was incubated at 37°c 
in 5% CO2 
3.2.6 P repa ra t i on o f New Stocks o f Н Е К 293 Cells 
Н Е К 293 cell stocks were prepared by the addition of trypsin-EDTA (4mL) to 
dissociate the cells for 1 minute at 37°c and 20mL of DMEM/F12 medium containing 
L-glutamine was added. The cells were centrifuged at 200xg for 5 minutes at 4°c. The 
pellet was resuspended in DMEM/F12 medium containing L-glutamine (4.8mL) 
supplemented with FCS (0.6mL) and dimethyl รนIphoxide (DMSO) (0.6mL). The cell 
suspension was immediately divided into three cryogenic vials and stored at -80°c for 
34 hours and then transferred to liquid nitrogen. 
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For the preparation of a new culture, a single cryogenic vial of frozen Н Е К 293 cells 
was thawed at ътс. The cells were centrifuged at 200xg for 5 minutes at 4 で and 
resuspended in DMEMF/12 medium containing L-glutamine (15mL). The cells were 
added to a tissue culture กask, which was incubated at ътс in 5 % CO2 and cultured. 
3.2.7 C a l c i u m Phosphate P rec ip i t a t i on -Med ia ted T rans fec t i on o f Н Е К 293 
Cells 
Н Е К 293 cells were transfected by the calcium phosphate precipitation method 
(Chazot et aly 1999). Cells were subcultured 24 hours prior to the transfection to a 
density of 〜4xlo6 cells per flask (approx 30% confluence). On the day of the 
procedure the medium was removed 3 hours prior to the transfection and replaced 
with lOmL of DMEM/F12 medium without L֊glutamine (Sigma, UK) . The cells were 
incubated at ътс in 7.5 % с Օշ. For the transfection of the cells tubes A and в were 
prepared. Tube A contained 440 IAL 1:10 ТЕ buffer and \0\kL DNA (10μg/μL) and 
Tube В contained 500&L of 2xHBS buffer pCISNRl/NR2A or 
pCISNR 1/NR2A/NR2B (1:3 or 1:3:3 cDNA ratios, respectively). Calcium chloride 
(2.5 M ) (50 цЬ) was warmed to 37°c and was slowly added to Tube A and mixed 
vigorously. The contents of Tube A were added to Tube в at a rate of 1 drop per 5 
seconds and the mixture was pipetted up and down until the solution appeared cloudy. 
The contents of Tube В were added slowly to the medium over Н Е К 293 cells and the 
medium was swirled to distribute the precipitate evenly. Following 3 hours incubation 
at ЪТС at 7.5% CO2, the medium from the cells was removed. 15% (v/v) glycerol in 
PBS was gently spread over the cells and incubated for 30 seconds at room 
temperature. The glycerol solution was removed and the cells were rinsed with 
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DMEM/F12 medium without L-glutamine (~5mL). Fresh DMEM/F12 medium 
without L-glutamine ( lOmL) was added to the cells and incubated at 37°c for 48 
hours with a 5% CO2 level. In the case of transfection of functional receptors, 
ketamine (lO '^M) was added to the medium to prevent receptor-mediated cytotoxicity. 
3.2.8 Rout ine Ha rves t i ng a n d M e m b r a n e P repa ra t i on o f H E K 293 Cells 
Transfected HEK 293 cells were harvested 48 hours fol lowing calcium phosphate 
precipitation transfection. Homogenisation buffer (50mM Tris, 5mM EDTA, 5mM 
EGT A, рН7.4) (5mL) was added and the cells were scraped using Greiner cell 
scrapers and placed into ice-cold centrifuge tubes. The cell suspension was washed by 
centrifugation for 3 minutes at 3000xg to pellet the cells. The pellet was resuspended 
in homogenistion buffer (5mL) and homogenised using a dounce glass/glass 
homogeniser (֊20 strokes). The homogenate was re-centrifuged for 30 minutes at 
11 ,ΟΟΟφΓΠ at 4°c. The supernatant was discarded and the cell pellet was then 
resuspended in ice-cold homogenisation buffer (6mL) and homogenised to a smooth 
suspension. The cell suspension was assayed for radioligand binding activity or was 
stored in ÌOOμL aliquots at -20°c until use for immunoblotting. 
3.2.9 Genera t ion o f a n t i - N R 2 A A f f i n i t y C o l u m n us ing I m u n o P u r e ® 
r P r o t e i n A I g G Plus O r i e n t a t i o n K i t 
The gel beads ( I m L ) were gently suspended by gentle stirring with a Pasteur pipette 
before allowing the storage solution to pass through the column under gravity. The 
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column was equilibrated with 2.5mL ImmunoPure® Antibody Binding/Wash buffer. 
The NR2A antibody ( 1 mg/mL) from Bleed 2 was diluted 1:1 wi th ImmunoPure® 
Antibody BindingAVash buffer to make a total volume of 8ml and added to the 
column, mixing batchwise over night at 4"'C. Under gravity, the unbound antibody was 
allowed to pass through the column and was retained at 4^c to determine binding 
efficiency. The column was washed 2 X 2.5mL with ImmunoPure® Antibody 
Binding/Wash buffer. Cross-linking buffer was prepared by reconstituting BupH™ 
Buffer Pack with sterile distilled water and Disuccinimidyl Suberate (DSS) was 
dissolved in 500I IL Dimethylsulfoxide (DMSO). The dissolved DSS was transferred 
to a new glass vial with the addition of 750μL cross-linking buffer. Once this solution 
was mixed, it was immediately pipetted onto the antibody-bound column and 
incubated batchwise for 1 hour at room temperature. Following incubation, the 
remaining solution was allowed to pass through the column before washing the gel 
beads with 2.5mL of cross-linking buffer. The remaining non-reacting NHS-ester 
(DSS) groups were blocked with the addition of ImL of ImmunoPure® Blocking 
Buffer to the column with gentle mixing batchwise for 10 minutes at room 
temperature. The remaining solution was allowed to pass through the column under 
gravity prior to the incubation with 2.5mL ImmunoPure® IgG Elution Buffer mixing 
batchwise for 5 minutes at room temperature. The solution was passed through the 
column but retained at 4°c to analyse the cross-linking efficiency. The column had a 
series of wash steps including I m L of ImmunoPure® IgG Elution Buffer, 2 X 2.5mL 
ImmunoPure® Antibody Binding/Wash buffer and 3 X 5mL 50mM diethylamine (pH 
11.5), to ensure all non-covalent attached antibody was removed from the column. 
The column was regenerated with PBS and stored in PBS with 0.02% (พ/v) sodium 
azide at 4。c (Figure 3.3). 
I l l 
Immobilized rProteín A Antibody Complexes 
เ»֊-0֊C֊0*,-0<֊CM,֊4>4,֊CM,֊4>V֊<ะ֊֊o-*< 
DMUccMmiM «ub«at* (OSS) 
Figure 3.3: Reaction Scheme of ImmunoPure® rProtein A IgG Plus Orientation Ki t 
(Pierce, Rockford, UK) 
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3.2.10 Iso la t ion o f N R 1 / N R 2 A a n d N R 1 / N R 2 A / N R 2 B Sub type Receptor 
f r o m Trans fec ted Н Е К 293 Cel ls 
250mL flasks of Н Е К 293 cells with a confluence of 30-40% were co-transfected with 
pCISNRl/NR2A or pCISNRl/NR2A/NR2B to a ratio of 1:3 or 1:3:3, respectively, 
with a total concentration of lOpg cDNA using the calcium phosphate precipitation 
transfection method. Cells were harvested 48 hours post-transfection. PBS (5mL) was 
added and the cells were scraped using Greiner cell scrapers and placed into ice-cold 
centrifuge tubes. The cell suspension was washed by centrifugation for 3 minutes at 
3000xg to pellet the cells. The pellet was resuspended in PBS (5mL) and 
homogenised using a do unce glass/glass homogeniser (-20 strokes). The homogenate 
was re֊centrifuged for 30 minutes at 11,000rpm at 4°c. The solubilisation of the 
membranes was essentially described by Hawkins et al (1999). The supernatant was 
discarded and the cell pellet was then resuspended in ice-cold solubilisation buffer 
(0.5M sodium chloride, 50mM Tris, 1% (v/v) Triton X 100, pH 7.4) (3.3ทาL) to give a 
final protein concentration of 1.5 mg/mL. Protease cocktail inhibitors (1:100) were 
added to the cells and were homogenised to a smooth suspension before dividing the 
volume into two eppendorfs. The eppendorfs were mixed for 30 minutes at 4°c 
followed by centrifugation at 13,000 фгп for 5 minutes at 4°c. Supernatants were 
pooled with an aliquot (25μL) taken for further analysis. The pellets were resuspended 
in solubilisation buffer (3.3mL) and homogenised before taking an aliquot (25цЬ) for 
further analysis. 
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3.2.11 P u r i f i c a t i o n of N R 1 / N R 2 A o r N R 1 / N R 2 A / N R 2 B Subtype Receptor 
us ing an a n t i - N R 2 A A n t i b o d y A f f i n i t y C o l u m n 
Immunopurification using the new anti-NR2A immunoaffinity column was carried out 
as described by Chazot et al (2002) (Figure 3.4). The solubilised material (from 
section 3.2.10) was dialysed for 2 X พ2 hours in dialysis buffer (0.45M potassium 
chloride, lOmM HEPES, I m M EDTA, 0 . 1 % (v/v) Triton X 100, 0.2% (พ/v) sodium 
deoxycholate, pH 7.6) at 4°c. Meanwhile, the anti-NR2A immunoaffinity column was 
equilibrated with dialysis buffer (20mL). The dialyste was diluted to 6mL with 
dialysis buffer, with an aliquot {25\լԼ) taken for further analysis. The solubilised 
membranes were filtered, applied to the column and re-circulated at a rate of 
lOmL/hour, overnight at 4°c. The unbound material was collected with an aliquot 
(25IXL) taken for further analysis. The column was washed with dialysis buffer for 2 
hours at a rate of 25mL/hour at 4°c. Fractions were eluted at a rate of lOmL/hour 
with elution buffer (50mM diethylamine, 0.05% (พ/v) sodium deoxycholate, pH 11.5) 
at 4 °c and immediately quenched with 2M glycine to a pH<9.0. Aliquots of the 
elution fractions 1-5 (ІООцЬ) were taken for further analysis. The column was 
regenerated with PBS and stored in PBS with 0.02% (พ/v) sodium azide at 4°c. 
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Transí๒etion ๙ НЕКгдз Calh 
^ ^ ^ ^ ^ NR2B ) щШ^ (աշ/Հ ]NR2B ไ 
Ponibh NMDA Reņptor Combinition 
I ļ foHetmļ Solubiliiitjon 
Anti-NR2A affinity 
purification column 
； 1NR2A{^NR2ธ ) 
Unbound NMDAraciptor 
subunit combiniti om 
Figure 3.4ะ Schematic diagram of the possible N M D A receptor subunit combinations 
following transfection, the bound subunit combinations to the anti-NR2A affinity 
purification column fol lowing solubilisation and unbound N M D A receptor subunit 
combinations fol lowing anti-NR2A affinity purification 
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3.2.12 Ana lys is o f the So lub i l i sa t ion and Pu r i f í ca t i on us ing the a n t i - N R 2 A 
A f f i n i t y C o l u m n 
Al l of the aliquots retained from the immunopurification of the N M D A receptor 
subtypes were prepared by chloroform/methanol extraction procedure of protein 
precipitation (Chazot et al., 1998) (see section 3.2.2.2) for SDS-PAGE (see section 
3.2.2.3) and Immunoblotting (see section 3.2.2.4) analyses. The nitrocellulose 
membrane was probed with ant i -NRl , anti-NR2A and anti֊NR2B antibodies 
( lμg /mL) respectively, for validation of all subtype subunits been present in the 
starting material and the efficiency of the anti-NR2A immunoaffinity column. 
3.2.13 Rad io l i gand Sa tu ra t i on B i n d i n g F o l l o w i n g I m m u n o p u r i f i c a t i o n o f 
p C I S N R l / N R 2 A ^ ՝ í R 2 B Trans fec ted Н Е К 293 Cel ls 
Following validation of the immunopurification of NR! /NR2A transfected Н Е К 293 
cell homogenates, triple subunit transfection (NR1 /NR2A/NR2B) was analysed. 
Immunopurified material (peak fractions 2 & 3) (100μL) were incubated, in duplicate, 
with radioligand assay buffer (25mM sodium phosphate buffer, pH 7.4), [^H] RGH-
896 (1.25nM - бОпМ) (20ĮXL) to a total volume of 200μน for 2 hours at 4°c. Non­
specific activity was defined using Ro 25,6981 (lO'^M) for [ 3 H] RGH-896 binding. 
The saturation binding assay was terminated and bound radioligand was collected by 
rapid filtration through Whatman GF/B filters, pre-soaked in 1% (v/v) 
poly(ethyleneimine) solution. The filters were washed (3 X 3mL) using ice-cold 
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lOmM sodium phosphate buffer, pH 7.4, using a Brandei cell harvester. Filters were 
transferred into scintillation vials with Ecoscint A liquid scintillation cocktail fluid 
( ImL) and incubated overnight at room temperature. Bound radioactivity was 
quantified using Packard Tri-Carb 1600TR scintillation spectrophotometer with a 
counting time of 3 minutes per vial. The data was anaylsed using Graph Pad Prism 
version 4.0. See section 2.2.4 for analysis of the radioligand binding data. 
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3.3 Resul ts 
3.3.1 A n t i b o d y concen t ra t ion f o l l o w i n g pept ide a f f i n i t y pu r i f í ca t i on 
When using a peptide-carrier protein conjugate to raise an antibody, high non-specific 
binding can cause a problem. It is therefore essential to carry out affinity purification 
of the anti-peptide antibodies from the resultant antiserum to remove the anti-carrier 
protein antibodies. The production of the peptide affinity column ensured the 
appropriate orientation of peptide coupling to the sepharose beads which mimics the 
coupling between the peptide and the carrier protein in the immunogen. Following the 
incubation of the antiserum on the column, the column is washed and the bound 
antibody is eluted and pH quenched in 1 ml fractions. These fractions are analysed by 
measuring the OD at λ=280ηηι. The results of the peptide affinity purification of the 
anti-NR2A antibody (1381-1394) (Bleed 2) are shown in Figure 3.5. The peak 
antibody containing fractions (1 and 2) were pooled and dialysed against PBS. The 
final antibody concentration of the dialysed fractions was l . lmg/ml . The yield of 
antibody from each bleed is shown below: 
Bleed Number Yie ld of antibodv per mi l l i l i t re of 
serum (ue/mL) 
1 128 
2 468 
3 487 
4 625 
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3.3.2. I m m u n o b l o t t i n g Ana lys is o f A d u l t Rat F o r e b r a i n M e m b r a n e s w i t h 
Bleeds 1， 2， 3 & 4 ^ the an t i - N R 2 A A n t i b o d y 
To assess the utility of the new anti-NR2A antibody from all bleeds, western blotting 
analysis was performed to determine i f the antibody recognised the NR2A receptor 
using an adult rat forebrain membrane preparation. Following SDS-PAGE under 
reducing conditions, the nitrocellulose was probed with varying concentrations (0.5 
and ^ g / m L ) of affinity purified anti-NR2A (1381-1394) antibody from bleeds 1, 2, 3 
& 4. The resultant immunoblot, shows a specific immunoreactive protein species with 
a molecular weight of Mr 180000 ± 8000 (mean 土 SD， ท=4) (Figure 3.6). The ISOkDa 
species is coincident with that previously identified as the NR2A subunit (e.g. 
Hawkins et ai, 1999). In Bleed 3, another immunoreactive band is been detected at a 
molecular weight of Mr 120000, which may refiect a calpain proteolytic fragment. 
The size of the fragment matched that of fragments that can be generated should NR2 
be cleaved at putative consensus sites located in the long intracellular C-terminal 
domain (Bi et al., 1998). Aff inity-purif ied anti-NRl (l7-38Cys) and anti-NR2B (40-
60) were assessed in an identical fashion; these labelled immunoreactive species of Mr 
120,000 and Mr 180,000, respectively (section 3.2.2.4), consistent with previous 
results (e.g. Chazot et al., 1997a^ 2002). 
3.3.3 I m m u n o b l o t t i n g Ana lys is o f T rans fec ted H E K 293 Ce l l Homogenates 
us ing the a n t i - N R 2 A (1381-1394) A n t i b o d y 
Transfection protocol was optimised, and fresh cDNA preparations generated. The 
original stock and freshly prepared preparations of pCISNR2A cDNA were assessed 
by transfection into HEK 293 cells. Following harvesting, the cells were subjected to 
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SDS-PAGE and immunoblotting. To analyse the transfection success, the 
nitrocellulose was probed with the new batch of anti-NR2A (1381-1394) antibody 
(\μg/mL·) (Figure 3.7). The resultant immunoblot showed a distinct co-incident 
immunoreactive band (Mr 180000) with both the original and freshly prepared 
preparations of pCISNR2A cDNA expressed in НЕК 293 cells. Importantly, no 
detectable immunoreactive bands were present from cells which have subjected to 
transfection without cDNA present (control) Н Е К 293 cells (Figure 3.7, Lane 1). 
3.3.4 I m m u n o b l o t t i n g Ana lys is o f the Speci f ic i ty o f the a n t i - N R 2 A (1381-
1394) A n t i b o d y 
To examine the specificity of the new anti֊NR2A (1381-1394) antibody, SDS-PAGE 
under reducing conditions was performed with control transfected Н Е К 293 cells, 
NR2A transfected Н Е К 293 cells, NR2B transfected Н Е К 293 cells and forebrain 
membranes. The immunoblot was probed with affinity-purified anti-NR2A receptor 
antibody at a final concentration of 1 μ g/mL in the presence and absence of the 
respective peptide (500μg/mL). 
The resultant immunoblot probed with anti-NR2A (1381-1394) receptor antibody 
shows no immmunoreactive band with control transfected cells and NR2B transfected 
НЕК 293 cells, whereas there is a distinct immunoreactive band (Mr 180000) with 
NR2A transfected НЕК 293 cells. A l l bands were abolished by prior incubation of the 
anti-NR2A receptor antibody with NR2A peptide (1381-1394) overnight at 4°c. Ant i -
NR2A (1381-1394) antibody displayed no immunocross-reactivity with other N M D A 
receptor subunits (not shown) when used against HEĶ 293 cells transfected, for 
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example, with pCISNR2B cDNA (Figure 3.8). 
3.3.5 P r o d u c t i o n a n d V a l i d a t i o n of a n t i - N R 2 A (1381-1394) I m m u n o a f f i n i t y 
C o l u m n 
The antibody prior and post affinity column application was assayed for 
immunoreactivity. The binding efficiency of the anti-NR2A (1381-1394) antibody to 
the column was very high (94.1%) column compared to that of Hawkins et al (1999), 
where only 67 ± 18% of the anti-NR2A antibody immunnoreactivity was retained. To 
further analyse the efficiency of the column, the various steps and washes undertaken 
while producing the column were subjected to immunoblotting. The immunoreactive 
protein bands that are detectable in Lane I and Lane 2 (Mr 50000) are the heavy chain 
of purified antibody that was applied to the column before coupling to the sepharose 
beads and the unbound antibody material after coupling to the sepharose beads, 
respectively (Figure 3.9). Interestingly, there was no antibody elution detected which 
has previously been a significant problem with earlier methodologies (Chazot and 
Stephenson, 1997a). To validate the efficiency of the anti-NR2A immunoaffinity 
column, Н Е К 293 cells were transfected with pCISNRl/NR2A, harvested and 
solubilised (see section 3.2.10) before isolation by immunopurification (see section 
3.2.11). The aliquoted fractions were subjected to immunoblotting and probed with 
the anti-NR2A (1381-1394) antibody ( ^ g / m L ) (Figure 3.10). Elution fractions 2 and 
3 were pooled and were used as a positive control for the anti-NR2A (1381-1394) 
antibody ๒ subsequent experiments. A single immunoreactive species (Mr 180,000) 
was detected in the eluted fractions. 
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3.3.6 Sa tu ra t i on B i n d i n g Ana lys is us ing N R 1 / N R 2 A / N R 2 B 
I m m u n o p u r í f í e d Homogenates 
Trimeric NR 1 /NR2A/NR2B immunopurified material was assayed in saturation 
binding studies using fu.] RGH-896 ( 1.25nM-60nM), defining non-specific binding 
with Ro 25,6981 (lO'^M) as determined in Chapter 2. Results shown in Figure 3.11 
were best fitted to a one-site binding hyperbola. Analysis of the saturation data using 
non-linear least square regression showed that [^H] RGH-896 bound with a KD of 7.2 
土 8.1 пМ, and a в max of 257 土 67 fmoles/mg of protein (two repeats of the same 
forebrain preparation). 
3.3.7 S D S - P A G E a n d I m m u n o b l o t t i n g Ana lys is o f N R 1 / N R 2 A / N R 2 B 
I m m u n o p u r í f í e d Homogenates 
The presence of N R l , NR2A and NR2B subunits in immunopurified material was 
assessed by immunoblotting analysis. Incubation with ant i -NRl , anti-NR2A and anti-
NR2B antibody (1ц§/тЬ) produced immunoreactive protein bands of Mr 120000 for 
anti-NRl antibody, Mr 180000 for anti-NR2A and Mr 180000 for NR2B, respectively, 
in anti-NR2A antibody immunopurified pooled fractions. 
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Figure 3.5: Absorbance measurements of the peptide affinity purification of anti-
NR2A (1381-1394) antibody. 
This graph shows the elution profile, fol lowing peptide affinity purification of anti-
NR2A receptor antibody. Fractions 1 and 2 were pooled together prior to dialysis. 
This is a representative experiment in which l . lmg of total antibody was purified. 
This purification profile was observed for all bleeds. 
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Figure 3.6: Representative immunoblot of adult rat forebrain membranes probed wi th 
Bleed 1 (A) , Bleed 2 (B), Bleed 3 (C) and Bleed 4 (D) o f the anti-NR2A receptor 
antibody at the specified concentrations. A l l bleeds gave an immunoreactive protein 
band o f Mr 180000 and occasionally a smaller proteolytic species o f Mr 120000 (A + 
С). 
Lanes 1 -4 Adult rat forebrain membranes ( 100μ§ protein) 
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Figure 3.7: Immunoblot showing successful cDNA preparation by transfection o f 
control, NR2A (original cDNA stock) and NR2A (freshly prepared cDNA stock from 
MaxiPrep) 
Lane 1 Control transfected cells (ЮОцЬ) 
Lane 2 Original NR2A cDNA stock (ЮОцЬ) 
Lane 3 and 4 Freshly prepared NR2A cDNA stock (1 OOpL) 
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Figure 3.8: Immunoblot showing the specificity o f the anti-NR2A antibody probed 
with affinity-purified anti-NR2A receptor antibody at a final concentration o f 1 μ g/mL 
in the absence (Lanes 1-4) and presence (Lanes 5-8) o f the respective peptide 
(1Ц8/тЬ). 
Lane 1 & 5 Control transfected Н Е К 293 cells (ЮОцЬ) 
Lane 2 & 6 NR2A transfected Н Е К 293 cells (1 ՕՕրԼ) 
Lane 3 & 7 NR2B transfected Н Е К 293 cells (ЮОцЬ) 
Lane 4 & 8 Adult rat forebrain membranes (100μg) 
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Figure 3.9: bnmunoblot o f the fractions from the production o f the anti-NR2A 
immunoaffinity column illustrating the heavy chain o f antibody at 55kDa. 
Lane 1 Pure anti-NR2A antibody @ 0.55mg/ml (10.7цЬ) 
Lane 2 Unbound antibody solution (10|iL) 
Lane 3 Cross-linking solution (ЮцЬ) 
Lane 4 Blocking Buffer ( 1 ОцЬ) 
Lane 5 Elution Buffer (ЮОцЬ) 
Lane 6 Wash with Elution Buffer (ЮОцЬ) 
Lane 7 Diethylamine wash 1 (ЮОцЬ) 
Lane 8 Diethylamine wash 2 (ЮОцЬ) 
Lane 9 Diethylamine wash 3 (ІООцЬ) 
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Figure ЗЛО: Immunoblot showing validation o f anti-NR2A (1381-1394) 
immunoaffinity column. The immunoblot was probed with affinity purified anti-
ŅR2A (1381-1394) ( \ ր տ / ա Լ ) yielding an immunoreactive band o f Mrl 80000 
Lane 1 Starting material {25րԼ) 
Lane 2 Solubilised membranes (25 
Lane 3 บทsolubilised membranes (25րԼ) 
Lane 4 Unbound protein {25րԼ) 
Lane 5 Elution fraction 1 (ІООцЬ) 
Lane 6 Elution fraction 2 (ІООцЬ) 
Lane 7 Elution fraction 3 (ІООцЬ) 
Lane 8 Elution fraction 4 ( 1 ООцЦ 
Lane 9 Elution fraction 5 (ІООцЬ) 
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F i g u r e 3 . 11 : Representative graph of saturation b ind ing analysis o f 
N R 1 / N R 2 A / N R 2 B immunopur i f i ed mater ial using [^H] RGH-896 ( 1 .25nM-60nM) , 
def in ing non-specif ic b ind ing w i th Ro 25,6981 (10" ' 'M). Representative results shown 
are best-f i t to a one-site b ind ing hyperbola. Analys is o f the saturation b ind ing data 
using non-l inear least square regression showed that [ ^ H ] R G H - 8 9 6 bound w i t h a K D 
o f 7.2 土 8.1 п М , and a в max o f 257 ± 67 fmo le /m l o f prote in. Th is 
immmunopur i f i ca t ion exper iment was repeated w i t h s imi lar results. 
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3.4 Discussion 
This chapter has described the product ion o f a panel o f po lyc lona l antibodies raised in 
rabbits, through to characterising the ant ibody in immunob lo t t i ng studies and the 
generation o f a new an t i -NR2A (1381-1394) immunoa f f i n i t y co lumn. The conjugated 
pept ide-protein carrier was emuls i f ied w i t h Freund'ร complete for inoculat ion into the 
rabbit. The use o f an adjuvant is required to nonspeci f ical ly st imulate ant ibody 
product ion. The use o f the adjuvant is to f o r m a deposit protect ing the antigen f r o m 
rapid catabol ism and a l lows fo r s low release. The f i rst in ject ion o f the conjugated 
pept ide-protein was per formed using complete Freund's adjuvant ( C F A ) , wh ich is a 
mix tu re that contains k i l l ed Mycobacterium Tuberculosis. Th is substance works by 
raising the level o f a large set o f soluble peptide g rowth factors k n o w n as 
lymphokines. These lymphok ines st imulate the act iv i ty o f antigen-processing cells 
d i rect ly and cause a local in f lammatory reaction at the site o f in ject ion, wh ich 
explains a large immune response to the f i rst inoculat ion. Subsequent booster 
inoculat ions were per formed using incomplete Freund'ร adjuvant ( I F A ) , wh ich does 
not contain k i l l ed Mycobacterium Tuberculosis. Th is methodology has been used to 
produce a range o f successful N M D A receptor antibodies (Chazot et al" 1992, 1993, 
1994, 1995 1997^ et ai, 1999). 
The product ion o f a peptide a f f i n i t y co lumn was designed to imitate the coup l ing o f 
the peptide to the carrier protein. When using a peptide-carr ier protein conjugate to 
raise an ant ibody, h igh non-specif ic b ind ing can cause a prob lem. It was therefore 
essential to carry out a f f in i ty pur i f i ca t ion o f the anti-peptide antibodies f r o m the 
resultant antiserum to remove the anti-carr ier prote in antibodies. F o l l o w i n g a f f in i ty 
pur i f ica t ion o f the an t i -NR2A ant ibody, i t was necessary to test the ant ibody using 
forebrain membranes by immunob lo t t i ng to ver i fy that the ant ibody recognised the 
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native N R 2 A subunit. The resultant immunob lo t , showed a speci f ic immunoreact ive 
protein species w i t h a molecular we ight o f M r 180000 土 8000 (mean 土 S D , ท=4) 
wh i ch was coincident w i t h that prev iously ident i f ied in the l i terature (Hawk ins et α ι . , 
1999). 
T o examine the speci f ic i ty o f the an t i -NR2A ant ibody, native forebrain preparations 
and ind iv idua l recombinant N M D A subunits expressed in Н Е К 293 cells were used. 
The immunob lo t was probed w i t h a f f in i t y -pur i f ied an t i -NR2A receptor ant ibody in the 
presence and absence o f the respective peptide. The resultant immunob lo t probed w i t h 
an t i -NR2A receptor ant ibody ident i f ied a single immunoreact ive species (Mr 180000) 
w i t h N R 2 A transfected Н Е К 293 cells and forebrain membranes (Hawk ins et al., 
1999). A l l bands were abolished by pr ior incubat ion o f the an t i -NR2A receptor 
ant ibody w i t h N R 2 A peptide (1381-1394) . A n t i - N R 2 A ant ibody displayed no 
immunocross-react iv i ty w i t h other N M D A receptor subunits when analysed against 
N R 1 / N R 2 B transfected Н Е К 293, thus indicat ing this ant ibody is specif ic on ly to 
N R 2 A subunits. Bo th the peptide blockade and lack o f immunocross-react iv i ty w i t h 
N R l and N R 2 B funct ioned as a sound contro l measure to conclude the an t i -NR2A 
ant ibody was specif ic fo r NR2A-subun i t only. The resultant panel o f an t i -NR2A 
antibodies was used to generate an an t i -NR2A immunoa f f i n i t y co lumn ( ImmunoPure® 
rProtein A I g G Plus Or ientat ion K i t , Pierce, Rock fo rd , U K ) . The b ind ing ef f ic iency o f 
the an t i -NR2A (1381-1394) ant ibody to the novel immunoa f f i n i t y co lumn was very 
h igh (94.1%) compared to that o f Hawk ins et al., (1999), where on ly 67 土 18% o f the 
an t i -NR2A ant ibody immunnoreac t iv i t y was retained. F o l l o w i n g va l idat ion o f the 
ab i l i ty and e f f i c iency o f this co lumn to b ind N R 2 A contain ing receptors, i t was used to 
further characterise the NR2B-se lec t ive compound RGH-896 . 
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Ro 25 ,6981 , an i fenprod i l analog, is selective for N R 2 B conta in ing N M D A receptors 
w i t h an approximate 5000- fo ld higher a f f i n i t y for heteromeric N R 1 / N R 2 B receptors 
than N R 1 / N R 2 A receptors, showing the select iv i ty fo r N R 2 B subunit (Mu te i et al., 
1998). Studies by Br imebcome et al., (1997) and Chazot (2000) have indicated CP-
101,606 may be inf luenced by the presence o f other NR2-subun i t types w i t h i n the 
N M D A receptor complex. These two NR2B-se lect ive l igands, [ 3 H ] Ro 25, 6981 
(Hawk ins et al., 1999) and [^H] CP-101,606 (Chazot et al., 2002) , show the presence 
o f d i f ferent N R 2 subunits in receptor complexes can effect the b ind ing o f related 
radiol igands. [ 3 H ] Ro 25,6981 binds to both N R 1 / N R 2 B and N R 1 / N R 2 A / N R 2 B 
subtype receptors w i t h s imi lar h igh af f in i t ies suggesting Ro 25,6981 is selective for 
al l N M D A receptors conta in ing the N R 2 B subunit. Conversely, [ 3 H ] CP 101,606 
appears to b ind on ly to N R 1 / N R 2 B subtype receptors and not to N R 1 / N R 2 A or 
N R 1 / N R 2 A / N R 2 B subtype receptors. Th is suggests that CP 101,606 is selective for 
d imer ic N R l / N R 2 B - s u b t y p e . 
In this chapter we have investigated the select iv i ty o f the novel NR2B-se lec t ive 
antagonist R G H - 8 9 6 , using the novel immunopur i f i ca t ion approach described by 
Chazot et al., 2002, to assess whether R G H - 8 9 6 behaves l ike Ro 25,6981 or CP-
101,606. Co-transfect ion o f mammal ian cells w i t h p C I S N R l , N R 2 A and N R 2 B 
c D N A produces a heterogeneous m i x o f N R l , N R 2 A , N R 2 B , N R 1 / N R 2 A , 
N R 1 / N R 2 B and N R 1 / N R 2 A / N R 2 B subtype receptors (Br imecombe et al., 1997). T o 
isolate the N R 1 / N R 2 A / N R 2 B f r o m N R 1 / N R 2 B receptors f o l l o w i n g t r ip le subunit-
transfect ion, we ut i l ised an immunopur i f i ca t ion strategy w i t h the novel anti֊NR2A 
(1381-1394) immunoa f f i n i t y co lumn produced in this project. The immunopur i f i ed 
material was subjected to immunob lo t t i ng and radio l igand b ind ing saturation analysis 
to fur ther characterise [^H] R G H - 8 9 6 b ind ing propert ies. The pooled fract ions when 
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analysed in radio l igand saturation b ind ing showed that [^H] R G H - 8 9 6 bound w i t h a 
K D o f 7.2 ± 8.1 n M . The N R 2 B radio l igand is therefore b ind ing to forebrain 
membranes ( K D 6.5 土 4.6 n M , Chapter 2 ) , N R 1 / N R 2 B cell homogenates (K i 9.5 п М , 
Chapter 2) and immunopur i f i ed mater ial ( K D o f 7.2 土 8.1 n M ) w i t h a s imi lar h igh 
a f f in i ty . Fo l l ow ing solubi l isat ion and immunopur i f i ca t ion o f the transfected mater ia l , 
subunits N R l , N R 2 A and N R 2 B were all present in immimopur i f i ed material (not 
shown) by using immunob lo t t ing procedure. A l l immunoreact ive bands detected were 
consistent w i t h the predicted molecular size o f the N R l , N R 2 A and N R 2 B subunit , 
respectively (Brose et al., 1993; Chazot et al., 1994; Blahos and Wen tho ld , 1996). 
In conc lus ion, the novel f ind ing f r o m this chapter indicates R G H - 8 9 6 binds w i t h a 
s imi lar h igh a f f in i ty to forebrain membranes, N R 1 / N R 2 B and N R 1 / N R 2 A / N R 2 B 
conta in ing receptors. Therefore, R G H - 8 9 6 binds to NR2B-con ta in ing receptors 
irrespective o f the N R 2 subunit compos i t ion (partners) s imi lar to Ro 25 ,6981 . The 
determinat ion o f the b ind ing properties o f the novel NR2B-se lect ive N M D A 
antagonist RGH-896 is important as previous studies have shown CP 101,606 can be 
inf luenced by the presence o f other NR2-subun i t types w i th in the N M D A receptor 
complex. The data generated in this chapter indicates RGH-896 is showing a b ind ing 
pro f i le s imi lar to Ro 25, 6981 . A number o f NR2B-select ive compounds have been 
developed to target specif ic areas o f the brain depending upon the affected bra in 
region. Th is chapter adds to the in fo rmat ion relat ing to the pharmacological p ro f i le o f 
these compounds; R G H - 8 9 6 and Ro 25,6981 being dist inct f r om CP 101,606. It s t i l l 
remains to be determined wh ich o f these two classes w i l l be most useful to target for 
therapeutic benefi t . N o w that subtype select iv i ty o f R G H - 8 9 6 has been def ined, the 
next chapter w i l l use [^H] RGH-896 to quant i fy NR2B-con ta in ing receptors in the 
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rodent and human brain using l igand autoradiography. The next chapter addresses 
whether levels o f NR2B-con ta in ing receptors (def ined using [^H] RGH-896 ) in the 
anterior cingulate cortex correlate w i t h specif ic psychot ic symptoms in human 
dementia w i t h L e w y bodies ( D L B ) . A compar ison w i l l also be made w i th ["Ή] Ro 
25,6981 and [^H] CP 101,606, in order to prov ide further evidence for N R 2 B receptor 
heterogeneity in the human brain. 
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Chapter 4 
Ligand Autoradiographical Analysis of Rodent and Human 
Brain Tissue using a Novel NR2B-selective Antagonist, RGH-
896 Focusing on the Anterior Cingulate Cortex 
4.1 Introduction 
In d i f ferent C N S disease states, many s imi lar adverse effects are seen in af fected 
patients. Schizophrenics can show hal lucinat ions, delusions, depression and cogni t ive 
def ic i ts i f not treated. In compar ison, A lzhe imer ' ร disease patients can show cogni t ive 
def ic i ts, dementias and depression but this disease w i l l be treated w i th alternative 
therapies. Th is is due to the dist inct brain region invo lved as there is an assortment o f 
exci tatory and inh ib i to ry pathways afferent and efferent to the target region (Lewis 
and L iebermann, 2000). There are two hypothesis that are bel ieved to be invo lved in 
schizophrenia and psychosis, these been the glutamate hypothesis and the dopamine 
hypothesis (see 1.10.6.7). Researchers f o l l o w their o w n thoughts to wh ich theory to 
investigate but i t is possible that both the dopamine and the glutamate hypotheses 
in ter l ink due to the various connect ing pathways invo lved between brain regions. For 
this thesis it is the glutamate hypothesis that w i l l be investigated. N M D A receptor 
channel b lockers, ketamine and phencycl id ine (PCP) are capable o f induc ing a 
number o f schizophrenic- l ike symptoms, inc lud ing posi t ive, negative and cogni t ive 
abnormal i t ies in normal humans as we l l as exacerbating exist ing symptoms in 
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schizophrenic patients (Steinpreis, 1996). In rodents, N M D A receptor channel 
blockers induce behavioural , cogni t ive and neurochemical changes m i m i c k i n g those 
observed in schizophrenic patients (Jentsch and Roth , 1999), therefore support ing an 
N M D A receptor hypofunct ion hypothesis o f schizophrenia (Olney et al., 1999). There 
is increasing evidence studying the N M D A receptor, to suggest a def ic iency in 
glutamatergic neurotransmission may under l ie the pathology o f psychosis (Rujescu et 
al., 2005). Th is N M D A hypofunct ion theory o f schizophrenia is indi rect ly supported 
by new genetic f ind ings. Several o f the recently discovered putat ive schizophrenia 
genes may funct ion by interact ing w i t h the glutamate act iv i ty through d i f ferent effects 
on the N M D A receptor mediated transmission (Harr ison and Weinberger, 2005). 
N M D A receptors have been impl icated as a mediator o f neuronal in ju ry associated 
w i t h many neurological disorders and consequently, compounds that enhance N M D A 
receptor-mediated transmission may be therapeutical ly benef ic ia l (Kemp and 
M c K e r n a n , 2002). Gao et al., (2000) and G r i m w o o d et al., (1999) have suggested that 
N R 2 B has a role to play in schizophrenia, where N M D A NR2B-subun i t m R N A and 
N R 1 /NR2B-subtype b ind ing sites have been shown to be select ively increased in 
h ippocampal and cort ical regions in schizophrenia ( rev iewed in Chazot, 2004). 
A French neurologist , Paul Broca ( 1878) noted on the media l surface o f the cerebrum, 
there was a group o f cort ical areas that were d is t inct ly d i f ferent f r o m the surrounding 
cortex. Broca named this co l lect ion the " l i m b i c l obe" as i t fo rmed a border around the 
brain stem. Papez (1937) proposed there was an "emot iona l sys tem" l y ing on the 
medial wa l l o f the brain that l inks the cortex w i t h the hypothalamus, wh ich became 
k n o w n as the Papez c i rcui t . In the c i rcu i t , the cingulate cortex affects the 
hypothalamus v ia the hippocampus and fo rn ix (a large bundle o f axons leaving the 
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hippocampus), whereas the hypothalamus affects the cingulate cortex v ia the anterior 
thalamus. The correlat ion between Broca 'ร l imb ic lobe and Papez'ร c i rcu i t gave rise 
to the l imb ic system wh ich are anatomical ly interconnected and are invo lved in 
emot ion, learning and memory . 
The cingulate cortex is situated roughly in the midd le o f the cortex (Figure 4.1). 
Cingulate cortex can also be di f ferent iated based on its thalamic connections (Vog t et 
al, 1979). In addi t ion, the anterior c ingulate cortex ( A C C ) can be di f ferent iated f r o m 
the posterior c ingulate cortex on the basis o f cytoarchitecture and patterns o f 
project ion (Vogt et al, 1992). The A C C receives signals p r imar i l y f r om the mid- l ine 
and intra- laminar nucle i and posterior c ingulate cortex receives signals ma in ly f r om 
the anterior thalamic nuclei . A C C is the f ronta l part o f the cingulate cortex and 
includes Brodmann'ร area 24 (ventral A C C ) and 32 (dorsal A C C ) . The anterior 
cingulate cortex fo rms a col lar around the corpus ca l losum, wh ich relays neural 
signals between the r ight and left hemispheres (Vog t et al, 1995). Neuro imag ing 
studies have ident i f ied the A C C ' s invo lvement in transient mood changes (Mayberg 
et al, 1999), depression and anxiety disorders (Mayberg et al, 2000; B rody et al, 
2001) and the percept ion o f pain (Ra inv i l le et al., 1997). I t is thought that the dorsal 
A C C is p r imar i l y related to rat ional cogn i t ion wh i le the ventral is more related to 
emot ional cogni t ion (Bush et al., 2000). The cingulate cortex is a key brain region 
invo lved in funct ional psychosis, for example, depression (George et al., 1997), 
delusions (B lackwood et al., 2000) , b ipolar disorder (B lumberg , 2000) and 
hal lucinat ions (Sherg i l l et al., 2000). Psychotic symptoms inc lud ing impaired 
consciousness, delusions, audi tory and visual hal lucinat ions occur f requent ly in 
dementia w i th L e w y bodies ( D L B ) patients. 
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L igand autoradiographical studies w i l l be per formed for the f i rst t ime using the novel 
radio l igand [^H] R G H - 8 9 6 in rodent brain. Condi t ions w i l l be opt imised and 
compared to other N M D A receptor NR2B-se lec t ive radiol igands. Based on these 
opt imised studies, human l igand autoradiography studies w i n be used to quant i fy 
levels and delineate the b ind ing expression pattern o f NR2B-se lect ive antagonist 
radio l igand [^H] R G H - 8 9 6 , focusing on the A C C area o f the brain and the psychot ic 
c l in ica l features o f the ind iv idua l D L B cases. 
Fornix 
Septal 
Nuclei 
Mammlllary 
body -
Amygdala 
Hippocampus 
Hippocampus ๗ 
right hemisphere 
(glK»ted เท) 
Cingulate 
เᄂ cortex 
Ч ノ 
F i g u r e 4 . 1 : Ma jo r structures o f the l imb ic system o f the brain showing the cingulate 
cortex (Le M o y n e Col lege, N e w Y o r k ) 
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).2 Methods 
5 .2 .1 R o d e n t A u t o r a d i o g r a p h y 
5.2.1.1 T issue I so la t i on a n d Sec t ion ing 
A n adult male w i ld - type Sprague Daw ley rat (250-300g) was deeply anaesthetised 
w i t h phénobarbi tal . T o ensure no pain to the an imal , the p inch ing and ref lex o f the 
h ind paw was tested as we l l as the eye b l i nk ing ref lex. Once these reflexes were 
abol ished, the animal was p inned out on the dorsal surface, w i t h the ribcage exposed 
and retracted. A cannula was inserted into the left ventr ic le o f the heart to perfuse ice-
co ld O . I M sod ium phosphate buf fer , p H 7.4, conta in ing 0 . 1 % (v /v ) sod ium ni tr i te via 
a peristalt ic pump. A n inc is ion was made to the r ight a t r ium o f the heart where the 
animal was exsanguinated in this way fo r 5 minutes. The perfusate was swi tched to 
the f ixa t ive o f ice-cold 4 % (พ / v ) paraformaldehyde in O . I M sod ium phosphate buf fer , 
p H 7.4 for 20 minutes. The rodent brain was removed f r o m the skul l and immersed in 
the same f i xa t ive overnight at 4°c and later stored in PBS (< 7 days). Pr ior to 
sect ioning o f the tissue, the brain was incubated in 10% ( พ / v ) sucrose in PBS for 48 
hours. The sucrose in f i l t ra ted brain was f rozen in isopentane over l i qu id ni t rogen for 1 
minute at -70°c, and was placed into the cryostat to equi l ibrate to -24°c. The who le 
brain was sectioned at 16μ, thaw-mounted onto po ly -D- lys ine coated slides and stored 
at -20°c. Var ious levels o f the brain was analysed in the rodent autoradiography study 
to ver i f y N R 2 B expression compared to the publ ished l i terature. 
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4.2.1.2 Recep to r A u t o r a d i o g r a p h y 
The method used was or ig ina l ly described by M u t e l et CiL, (1998) w i t h modi f icat ions 
made specif ic to the radio l igand. Sections were lef t to equi l ibrate to room 
temperature f r o m -20°c fo r at least 1 hour pr ior to the exper iment. The same method 
was repeated wi thout 0 . 1 % (พ / v ) B S A throughout , w i t h 0 . 1 % (พ / v ) BS A post-
radio l igand incubat ion and 0 . 1 % (พ /v ) B S A throughout the who le exper iment. The 
sections were pre-incubated for 2 X 10 minutes in 5 0 m M T r i s - H C l buf fer , p H 7.4 
contain ing l O m M E D T A at room temperature to remove endogenous l igands. Us ing 
pre- incubat ion buf fer supplemented w i t h l O n M [^H] RGH-896 (approximate K D 
value) (specif ic act iv i ty = 2 3 C i / m m o l , stored at —20°c)， the sections were incubated 
for 90 minutes at 4 。 c to achieve equ i l i b r ium. Non-speci f ic b ind ing was def ined in 
the presence o f spermidine (10"^M) or Ro 25,6981 ( lO ' ^M) . F o l l o w i n g incubat ion in 
radio l igand, sections were washed in 5 0 m M T r i s - H C l buf fer , p H 7.4 conta in ing 
l O m M E D T A , for a total o f 25 minutes ( 2 x 5 minutes, 1 X 15 minutes) at 4°c, and 
d ipped in ice co ld d H i O . Sections were lef t to air dry under a stream o f co ld air un t i l 
complete ly dry at r oom temperature. The dr ied slides were opposed to [՝^H]֊ 
H y p e r f i l m fo r 4 or 6 weeks alongside [^H]-autoradiography standards at room 
temperature. F o l l o w i n g development in D֊19 developer (Kodak) at r oom temperature 
and f ixa t ion in บ ท i f i x (Kodak) at r oom temperature, the autoradiographic data was 
quant i f ied using image analysis. 
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4.2.1.3 I m a g e Ana l ys i s 
The developed brain images were scanned onto a f lat-bed scanner and analysed using 
Image J imag ing program, by captur ing 5 areas ( 2 m m X 2 m m ) o f the region to be 
analysed f r o m various autoradiograms. The [• 'Hl-autoradiography standards were 
ut i l ised to produce a standard curve for each autoradiogram. The density o f b ind ing 
was calculated in fentomole per m i l l i g ram of tissue ( fm /mg) , wh i ch was based on the 
compar ison o f optical density o f sections w i th that o f the autoradiographic standards. 
Adjustments were made according to the specif ic act iv i ty o f the radio l igand. N o n ­
specif ic slides were adjacent sections f r o m the total b ind ing slides. Specif ic b ind ing 
was calculated by subtract ing the average of non-specif ic b ind ing f r o m the average in 
total b ind ing. Bra in structures to be analysed were ident i f ied f r o m each 
autoradiogram. Five areas ( 2 m m X 2 m m ) f r om a part icular structure were captured in 
Image J， and the mean and standard deviat ion o f the 5 areas fo r each brain region 
(hippocampus (subfields C A I , С А З and dentate gyrus) , cort ical laminae and 
cerebel lum) were calculated. Graphs corresponding to where the radiol igand was 
b ind ing were constructed using M ic roso f t Exce l . 
4 .2 .2 H u m a n A u t o r a d i o g r a p h y 
A l l D L B cases were autopsy conf i rmed D L B patients who had been assessed dur ing 
l i fe as part o f the Newcast le Dement ia Case Register series. Diagnosis at autopsy was 
in accordance to the Consensus cr i ter ia fo r c l in ica l and neuropathological diagnosis o f 
D L B , Wr i t t en consent was received f r o m the next o f k in to use the tissue in the study. 
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The studies were approved by Newcast le and No r th Tyneside Loca l Research Ethics 
Commi t tee . Tissue was obtained f r o m the Bra in Bank in Newcast le General Hospi ta l , 
Tyne & Wear. Sections chosen to be analysed contained c ingulate cortex in contro l 
cases, dementia w i t h L e w y bodies ( D L B ) cases, and Park inson's Disease w i th 
dement ia (PD + D L B ) cases using the Coronal M a p o f B rodmann Areas in the Human 
Bra in (Perry et al.， 1993). F ive contro l cases w i th no evidence o f neurological or 
psychiatr ic disease (4 male and 1 female) w i t h age ranging f r om 67-78 were 
compared to eight pooled D L B and P D + D L B cases (5 male and 3 female) w i t h age 
ranging f r o m 72-87. The demographic data are shown in Table 4 . 1 . A t the t ime o f this 
pre l iminary invest igat ion, human tissue was l im i ted and hence the var iat ion o f the 
demographics o f the chosen cases, where ranges vary f r o m a M M S E score o f 6 to an 
M M S E score o f 22, as a M M S E score over 24 out o f a possible 30 is classed as 
e f fec t ive ly normal . 
Assessments inc lud ing a standardised psychiatr ic history (Dewey et α/., 1992) and 
assessment o f cogni t ive func t ion (Roth et al., 1986) were completed. 
Neuropsychiatr ie evaluat ion was measured using the Co lumb ia Univers i ty Scale for 
Psychopathology in Alzheimer 's Disease ( C U S P A D ) to evaluate psychotic features 
(Devanand et al., 1992). The M i n i Menta l State Examinat ion ( M M S E ) (Folstein et α/·， 
1975) explores the or ientat ion, short- term memory , at tent ion, concentrat ion, 
ca lcu lat ing abi l i ty and motor act iv i t ies. The assessments and evaluations were 
repeated at least annual ly unt i l death and symptoms were classif ied as persistent i f 
they were present cont inuously for at least six months at some stage o f the dementia. 
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4.2.2.1 T issue I so la t i on 
The brain was d iv ided into two hemispheres at autopsy, where the r ight hemisphere 
was f i xed in fo rma l in for neuropathological analysis and the left hemisphere was 
sl iced coronal ly into 1cm slices. The 1cm slices were sealed in air t ight polythene, 
rap id ly f rozen in Arc ton at -70°c, fur ther cooled over l i qu id ni t rogen and stored at 
-80°c. Pr ior to sect ioning the tissue was sub-dissected to prov ide blocks conta in ing 
cingulate cortex (Perry et al, 1993). The 1cm slices o f tissue were a l lowed to wa rm 
to 15°c. Tissue was mounted onto cryostat blocks w i th 8 % carboxymethylcel lu lose. 
Coronal sections were cut at 20 microns f r o m snap-frozen tissue and thaw mounted 
onto Vectabond coated slides (Vector Laborator ies, U K ) . Sections were lef t to air dry 
fo r 1-2 hours and were stored at -80°c un t i l use fo r receptor autoradiography. 
4.2.2.2 Recep to r A u t o r a d i o g r a p h y 
The method used was or ig ina l ly described by M u t e l et ö/. ,(1998) w i th modi f icat ions 
made specif ic to the radio l igand. Sections were left to equi l ibrate to room 
temperature f r o m -80°c fo r at least 1 hour p r io r to the exper iment. The sections were 
pre- incubated for 2 X 10 minutes in 5 0 m M T r i s - H C l buffer , p H 7.4 conta in ing l O m M 
E D T A and 0 . 1 % B S A at room temperature to remove endogenous l igands. Us ing 
pre- incubat ion buf fer supplemented w i t h 5 n M [^H] R G H - 8 9 6 (specif ic act iv i ty = 
2 3 C i / m m o l , stored at -20°C) , the sections were incubated fo r 90 minutes at 4°c to 
achieve equ i l i b r i um. Non-speci f ic b ind ing was def ined in the presence o f Ro 25,6981 
( lO ' ^M) (See Chapter 2). Fo l l ow ing incubat ion in radio l igand, sections were washed 
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in 5 0 m M T r i s - H C l buf fer , p H 7.4 conta in ing 0 . 1 % B S A , for a total o f 25 minutes (2 
X 5 minutes, 1 X 15 minutes) at 4°c, and d ipped in ice co ld d H 2 0 . Sections were left 
to air dry under a stream o f co ld air un t i l complete ly dry at r o o m temperature. The 
dr ied slides were opposed to [^H]֊Hyperfi lm for 4 weeks alongside ["^H]-
autoradiography standards at 4°c. F o l l o w i n g development in Devalex (Patterson 
Scient i f ic) for 5 minutes at room temperature, rinse in co ld water for 1 minute and 
f ixa t ion in B lack and W h i t e A m f i x (Patterson Scient i f ic) for 6 minutes at r oom 
temperature, the autoradiographic data was quant i f ied using image analysis. 
4.2.2.3 I m a g e Ana l ys i s 
The developed brain images were captured using a Dage 72 M T I C C D 7 2 ร video 
camera and were quant i tat ively analysed by computer-assisted densitometry using 
Mic rocomputer Imag ing Device ( М С Ю El i te) Vers ion 7.0 software f r o m Imag ing 
Research I n c , Ontar io , Canada. The [՝^H]֊autoradiography standards were ut i l ised to 
produce a standard curve for each autoradiogram. The density o f b ind ing was 
calculated in fentomole per m i l l i g r a m o f tissue ( fm /mg) , wh ich was based on the 
compar ison o f opt ical density o f sections w i t h that o f the autoradiographic standards. 
Adjustments were made according to the specif ic act iv i ty o f the radio l igand. N o n ­
specif ic slides were adjacent sections f r o m the total b ind ing slides. Speci f ic b ind ing 
was calculated by subtract ing the average o f non-speci f ic b ind ing f r o m the average in 
total b ind ing. B ra in structures were ident i f ied using the At las o f the H u m a n Bra in 
( M a i et al, 2004). The mean and standard dev ia t ion for the various dissections o f the 
anterior c ingulate cortex were calculated. Statist ical analysis іпсофога1е( і correlat ion 
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analysis where statistical s igni f icance was deemed at p<0.05， students't-test and 
unpaired t"test where statistical s igni f icance was deemed at p<0.05， using M ic roso f t 
Exce l . Graphs were constructed using M ic roso f t Exce l . 
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4 . 3 R e s u l t s 
4 . 3 . 1 O p t i m i s a t i o n o f R o d e n t A u t o r a d i o g r a p h y 
Previous work, in the laboratory has successful ly used 1 m M spermidine to def ine non­
specif ic b ind ing o f two N R 2 B selective radiol igands ( [ 3 H ] Ro 25,6981 and [ 3 H ] CP-
101,606) for both rodent and human l igand autoradiography (Sheahan and Chazot, 
manuscripts in preparat ion) (Figure 4 .3) , in agreement w i t h the autoradiography 
protocol used by M u t e l et al., (1998). 
In this study, [ 3 H ] R G H - 8 9 6 b ind ing was poor ly displaced by I m M spermidine 
compared to other radiol igands (Figure 4.2 and Figure 4.3) , [ ՝ Ή ] Ro 25,6981 and ["Ή] 
CP 101,606, where there was l i t t le d i f ference in specif ic and non-specif ic b ind ing in 
al l regions o f the brain. The second suφ r i s i ng observat ion to note is the label l ing in 
the cerebel lum using [^H] R G H - 8 9 6 where there is a dist inct label l ing pattern 
compared to very low/zero b ind ing levels us ing [^H] Ro 25,6981 and [^H] CP 
101,606 (Sheahan et al, unpubl ished) (Figure 4.3) . The use o f 0 . 1 % (พ / v ) B S A was 
introduced to the protocol to reduce the h igh level o f apparent non-specif ic b ind ing . In 
order to reduce this apparent non-specif ic b ind ing and insensi t iv i ty to spermidine, the 
protocol was repeated tw ice , f i rs t ly w i t h 0 . 1 % (พ /v ) B S A in the post- incubat ion 
buf fer and, secondly w i t h 0 . 1 % (พ /v ) B S A present throughout the procedure, w i t h 
non-speci f ic b ind ing def ined in both cases in the presence o f Ro 25,6981 (10"^M). 
The addi t ion o f 0.1 % (พ / v ) B S A greatly reduced the apparent non-specif ic b ind ing o f 
[ 3 H ] RGH-896 (Figure 4.4) . The use o f Ro 25,6981 greatly improved the 
specif ic : non-speci f ic rat io. 
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4.3 .2 A n a l y s i s o f R o d e n t A u t o r a d i o g r a p h y 
The areas o f the rodent b ra in analysed were h ippocampus (subfields C A I , С А З and 
dentate gyras) , cort ical laminae and cerebel lum (Figure 4.5) . Ana lys is shows there 
are h igher b ind ing levels o f [^H] R G H - 8 9 6 i n the C A I reg ion and the dentate gyrus o f 
the h ippocampus compared to the b ind ing levels i n the С А З reg ion o f the 
hippocampus and the cort ical laminae. A s ign i f icant ly l ower level o f specif ic b i n d i n g 
is seen i n the cerebel lum (Figure 4.6) . 
Cor t ica l 
laminae 
hippocampus 
cerebel lum 
T o t a l B i n d i n g Non-Spec i f i c 
F i g u r e 4.2: Rqj resentat ive l igand autoradiographical image o f a rat hor izonta l ventral 
bra in sl ice us ing [ 3 H ] R G H - 8 9 6 de f in ing non-speci f ic b i nd ing us ing spermidine (10՜ 
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A cerebel lum 
hippocampus 
Cor t i ça 
laminae 
В cerebel lum 
hippocampus 
Cor t iça 
laminae 
С 
cerebel lum 
hippocampus 
Cort iça 
laminae 
T o t a l Non-spec i f i c 
F i g u r e 4.3ะ Representative comparat ive autoradiograms o f ( A ) [ 3 H ] R G H - 8 9 6 , (B ) 
[ 3 H ] Ro 25 ,6981 , and ( C ) [ 3 H ] CP-101,606 carr ied out under ident ical condi t ions, 
de f in ing non-speci f ic b i nd ing us ing spermidine ( l O ' ^ M ) ( B & С ) and Ro 25,6981 (10՜ 
5 М ) ( A ) , respect ively show ing higher b ind ing levels i n the cerebel lum using [ 3 H ] 
R G H - 8 9 6 compared to b i nd ing levels us ing [ 3 H ] Ro 25,6981 and [ 3 H ] CP-101,606 
(Sheahan et al, unpubl ished) . 
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A 
В 
T o t a l 
cerebel lum 
hippocampus 
Cort iça 
laminae 
cerebel lum 
hippocampus 
Cor t i ça 
laminae 
Non-Spec i f i c 
T o t a l Non-Spec i f i c 
F i g u r e 4.4: Representative autoradiogram o f comparat ive analysis o f the 
exper imental procedure w i t h the addi t ion o f 0 . 1 % ( พ / v ) B S A de f in ing non-speci f ic 
b ind ing us ing Ro 25,6981 ( l O ' ^ M ) . 
(A ) Exper imenta l procedure w i t h 0.1 % ( พ / v ) B S A i n post- radio l igand incubat ion 
buf fers 
(B) Exper imenta l procedure w i t h 0 . 1 % ( พ / v ) B S A present throughout the protocol 
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Cerebel lum 
ppocampuร 
t ical laminae 
F i g u r e 4.5: Representative sample o f regions o f the rodent b ra in analysed inc lud ing 
hippocampus (subf ields C A I , С А З and dentate gyrus) , cort ical laminae and 
cerebel lum 
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F i g u r e 4.6: Compar ison o f various structures analysed in rodent l igand 
autoradiographical study showing [^H] RGH֊896 b ind ing levels w i t h the addi t ion o f 
0 . 1 % (พ /v ) B S A and def in ing non-specif ic b ind ing using Ro 25,6981 ( lO ' ^M) 
(ท = 6-12 randomly selected sections f r o m the same rat brain) 
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4.3 .3 A n a l y s i s o f H u m a n A u t o r a d i o g r a p h y 
Fo l l ow ing on f r o m the image analysis, the density o f b ind ing ( fmoles/mg) was 
determined fo r various sections o f the A C C , inc lud ing the cingulate cortex as a who le , 
the inner and outer areas, the infer ior c ingulate and the superior c ingulate (Figure 4.7) . 
Representative autoradiograms o f [^H] R G H - 8 9 6 b ind ing def in ing non-specif ic 
b ind ing using Ro 25,6981 ( lO ' ^M) are shown in Figure 4.8 as observed images, but i t 
is important to note that these observed images were magn i f ied fo r analysis. 
The range o f areas analysed were compared to matched contro l data. A l t hough no 
signif icance was established, a trend was observed w i t h a smal l reduct ion in specif ic 
b ind ing in al l D L B cases compared to contro l cases in the various areas o f the 
cingulate cortex analysed (Figure 4.9). The levels o f b ind ing compared we l l w i t h 
those seen w i t h [ 3 H ] Ro 25,6981 (i.e. approx 200 fmo l /mg ) , wh ich are s ign i f icant ly 
higher than those seen w i t h [^H] CP֊101,606. Fur thermore, the overal l preservation o f 
b ind ing sites was also consistent w i t h studies per formed w i th [ 3 H ] Ro 25,6981 
(Sheahan, unpubl ished). 
A range o f psychot ic symptoms occur f requent ly in D L B patients, wh ich include 
impai red consciousness, delusions, audi tory and visual hal lucinat ions. To evaluate 
these symptoms and their potential relat ionship to N R 2 B receptors, specif ic [Зн] 
RGH-896 b ind ing was determined in con junct ion w i t h the c l in ica l data as not al l 
cases experienced the same symptoms. W i t h the except ion o f the superior c ingulate 
data, there was l i t t le change in specif ic b ind ing levels when analysing the patients that 
had experienced delusions compared to those w h i c h had not (Figure 4.10). A l l areas 
analysed o f the c ingulate cortex show s ign i f icant ly higher [՝^H] RGH-896 b ind ing in 
cases that had endured auditory hal lucinat ions in compar ison to those who had not 
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(Figure 4.11). In contrast, no such signi f icant di f ferences were seen w i t h respect in 
patients w i t h visual hal lucinat ions (Figure 4.12) or impai red consciousness (Figure 
4.13) , al though there was a trend in the superior c ingulate cortex in Figure 4.13. 
Dorsal 
• 
Lateral <• 
F i g u r e 4.7: The various regions o f the A C C analysed ( C G - cingulate gyrus; cgs 
cingulate sulcus) 
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T o t a l B i n d i n g Non-Spec i f i c B i n d i n g 
F i g u r e 4.8: Representative autoradiogram o f [^Н] RGH-896 b ind ing levels in the 
presence o f 0 . 1 % ( พ / v ) B S A and def in ing non-specif ic b ind ing us ing Ro 25,6981 (10՜ 
5 M ) / A r r o w marks the posi t ion o f the anterior cingulate cortex. 
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F i g u r e 4.9: Compar ison o f contro l and D L B data ๒ ( A ) W h o l e Cingulate Cortex, (В) 
Outer Cingulate Cor tex, (С) Inner Cingulate cortex, (D ) In fer ior Cingulate, (E ) 
Superior Cingulate (ท = 4-8 cases) 
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F i g u r e 4.10: Compar ison o f contro l and D L B data in ( A ) W h o l e Cingulate Cortex, 
(B) Outer Cingulate Cor tex, (C ) b n e r Cingulate cortex, (D ) In fer ior Cingulate, (E ) 
Superior Cingulate where Delus ion (0) indicates no delusions and Delus ion (1) 
indicates the patient had experienced delusions (ท = 5-8 cases) 
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F i g u r e 4 .11 : Compar ison o f audi tory hal lucinat ions data in ( A ) W h o l e Cingulate 
Cor tex, (B) Outer Cingulate Cortex, (C ) Inner Cingulate Cortex where *p<0 .05 , 
* *p<0 .001 (ท = 3-5 cases), where A u d Ha l l (0) indicates no audi tory hal lucinat ions 
and A u d Ha l l (1) indicates the patient had experienced auditory hal lucinat ions 
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F i g u r e 4 Л 2 : Compar ison o f v isual hal lucinat ions data in ( A ) W h o l e Cingulate 
Cor tex, (B) Outer Cingulate Cortex, (c) Inner Cingulate Cor tex, (D) In fer ior 
Cingulate, (E ) Superior Cingulate (ท = 2-5 cases), where V i s Ha l l (0) indicates no 
visual hal lucinat ions and V i s Ha l l (1) indicates the patient had experienced visual 
hal lucinat ions 
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F i g u r e 4.13: Compar ison o f impai red consciousness data in ( A ) W h o l e Cingulate 
Cortex, (B) Outer Cingulate Cor tex, (C) Inner Cingulate Cortex (ท = 3 ^ cases) where 
Imp Cons (0) indicates no impai red consciousness and I m p Cons (1) indicates the 
patient had experienced impaired consciousness 
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4.4 Discussion 
The use o f l igand autoradiography can determine the mapping o f cel lu lar components 
o f the brain that have been radioact ively label led. Previous studies in the laboratory 
and publ ished data have successfully ut i l ised polyamines to def ine non-specif ic 
b ind ing o f N R 2 B radiol igands (Sheahan and Chazot, unpubl ished; M u t e l et ed., 1998). 
The marked di f ference o f ['^Η] RGH-896 b ind ing sensi t iv i ty to spermidine ( lO ' ^M) 
compared to other radiol igands, [^H] Ro 25,6981 and [-^H] CP 101,606 was fo l l owed 
up w i t h a series o f invest igat ive radio l igand b ind ing experiments (See Chapter 2). 
Us ing male adult rat forebrain membranes, compet i t ion b ind ing studies conf i rmed 
that spermidine displays a s igni f icant ly lower (42- fo ld ) a f f in i ty fo r [ 3 H ] RGH-896 
than [ 3 H ] Ro 25， 6981 (Chapter 2, Figure 2.1). Th is explained the lack o f apparent 
specific ["Ή] RGH-896 binding when spermidine was used to define non-specific 
b ind ing in the in i t ia l rodent l igand autoradiographical studies. 
The next series o f l igand autoradiography were per formed using Ro 25, 6981 ( l O '^M) 
to def ine non-specif ic b ind ing. Th is was selected as Ro 25,6981 displaced [^H] R G H -
896 w i t h an a f f in i t y close to the value previously determined us ing direct [ 3 H ] Ro 
25,6981 b ind ing studies in rat forebrain membranes and N R 1 / N R 2 B transfected Н Е К 
293 cells (Chazot et al., 2002) (Chapter 2, Figure 2.2). Fur thermore, the K D value for 
[ 3 H ] R G H - 8 9 6 in male adult rat forebrain membranes using Ro 25,6981 ( l O '^M) to 
def ine specif ic b ind ing , was in close agreement w i t h previous unpubl ished Gedeon 
Richter studies (Chapter 2, Figure 2.3). The amendment to the l igand 
autoradiography protocol w i th the addi t ion o f 0 . 1 % (พ / v ) BS A , successful ly def ined 
specif ic b ind ing o f [^H] RGH-896 to many forebrain structures, consistent w i t h both 
[ 3 H ] Ro 25,6981 and [^H] CP 101,606 (Figure 4.4) (Sheahan and Chazot, 
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unpubl ished). The areas o f the rodent brain analysed in this study were the 
hippocampus ( C A I , С А З and dentate gyrus) , cort ical laminae and cerebel lum (Figure 
4.5). The hippocampus is spl i t up into these three sub-regions as there appears to be 
signi f icant di f ferences in the mechanism by wh i ch L T P is expressed (Schulz et CiL, 
1999; Song et al., 2001). Furthermore, neurons in the C A I , С А З and denate gyrus 
are d i f fe rent ia l ly sensitive to exc i to tox ic cel i death (Ben -A r i et al., 1980; Golarai et 
al, 2 0 0 1 ; Grady et ai, 2003; Olsson et al, 2003). Autorad iography analysis showed 
higher b ind ing levels o f [ Ή ] RGH-896 in the C A I region and the dentate gyras o f the 
hippocampus compared to the b ind ing levels in the С А З region o f the hippocampus 
and the cort ical laminae. Previous studies using a semi-quanti tat!ve Western b lo t t ing 
technique have shown expression levels o f N R 2 B has been found to d i f fe r among the 
C A I , С А З and dentate gyrus o f the hippocampus. Th is study demonstrated a greater 
expression o f N R 2 B levels in the C A I region relat ive to the С А З and dentate gyrus o f 
the hippocampus (Coul t rap et al., 2005) , f o l l o w i n g a s imi lar trend w i t h the b ind ing 
levels o f [^H] R G H - 8 9 6 . The outer laminae appeared more heavi ly label led than the 
inner laminae o f the cortex consistent w i t h other label l ing observed w i t h both [^H] Ro 
25,6981 and [ 3 H ] CP 101,606. The di f ferences in specif ic b ind ing levels o f [ 3 H ] 
RGH֊896 in the hippocampus are due to d i f ferent ia l expression o f N R 2 B subunits. A 
lower level o f specif ic b ind ing was seen in the cerebel lum (Figure 4.6) wh ich was 
expected as the N R 2 B subunit is predominant ly found in the h ippocampus, cerebral 
cortex, str iatum and the o l factory bulbs (Luo et al., 1997; Charton et al., 1999) and 
not the cerebel lum. The apparent b ind ing in the cerebel lum using [^H] RGH-896 
requires fur ther invest igat ion, and may represent an addit ional b ind ing site for this 
l igand, not detected w i t h [ 3 H ] Ro 25,6981 or [ 3 H ] CP 101,606. Previous reports f r o m 
the laboratory have shown that the N R 2 B is expressed in smal l amounts in the 
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cerebel lum, a l though no funct ional support has thus far surfaced (Thompson et al., 
2000). F o l l o w i n g the amendments in the rodent studies, the improved condi t ions w i t h 
the addi t ion o f 0 . 1 % (พ /v ) B S A to reduce the high level o f apparent non-speci f ic 
b ind ing, were adopted for the human autoradiography study. A po in t to note is due to 
the use o f human tissue in the next section, the rodent and the human autoradiography 
were conducted in two separate establishments and hence there are di f ferences in the 
resolutions o f the rodent autoradiography compared to the human autoradiography. 
The focus o f the human autoradiography study was to look at the anterior c ingulate 
cortex ( A C C ) in relat ion to psychotic symptoms experienced in D L B patients 
( M c K e i t h et al., 2004) . There is g row ing evidence that l imb ic cort ical abnormal i t ies 
exist in psychosis (Shapiro, 1993; Tamminga, 1997, 1998; Weinberger, 1996). The 
hippocampal and parahippocampal cort ices, alongside the cingulate cort ices were 
def ined by Broca as the l imb ic lobe (Vogt et ai, 1997). The cingulate cortex can be 
d iv ided into anter ior (Brodmann 'ร Area 24， B A 2 4 ) and posterior domains where the 
anterior lacks a granular layer rv but has a prominent layer V a , wh i le the posterior 
Gingillate is granular (Vogt et al., 1995). The A C C is associated w i th at tent ional , 
emot ional and cogn i t i ve funct ions. The A C C has s igni f icant reciprocal connections 
part icular ly f r o m the inner lay er ร to the amygdala (Vog t et al., 1992), a brain structure 
thought to be central to emot ional processing, whereas the outer layers receive 
project ions f r o m the hippocampus (Vog t et al., 1979; Tamminga et ai, 2000) . The 
psychosis associated w i t h D L B patients can include schizophrenic- l ike episodes 
( M c K e i t h et al., 2004) . Abnormal i t ies in glutamatergic neurotransmission have been 
reported in the A C C in schizophrenia (Benes, 2000; see rev iew Tamminga et al, 
2000). In add i t ion , there is also evidence indicat ing abnormal i t ies in other 
neurotransmitter systems in the A C C in schizophrenia inc lud ing dopamine, G A B A 
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and serotonin, wh i ch cou ld al l inf luence abnormal exci tatory act iv i ty in the A C C 
(Benes, 2000; Zavi tsanou and Huang, 2002). 
I n this small p i lo t study, a trend was observed w i t h a modest reduct ion in specif ic 
b ind ing o f ['^Η] RGH-896 in al l D L B cases compared to cont ro l cases in the various 
areas o f the A C C analysed. W h e n compar ing [ 3 H ] R G H - 8 9 6 to a we l l def ined N R 2 B -
selective antagonist [^น] Ro 25 ,6981 , there was also a modest comparable decrease in 
specif ic b ind ing in the A C C o f D L B cases compared to age-matched controls lending 
weight that this may be s igni f icant (Sheahan et al., unpubl ished). The predominant 
neurotransmitters in the l imb ic cortex are glutamate and G A B A , where glutamate is 
present in pyramida l and granule cells (Ottersen et al., 1989). M a n y studies have 
looked at the fluctuations o f d i f ferent neurotransmitter levels in neuropathological 
cases, but Deak in et al., (1989) interest ingly found a reduct ion in D-[^H]-aspartate 
b ind ing, wh ich is a putat ive marker for glutamate terminals. A n explanat ion o f the 
reduct ion in [^H] R G H - 8 9 6 b ind ing is a small decl ine in NR2B-con ta in ing receptors 
in the A C C i n D L B cases. NR2B-con ta in ing receptor densit ies in the A C C were 
further measured in a prospect ively assessed series o f patients diagnosed as D L B and 
age matched controls. Compar isons were determined w i t h i n the D L B cohort between 
groups w i th and w i thou t psychot ic symptoms that occur f requent ly in D L B patients 
these include impai red consciousness, delusions, auditory and visual hal lucinat ions. 
T o evaluate these symptoms, specif ic b ind ing was determined in conjunct ion w i th the 
c l in ica l data since not al l cases experienced the same symptoms. Delusions are 
frequently seen in D L B cases (Bal lard et CiL, 1999; Aars land et al., 2 0 0 1 ; Bal lard et 
al., 2 0 0 1 ; Marantz and Verghese, 2002). Our results, w i t h the except ion o f the 
superior cingulate data, indicate there was an apparent modest increasing trend in 
specif ic b ind ing levels in patients that had experienced delusions, a l though these d id 
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not reach signif icance. Abnormal i t ies in the A C C may be related to delusions. 
Research shows in A lzhe imer 'ร disease that patients, who have experience delusions, 
are reported to have a lower metabol ic rate (Ment is et al" 1995; Sultzer et aL, 2003) 
and lower regional b lood perfusion in the A C C (Mega et αί.， 2000). I n contrast, 
schizophrenic patients exper iencing hal lucinat ions have a h igh metabol ic rate o f 
glucose in the A C C (Cleghorn et αι., 1990) and display h igh neuronal act iv i ty 
measured by fluorescence magnetic resonance imag ing ( f M R I ) (Shergi l l et αι., 2000). 
A u d i t o r y hal lucinat ions are elementary and do not appear to include command or 
single voice hal lucinat ions. Examples o f elementary audi tory hal lucinat ions include 
banging, knock ing , s izz l ing, a doorbe l l , footsteps, muf f led voices, sounds o f many 
people ta lk ing in a room or rummag ing sounds. Notab ly , a l l areas analysed o f the 
A C C show a signi f icant 2- fo ld increase in b ind ing levels in cases that had endured 
audi tory hal lucinat ions compared to cases w h i c h d id not. Aud i t o r y hal lucinat ions 
have been measured in schizophrenic patients by funct ional magnetic resonance 
imag ing ( f M R I ) and this study indicated the A C C is associated w i t h the act ivat ion o f 
audi tory hal lucinat ions (Shergi l l et α ϊ , 2000). Cleghorn et CiL, ( 1990) has analysed 
regional brain metabol ism, wh i ch has demonstrated audi tory hal lucinat ions rates 
correlate w i t h the changing metabol ism in the A C C . These data represent the f i rst 
evidence that a change in N R 2 B receptor may underl ie audi tory hal lucinat ions 
observed in a subpopulat ion o f D L B cases. Recurrent visual hal lucinat ions are a core 
feature o f D L B cases. V isua l hal lucinat ions are associated w i t h greater defici ts in 
cor t ica l acetylchol ine (Perry et aL, 1991). The analysis o f v isual hal lucinat ions in the 
var ious areas o f the A C C produced very s imi lar levels o f specif ic b ind ing , and 
therefore no signi f icant di f ferences were seen, ind icat ing there is no apparent change 
in NR2B֊containing receptor levels. A support ing feature o f D L B is impaired 
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consciousness. A l t hough not s igni f icant , all areas analysed o f the A C C displayed an 
apparent trend o f a decrease in specif ic b ind ing levels when examin ing patients that 
had experienced impai red consciousness. 
In conc lus ion, both radio l igand b ind ing (Chapter 2) and rodent autoradiography 
(Chapter 4)， showed a marked di f ference in ["^H] RGH֊896 b ind ing sensi t iv i ty to 
spermidine (10"^M) compared to [ 3 H ] Ro 25,6981 and [^H] CP 101,606. Thus 
indicat ing [ 3 H ] RGH-896 is b ind ing to a dist inct but over lapping b ind ing site to [ 3 H ] 
Ro 25,6981 and [^H] CP 101,606. Us ing rodent autoradiography, the b ind ing pro f i le 
o f [ 3 H ] RGH-896 was s imi lar to publ ished expression prof i le o f N R 2 B subunit 
conta in ing receptors (Coul t rap et al" 2005)， indicat ing NR2B֊subunit speci f ic i ty o f 
[՝*H] RGH-896 . Hence this compound can be used as a useful too l i n the future to 
probe for N R 2 B expression. The expression o f N R 2 B subunits using human l igand 
autoradiography was established in the A C C (at levels comparable to [^H] Ro 25,6981 
and s ign i f icant ly higher than [^H] CP 101,606) wh ich is associated w i t h psychosis in 
D L B patients. Th is smal l p i lo t study indicates that along w i th c l in ica l data o f affected 
patients, this l igand autoradiography method is able to quant i fy and map the cel lular 
components o f the brain that are related certain symptoms by the use o f a specif ic 
rad io l igand. Here in , th is chapter provides the f i rs t pre l iminary evidence o f cases 
wh i ch had experienced audi tory hal lucinat ions d isplay ing a s igni f icant increase in 
NR2B֊containing receptors in the A C C . In addi t ion, a general overa l l preservation o f 
N R 2 B receptors were observed in D L B patients compared to age matched controls in 
the A C C , wh ich correlates w i th paral lel studies using [ 3 H ] Ro 25,6981 and [ 3 H ] CP 
101,606 (unpubl ished observat ions), ind icat ing that this subtype remains a viable 
target for therapeutic manipu la t ion in patients suf fer ing f r om D L B . 
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Overall Discussion and Future Direction 
Pharmacological and funct ional properties o f the N M D A receptor are h igh ly 
dependent on the const i tut ion o f the receptor complex. The main a im o f this project 
was to investigate N M D A receptor subtype select iv i ty o f a novel N R 2 B receptor 
antagonist, R G H - 8 9 6 , the most advanced c l in ica l drug o f this class, current ly in Phase 
I I tr ials. Here in , native, recombinant and immunopur i f i ed preparations have been 
ut i l ised to determine the pharmacological properties o f RGH-896 using radio l igand 
b ind ing techniques. Further characterisation o f this l igand was employed to delineate 
the level o f N R 2 B receptors and the regional d is t r ibut ion o f these receptors in rodent 
and human tissue using a novel radio l igand, [Зщ RGH-896 and an opt imised l igand 
autoradiographical protocol . 
Rout ine ly , spermidine is ut i ł ised to def ine non-specif ic b ind ing o f NR2B-subun i t 
conta in ing receptors (Hawk ins , 1999; Chazot et al, 2002). A series o f radio l igand 
b ind ing studies showed spermidine displayed a s igni f icant ly lower a f f i n i t y for 
R G H - 8 9 6 b ind ing site compared to the [ 3 H ] Ro 25,6981 b ind ing site, ind icat ing [ 3 H ] 
R G H - 8 9 6 binds to a dist inct b ind ing site other than the usual N R 2 B b ind ing domain 
for [ 3 H ] Ro 25,6981 and [ 3 H ] CP-101,606. Radio l igand b ind ing compet i t ion studies 
indicated [ 3 H ] Ro 25,6981 was h igh ly sensit ive to R G H - 8 9 6 , whereas [^H] M K - 8 0 1 
was insensit ive to RGH-896 . In contrast, compet i t ion b ind ing studies showed 
comparable displacement by i fenprod i l o f both [ 3 H ] M K - 8 0 1 and [ 3 H ] Ro 25,6981 
b ind ing . Th is contrast ing allosteric coup l ing to the M K - 8 0 1 b ind ing site displayed by 
i fenprod i l and RGH-896 indicate fur ther evidence for a fundamental d i f ference in the 
b ind ing sites o f NR2B-select ive l igands. Recombinant studies in the thesis suggested 
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R G H - 8 9 6 w i l l b ind to NR2B-con ta in ing receptors irrespective o f N M D A receptor 
subunit combinat ions. T o direct ly demonstrate this pharmacological p ro f i le proposed, 
a novel immunopur i f i ca t ion procedure was employed. 
A new panel o f po lyc lona l antibodies was produced and used to generate a novel ant i -
N R 2 A immunoa f f i n i t y co lumn. T o examine the speci f ic i ty o f the an t i -NR2A 
ant ibody, native forebra in and recombinant N M D A subunits were transfected into 
Н Е К 293 cells. The an t i -NR2A ant ibody displayed no immunolog ica l cross-react ivi ty 
w i th other N M D A receptor subunits when analysed against various N M D A receptor 
subunits transfected into Н Е К 293, thus indicat ing this ant ibody is specif ic on ly to the 
N R 2 A subunit. Fo l l ow ing val idat ion o f the e f f ic iency o f the resultant immunoa f f i n i t y 
co lumn, it was used to further con f i rm the select iv i ty o f the novel NR2B-se lec t ive 
compound RGH-896 . Fo l l ow ing detergent-extract ion and immunopur i f i ca t ion o f the 
trans fee ted mater ia l , a l l subunits N R I , N R 2 A and N R 2 B were shown to be present in 
immunopur i f i ed material consistent w i t h previous studies (Brose et al, 1993; Chazot 
et al., 1994; Blahos and Wen tho ld , 1996; Chazot et al., 2002). The N R 2 B antagonists, 
Ro 25,6981 and CP-101,606, show subtype select iv i ty. Ro 25,6981 binds to 
N R 1 / N R 2 B and N R 1 / N R 2 A / N R 2 B subtype receptors w i t h s imi lar h igh af f in i t ies, 
indicat ing Ro 25,6981 to be selective for al l NR2B-con ta in ing subtype receptors 
(Hawk ins et al, 1999). In contrast, CP-101,606 shows further select iv i ty as i t can 
dist inguish between N R 1 / N R 2 A , N R 1 / N R 2 B and N R 1 / N R 2 A / N R 2 B subtype 
receptors w i th higher apparent select iv i ty for N R 1 / N R 2 B as has been shown in single 
channel recordings (Br imecombe et al, 1997), cy to tox ic i ty (Boeckmann and 
A izenman, 1996) and immunob iochemica l studies (Chazot et al., 2002). In this thesis, 
the f i rst evidence is prov ided that R G H - 8 9 6 has a s imi lar pharmacological p ro f i le to 
Ro 25 ,6981 , based on the direct measurement o f the a f f in i t y o f R G H - 8 9 6 for 
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N R 1 / N R 2 A / N R 2 B subtype using an immunopur i f i ca t ion approach. R G H - 8 9 6 binds 
w i t h a s imi lar h igh a f f i n i t y to forebrain membrane N M D A receptors, N R 1 / N R 2 B and 
immunoiso la ted N R 1 / N R 2 A / N R 2 B receptors. Therefore, this thesis provides strong 
evidence that RGH-896 binds to NR2B֊containing receptors irrespective o f the N R 2 
subunit composi t ion (partners) analagous to Ro 25»6981. 
F o l l o w i n g the def in i t ion o f the subtype select iv i ty o f R G H - 8 9 6 , the l igand 
autoradiography approach was employed to quant i fy NR2B֊containing receptors in 
the rodent and human brain. T o compare the b ind ing expression topology o f [՝^H] 
RGH-896 to [ 3 H ] Ro 25,6981 and [ 3 H ] CP-101,606, various areas o f the rodent brain 
were quant i f ied. The analysis showed higher b ind ing levels o f [Зн] RGH-896 in the 
C A I region and the dentate gyrus o f the hippocampus compared to the b ind ing levels 
i n the САЗ region o f the hippocampus and the cort ical laminae. In addi t ion, the outer 
laminae appeared more heavi ly labelled than the inner laminae o f the cortex. The 
expression prof i le o f [՝*H] RGH-896 was consistent w i t h other label l ing patterns 
observed w i t h both [^H] Ro 25,6981 and [-^H] CP-101,606 (Sheahan et aL, 
unpubl ished). A lower level o f specif ic b ind ing was seen in the cerebel lum wh ich was 
to be expected as the N R 2 B subunit is predominant ly found in the hippocampus, 
cerebral cortex, str iatum and the o l factory bulbs (Luo et aL, 1997; Charton et al., 
1999), and not the cerebel lum. The apparent s igni f icant b ind ing in the cerebel lum 
using [ 3 H ] RGH-896 compared to background levels using [ 3 H ] Ro 25,6981 or [ 3 H ] 
CP-101,606 requires further invest igat ion as this may represent an addi t ional b ind ing 
site for this l igand wh i ch is not detected w i th [ 3 H ] Ro 25,6981 or [ 3 H ] CP-101,606. 
F o l l o w i n g rodent autoradiography analysis, a series o f l igand autoradiography 
exper iments were conducted us ing human brain tissue f r o m patients that had suffered 
D L B , to investigate the specif ic b ind ing prof i le o f [ 3 H ] RGH֊896, in part icular, in the 
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anterior cingulate cortex ( A C C ) . The A C C was chosen for this invest igat ion as i t is a 
key brain region invo lved in funct ional psychosis, a common but heterogeneous set o f 
symptoms observed in D L B . The c l in ica l in format ion for the human autoradiography 
study was gathered throughout i l lness as these cases were assessed as part o f the 
Newcast le Dement ia Case Register series. Au topsy analysis con f i rmed D L B cases in 
accordance to the Consensus cr i ter ia and studies using human tissue were approved 
by Newcast le and Nor th Tyneside Local Research Ethics Commi t tee . Cont ro l tissue 
used showed no evidence o f neurological or psychiatr ic disease, whereas diseased 
tissue was obtained f r o m patients w i th a history o f D L B . C l in ica l evaluat ion 
accumulated throughout the assessment process inc luded effects that are common 
w i t h patients. These psychot ic symptoms inc luded impaired consciousness, 
delusions, auditory hal lucinat ions and visual hal lucinat ions. For evaluat ion o f these 
symptoms, specif ic [^H] RGH֊896 b ind ing was determined i n conjunct ion w i t h the 
c l in ica l data as not al l cases experienced the same symptoms. 
The analysis o f [^H] RGH֊896 b ind ing showed a surpr is ing overal l preservation o f 
N R 2 B subunits in D L B patients, compared to age-matched controls, inc lud ing the 
A C C . Analys is w i th other NR2B֊specific l igands, [ 3 H ] Ro 25,6981 and [^H] CP-
101,606, replicated this f i nd ing o f an overal l preservation o f N R 2 B receptors in the 
A C C (and many other brain stmctures). [^H] R G H - 8 9 6 produced a s imi lar b ind ing 
expression prof i le to [ 3 H ] Ro 25,6981 and [^H] CP-101,606. The levels o f [ Ή ] CP-
101,606 b ind ing were general ly lower than both [՝^H] R G H - 8 9 6 and [՝^H] Ro 25,6981 
(comparable levels), consistent again w i t h the proposed relat ive select iv i ty o f CP-
101,606 for a subpopulat ion o f N R 2 B receptors. Fur thermore, this thesis provides the 
f i rst evidence for a correlat ion between higher N R 2 B receptors in the A C C o f D L B 
cases w i th the presence o f audi tory hal lucinat ions. Such as, correłat ion was not seen 
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wi th other psychotic symptoms. 
T o achieve addit ional in fo rmat ion about RGH֊896 pharmacology may other 
experiments could be proposed. Here, on ly N R 1 / N R 2 A / N R 2 B combinat ion o f 
N M D A subunit complexes has been investigated. It wou ld be very useful to look at 
other subunit combinat ions k n o w n to exist in the C N S ( for example, 
N R 1 /NR2B/NR2D) as th is w o u l d c o n f i r m the overal l subuni t select iv i ty o f this novel 
l igand. Compet i t ion curves in Chapter 2 for RGH-896 b ind ing to Н Е К 293 cel l 
homogenates revealed the presence o f an apparent l ow-a f f i n i t y b ind ing site. The 
b ind ing o f RGH-896 to the low a f f in i t y site requires further invest igat ion as 
pre l iminary results indicate RGH֊896 is not b ind ing to the σ-site, being insensit ive to 
1,3-di-o-tolylguanidine ( D T G ) (unpubl ished observations). Regarding the rodent 
autoradiographical study, al though R G H - 8 9 6 is h igh ly selective for structures o f the 
brain that contain predominant ly NR2B-con ta in ing receptors, the ident i ty o f the 
R G H - 8 9 6 b ind ing site in the cerebel lum remains unclear. There may st i l l be the 
possib i l i ty that this l igand is b ind ing addit ional b ind ing sites other than the 
N R 1 / N R 2 B and N R 1 / N R 2 A / N R 2 B combinat ion. A more detai led human 
autoradiography study w o u l d provide addi t ional in format ion as the number o f cases in 
this p i lo t study was modest; a larger cohort o f cases and invest igat ing more 
anatomical regions o f the brain wh i ch are l inked to psychosis and other D L B 
symptoms w o u l d be benef ic ia l . T o determine the exact b ind ing site for RGH"896 , 
site-directed mutagenesis studies cou ld be considered as these studies determine the 
residues wh ich are absolutely required fo r h igh-a f f in i t y b ind ing (See Gal lagher et al, 
1996). As the data in this thesis is in vitro and ex vivo, there is a huge potential fo r in 
vivo models to help acquire more in fo rmat ion . In vivo models cou ld potent ial ly be 
ut i l ised to investigate the effects o f RGH֊896, in part icular, its effects upon in 
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emot ional and cogni t ive behaviours (both are k n o w n to invo lve the A C C and are 
c o m m o n symptoms in D L B ) . The A C C seems to be especial ly invo lved when ef for t is 
required to conduct a task i nvo lv ing early memory and prob lem so lv ing ( A l l m a n et 
al., 2001) . N M D A receptors are cr i t ica l fo r learning and memory as non-select ive and 
uncompet i t ive N M D A receptor antagonists disrupt learning and memory in animals 
and humans. Nove l al l - in-one animal behavioural models developed in our laboratory 
may prove very useful to assess the effects o f R G H - 8 9 6 upon emot ional and cogni t ive 
behaviours (Ennaceur et al., 2006a,b, unpubl ished manuscripts). In i t ia l studies 
showed i fenprodi l and e l ip rod i l to be ef fect ive in seizure and stroke models at doses 
wh ich do not disrapt learning and memory (Sanger and Joly, 1991; Cl issold et al., 
1992; Patat et al., 1994; Doy le et al., 1998). M o r e recently, Guscott et al (2002) 
showed pre-treatment o f CP-101,606 had no effect on acquis i t ion t ra in ing in the 
Mor r i s watermaze task, s ign i fy ing the selective N R 2 B receptor antagonist does not 
impai r spatial memory in rats. These studies indicate R G H - 8 9 6 , an overal l 
N R 1 / N R 2 B selective receptor antagonist, ought to prov ide therapeutic effects w i thout 
unwanted cogni t ive def ic i ts. Several major pharmaceutical companies have reported 
news o f N R 2 B receptor antagonists in Phase I and Phase I I c l in ica l tr ials for various 
C N S pathologies, most notably chronic pain ( A C C plays a role in this process) 
( B r o w n and K rupp , 2006; Ch izh and Headley, 2005; M u i r , 2006; McCau ley , 2005). 
T o date, any further w o r k o f the N R 2 B receptor antagonists have been deferred unt i l 
Phase I I results o f RGH-896 are publ ished by Gedeon Richter. Th is Phase I I c l in ica l 
t r ia l fo r R G H - 8 9 6 is invest igat ing its role fo r the treatment o f neuropathic pain. R G H -
896 and its related compounds f r o m the company can potent ia l ly b lock pain s ignal l ing 
w i thout interact ing w i t h other N M D A receptor subtypes thus have the abi l i ty to 
improve the therapeutic index and the side effect pro f i le o f this class o f compound. I f 
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this class o f compound is successful for treating pain states, then companies w i l l test 
the potential for this compound in many other disease areas, inc lud ing psychosis, 
where glutamate transmission plays a key role. Th is thesis forms the basis o f novel 
methodologies and investigations into the molecular pharmacology o f R G H - 8 9 6 . The 
f ind ings presented in this thesis should f o r m a sol id foundat ion for the 
commencement o f addi t ional projects in the future. 
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Appendix 1 
Sources of Materials 
Amersham International, Aylesbury, Buckinghamshire, UK 
Blo t t i ng Paper 
HRP- l i nked secondary ant ibody, Mouse 
HRP- l i nked secondary ant ibody, Rabbit 
H y p e r f i l m ™ 
Hybond Ni t roce l lu lose 
Cambrex Bio Science Verviers, Belgium 
D M E M / F 1 2 (1:1 m i x ) w i th 1 5 m M HEPES and L-g lu tamine 
Kodak Professional, UK 
Polymax R T , developer and replenisher 
Po lymax R T , f ixer and replenisher 
National Diagnostics, UK 
Ecoscint A 
Patterson Scientific, UK 
Devalex 
B lack and Wh i t e A m f i x 
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Pierce, Rockford, UK 
Immunopure® rProtein A I g G Or ientat ion K i t 
Promega Ltd, Southampton, UK 
H B 101 Competent E-coli cells 
Qiagen, Crawley, West Sussex, UK 
Qiagen® Plasmid M a x i K i t 
Semat International, Hertfordshire, UK 
Radio l igand f i l ter paper 
Sigma-Aldrich Company, Poole, Dorset, UK 
Acry lamide/b is -acry lamide ( 3 0 % solut ion) 
A l b u m i n , Bov ine 
A m m o n i u m Persulfate 
A m p i c i l l i n 
ß-actin 
Bacter ia l agar 
Br i l l i an t B lue G (Coomassie Blue) 
Bromopheno l B lue 
Butano l 
Ch lo ro fo rm 
p-Coumarie A c i d 
Cupr ic Sulfate, anhydrous 
Dia lys is tub ing (v isk ing size 11/4") 
D ie thy lamine 
D ime thy l Su l fox ide ( D M S O ) 
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Di th io th re i to l ( D T T ) 
Ν ,Ν-D ime thy l f o rmamide 
D M E M / F 1 2 (1:1 m i x ) w i thou t L-g lu tamine 
D u l becco's Phosphate Buf fered Saline 
Ethanol 
Ethylenediaminetetraacetic A c i d ( E D T A ) 
Ethylene Glyco l -b is (ß-aminoethy l e ther) -N,N,N' ,N ' - te t raacet ic A c i d ( E G T A ) 
Fo l in & C ioca l teu 'ร Phenol Reagent 
Gentamyc in Solu t ion 
Gluteraldehyde 
Glycero l 
G lyc ine 
G lyc ine Ethy l Ester 
Hydroch lo r ic A c i d 
Hydrogen Peroxide (30% พ / พ solut ion) 
Freund's Ad juvan t Complete 
Freund 'ร Ad juvan t Incomplete 
I fenprod i l 
Isopropanol 
Laury l Sulfate (SDS) 
L B (Lu r i a Bertani ) Bro th 
L u m i n o l 
3-Male imidobenzo ic A c i d N-hydroxysucc in imide Ester ( M B S ) 
Methano l 
Poly(ethy leneimine) solut ion 
Ponceau ร 
Potassium Chlor ide 
Potassium Phosphate, Monobasic 
Potassium Sod ium Tartrate 
Prestained Mo lecu la r Weigh t M arkers K i t 
Protease inh ib i tor cocktai l I I I 
Sod ium Az ide 
Sod ium Bicarbonate Solut ion (7.5%) 
Sod ium Carbonate 
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Sod ium Chlor ide 
Sod ium Deoxycholate 
Sod ium Hydrogen Carbonate 
Sod ium Hydrox ide 
Sod ium Ni t r i te 
Sod ium Phosphate, Dibasic 
Sod ium Phosphate, Monobasic 
Sucrose 
Ν,Ν,Ν ' ,Ν ' -Te t ramethy le thy lened iamine ( T E M E D ) 
Thyrog lobu l in , Bov ine 
T r i zma Base 
T r i zma Hydroch lor ide 
T r y p s i n - E D T A Solut ion 
Tween-20 
Vector Laboratories, UK 
Vectabond coated slides 
Miscellaneous 
N R 2 A peptide f r o m Sigma-Genosys L t d , Cambr idge, U K 
Plasmid D N A f r o m D r Paul Chazot, Du rham Univers i ty , U K 
M a r v e l , dr ied sk immed m i l k , < 1 % fat 
[•^H]-compounds f r o m Gedeon Richter L t d , Hungary 
บทlabel led compounds f r o m Gedeon Richter L t d , Hungary 
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